<PAGE>
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND
EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1996 Commission file number 0-18044
PROCYTE CORPORATION
(exact name of registrant as specified in its charter)
91-1307460
Washington (I.R.S. Employer
(State of incorporation) Identification No.)
12040-115th Avenue N.E., Suite 210, Kirkland, WA 98034-6900
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code (206) 820-4548
Securities registered pursuant to Section 12(b) of the Act None
Securities registered pursuant to the Section 12(g) Common Stock,
of the Act: par value $.01 per share
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to the filing
requirements for the past 90 days.
Yes X No
---- ----
Indicate by check mark if disclosure of delinquency filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to
the best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K {X}.
As of March 26, 1997, there were issued and outstanding 13,381,625 shares of
common stock, par value $.01 per share.
The aggregate market value of common stock held by non-affiliates as of March
26, 1997 was $26,763,250, based upon the average of the closing high and low
prices of such stock as reported by the Nasdaq Stock Market.
DOCUMENTS INCORPORATED BY REFERENCE
Parts of the following documents are incorporated by reference in Parts I,
II, III and IV of this Form 10-K report (1) the Proxy Statement for the
Registrant's 1997 Annual Meeting of Shareholders scheduled to be held May 15,
1997, and (2) the Registrant's Annual Report to Shareholders for the fiscal
year ended December 31, 1996.
<PAGE>
ProCyte Corporation
1996 Form 10-K
TABLE OF CONTENTS
Page
Part I
Item 1: Business.................................................... 1
Item 2: Properties..................................................11
Item 3: Legal Proceedings...........................................11
Item 4: Submission of Matters to a Vote of Security Holders.........11
Part II
Item 5: Market for the Company's Common Stock and Related
Shareholder Matters.........................................11
Item 6: Selected Financial Data.....................................11
Item 7: Management's Discussion and Analysis of Financial Condition
and Results of Operations...................................12
Item 8: Financial Statements........................................12
Item 9: Changes in and Disagreements with Accountants...............12
Part III
Item 10: Directors and Executive Officers of the Company............12
Item 11: Executive Compensation.....................................12
Item 12: Security Ownership of Certain Beneficial Owners............12
Item 13: Certain Relationships and Related Transactions.............12
Part IV
Item 14: Exhibits, Financial Statements Schedules, and Reports
on Form 8-K................................................12
<PAGE>
PART I
ITEM 1: BUSINESS
Certain of the information required by this Part is incorporated by
reference to the information under the caption "Management's Discussion and
Analysis of Financial Conditions and Results of Operations" on pages 10-14 of
the Registrant's 1996 Annual Report to Shareholders.
Introduction
ProCyte Corporation ("ProCyte" or the "Company") continued its important
restructuring in 1996 - building upon the Company's technology strengths and
seeking to build near-term revenue opportunities. The Company's primary
objectives set into motion in 1995 continued to serve as fundamental elements
in the Company's positioning for future growth.
ProCyte's mission is to provide innovative, user-responsive and cost
effective wound care products - a growing segment of disease management that
has long been underserved. To accomplish this objective, the Company
continued to build on its technical foundation that features two unique
technologies - copper peptide compounds and polymers.
In February 1996, ProCyte received clearance under the United States Food
and Drug Administration's ("FDA") 510(k) Class I medical device regulations
to market Iamin-Registered Trademark- Hydrating Gel for the care and
management of acute and chronic wounds. U.S. product launch occurred in late
July 1996.
A related product, Iamin-Registered Trademark--Vet Skin Care Gel, was
introduced to the veterinary wound care market during the year, and is used
to treat dermatological disorders and acute and chronic wounds in large and
small animals.
Kissei Pharmaceutical Co., Ltd., ProCyte's former partner in Japan,
China, Taiwan and Korea for the development of the Iamin-Registered
Trademark-compound, successfully completed its Phase I study in Japan during
the year. On March 7, 1997, the Company received notice from Kissei that it
intends to terminate the license agreement, in large part because the
Iamin-Registered Trademark- compound was cleared to be marketed in the U.S.
as a device and is not presently being developed in the U.S. as a drug, which
makes it difficult for Kissei to pursue drug registration in Japan. As a
result of the license termination, ProCyte will regain all rights to the use
of its technology for wound care and healing in Asia. No monies paid by
Kissei to the Company during the period of the agreement are refundable to
Kissei.
In July 1996, ProCyte commenced a Phase II study of the Iamin-Registered
Trademark- copper peptide compound in the United Kingdom for the treatment of
venous leg ulcers. That study is presently in process.
In December 1996, ProCyte received its second 510(k) medical device
product clearance - for the OsmoCyte-TM- Pillow Wound Dressings. These
highly absorptive wound care products incorporate the unique polymer
technology to which ProCyte licensed the worldwide rights, outside of Asia,
for wound care applications, and the worldwide rights for wound care drug
delivery. U.S. product launch occurred in late December 1996.
ProCyte presently plans to sell its human wound care products through its
own sales and marketing personnel and distribution networks. The Company's
initial products are promoted to the veterinary wound market by specialty
distributors.
-1-
<PAGE>
The Company plans to continue to build upon its wound care commitment,
and related market applications, and expects to introduce additional products
in 1997. At year end, the Company had five new 510(k) submissions pending
with the FDA. One of these wound care product submissions received clearance
in March 1997 for the copper peptide-containing gauze dressings called
GraftCyte-TM-Moist Dressings for use in post-operative hair restoration
procedures.
The Company is seeking registration and distribution for its products in
Europe, Latin America, the Middle East and Asia, and plans to continue to
evaluate complementary products and technologies for North American
distribution by the Company.
In November 1996, ProCyte completed an early-stage, Phase II,
placebo-controlled, multi-center clinical trial of investigational
Iamin-IB-Registered Trademark- solution (GHK:Cu 2:1 administered via
retention enema) for the treatment of mild to moderate ulcerative colitis, a
form of inflammatory bowel disease. Results of the study, based on the
prospectively designed clinical endpoints, showed that the high dose
investigational compound induced slight improvement in disease remission and
statistically significant differences in the number of patients with improved
disease symptoms.
The patient enrollment and treatment phases of the Company's initial
Phase II effectiveness evaluation study of another proprietary peptide-copper
compound, PC1358, tradenamed Tricomin-Registered Trademark- solution, was
completed in late 1996. The study was designed to evaluate effectiveness of
two different doses of the compound versus placebo in the treatment of
androgenetic alopecia - also known as male pattern baldness. Data analysis
from this initial effectiveness study is underway.
The Company intends to seek suitable corporate partners or licensees for
the hair growth and inflammatory bowel disease applications of its technology
and is also evaluating alternative registrations of the technologies
worldwide.
The Company continued to provide contract manufacturing services to
select clients in the biotechnology and pharmaceutical industries in 1996.
ProCyte also expanded its wound care production facility in 1996 while
entering working relationships with specialty manufacturers for components of
certain of the Company's wound care products.
ProCyte Corporation is a Washington corporation organized in 1986.
Important Factors Regarding Forward-Looking Statements
The entire discussion in this report, as well as other management
discussion of the Company's goals and expectations as reported in the
Company's Annual Report to Shareholders for the year ended December 31, 1996,
contains forward-looking statements. Any and all statements of goals,
beliefs, intent, plans, anticipation or expectations set forth in the
Company's SEC reports and other communications may be forward-looking
statements. Readers are cautioned not to place undue reliance on these
forward-looking statements which reflect the Company's position only as of
the date hereof. The Company undertakes no obligation to publicly release
the result of any revisions to these forward-looking statements which may be
made to reflect events or circumstances after the date hereof or to reflect
the occurrence of unanticipated events.
The following factors, among others, could affect the Company's actual
results with regard to such forward-looking statements, and could cause such
results to differ materially from those expressed in the Company's
forward-looking statements.
-2-
<PAGE>
General Financial Position of the Company
The Company may be required to raise additional capital through equity
offerings, strategic alliances or other sources. There can be no assurance
that such funds will be available to the Company on acceptable terms, if at
all.
There can be no assurance that the Company will be successful in
attracting or retaining corporate alliances on terms favorable to the
Company, whether for the Company's hair technology or otherwise, that the
interests and motivations of any corporate partner or licensee would be or
remain consistent with those of the Company, or that such partners or
licensees would successfully perform the necessary technology transfer,
clinical development, regulatory compliance, manufacturing, marketing or
other obligations. Suspension or termination of agreements with the
Company's current or future partners or licensees could have a material
adverse effect on the development of the Company's proposed products and
could materially adversely affect the Company's financial position.
Clinical and Commercial Development of Novel Compounds and Products
There can be no assurance that the Company will commence, continue or
successfully complete preclinical or clinical testing or commercial
development, including commercial-scale manufacturing and market launch of
any of the product candidates identified above, or that, if successfully
developed, such product candidates would be cleared by the FDA for sale in
the United States or by comparable regulatory authorities for sale in other
countries. Approval of a product for marketing in one country does not
ensure approval for marketing in other countries. Launch of a product does
not ensure market acceptance. The results of Phase I, Phase II or Phase III
studies are not necessarily indicative of efficacy or safety of a commercial
product for human use.
Contract Manufacturing
ProCyte's other source of revenue is its manufacturing plant, which was
commissioned in 1994, and expanded in 1996, and in which the Company provides
select contract manufacturing services to industry clientele in addition to
serving certain of its own product manufacturing requirements. By December
31, 1996, ProCyte had provided or was still performing contract manufacturing
services on behalf of several clients, including one multinational
pharmaceutical company and four biotechnology companies.
The Company expects to utilize at least 75% of the plant's current
capacity for these endeavors in 1997, though, for the reasons outlined
elsewhere in this report, and including such things as unexpected or
unsuccessful plant audits or regulatory inspections, the potential impact of
adverse weather conditions on plant operations, the decision of a client to
manufacture its own products or have them manufactured elsewhere, market
acceptance of the Company's or clients' products, and competition, there can
be no assurance that it will be successful.
ProCyte expects to continue to provide contract manufacturing services in
the future, and to produce clinical and commercial quantities of certain of
its peptide-copper compounds for its use and those of future partners.
Given the risks and uncertain timelines associated with device,
pharmaceutical and biotechnology products being developed, tested, reviewed
or sold by clients of the manufacturing facility, and the Company's own
products, the Company will be required to strive to maintain sufficient
clientele to counter the effect that regulatory delays, product failures,
product recalls, and other such circumstances may have on its contract
manufacturing capabilities and revenues. Also, such factors as unexpected or
unsuccessful plant audits or regulatory inspections, the potential impact of
adverse weather conditions on plant operations, the decision of a client to
manufacture its own products or have them manufactured elsewhere, inability
or failure to manufacture a product to established product specifications,
market acceptance of clients' products, and
-3-
<PAGE>
competition, mean there can be no assurance that the Company will be successful
in its contract manufacturing endeavors.
Wound Care Product Development, Manufacture and Distribution
Factors beyond the Company's control, such as delays in obtaining FDA
clearance to market new products, delays in product launch, the promotion and
introduction of competitive products by others with larger and more
established sales and marketing organizations, lack of product acceptance by
the marketplace, changes in Medicare reimbursement and the impact this would
have on product pricing, unexpected difficulties in scaling-up the full scale
commercial manufacturing processes, obtaining suitable raw materials, and
staffing the production operation, mean that there can be no assurance that
the Company will be able to commercialize any of its planned wound care
products in a cost-effective, timely manner, if at all.
Patents and Proprietary Rights
ProCyte's success depends in part upon its ability to protect its
products and technology under intellectual property laws in the Unites States
and abroad. As of December 31, 1996, the Company had 18 issued United States
patents expiring between 2005 and 2010, and 128 issued foreign patents and
patent registrations. The patents relate to use of the Company's
copper-based technology for a variety of healthcare applications, and to the
composition of certain biologically active, synthesized compounds. The
Company's strategy has been to apply for patent protection for certain
compounds and their discovered uses that are believed to have potential
commercial value in countries which offer significant market potential.
The Company currently holds several registered trademarks for its
products and product candidates. There can be no assurance as to the breadth
or degree of protection that the Company's existing trademarks or patents, or
any additional trademarks or patents that may be granted in the future, will
afford the Company, or that any additional trademarks or patents will be
issued to the Company. In addition, there can be no assurance that others
will not independently develop substantially equivalent proprietary
technology that is not covered by the Company's patents or that others will
not be issued patents that may prevent the Company's manufacture, sale or use
of the Company's proposed products or require licensing and the payment of
significant fees or royalties by the Company for the pursuit of its business.
Litigation, which could result in substantial cost to the Company, may be
necessary to enforce the Company's patents or to determine the scope and
validity of other parties' proprietary rights. If the outcome of any such
litigation were adverse, the Company's business could be materially affected.
The Company is unable to predict how courts would resolve any future issues
relating to the validity and scope of the Company's patents or trademarks
should they be challenged.
The Company also intends to rely on its unpatented proprietary know-how,
and there can be no assurance that others will not develop or acquire
equivalent proprietary information. To the extent that corporate partners,
consultants, or former employees apply Company technological information
independently developed by them or by others to Company projects or apply
Company technology or know-how to other projects, disputes may arise as to
the ownership of proprietary rights to such information.
Competition
Competition in the Company's planned area of marketing, wound care and
related applications, is particularly intense, involving a number of
well-established, major pharmaceutical and healthcare companies, such as
Bristol Myers Squibb's Convatec division, Kendall Healthcare Company, and
Johnson & Johnson. A significant number of smaller companies as well are
developing or marketing competitive wound care products, some of which may
have an entirely different approach than products being developed by the
Company.
-4-
<PAGE>
Wound care is an evolving field as far as technology, regulations, and
products are concerned. The Company believes that its most substantial
competition with respect to its planned wound care product line will come
from established pharmaceutical and healthcare companies, including, but not
limited to, those listed above, which are significantly larger than the
Company and have substantially greater financial resources, marketing and
sales staffs, and experience in obtaining regulatory approvals, as well as in
manufacturing and marketing wound care products, and where they have
considerable years of experience, and established reputations, promoting to
healthcare providers.
Competition in the Company's areas of interest, other than wound care is
based on scientific and technological advances, the availability of patent
protection, access to adequate capital, the requirement for and ability to
obtain government approval for new products or testing, timing and scope of
regulatory approvals, product pricing, manufacturing and marketing
capability. There can be no assurance that the Company's competitors will not
succeed in bringing to market technologies and/or products that may make the
proposed products being developed by the Company obsolete or noncompetitive.
Some of the Company's competitors may achieve product commercialization
earlier than the Company, which may adversely affect market introductions and
sales of the Company's proposed products. Competition for highly qualified
scientific, technical, and managerial personnel, consultants and advisors on
whose services the Company depends is also intense.
The contract manufacturing service business also is highly competitive.
Competitors include major chemical and pharmaceutical companies, as well as
specialized biotechnology firms, smaller contract chemical manufacturers and
some universities. Many of these companies or institutions have greater
financial, technical and marketing resources than the Company.
The chemical, commodity-products and pharmaceutical industries have
undergone and are expected to continue to undergo significant technological
and strategic change, and the Company expects the competition to intensify as
technical advances or business alliances are made by others in fields of
interest to the Company. The Company believes that its success in competing
with others will depend on such things as its ability to retain scientific
expertise and capable, experienced management, and identifying and pursuing
scientifically feasible, medically relevant, and commercially viable
opportunities.
Government Regulation
The manufacture and marketing of ProCyte's products, whether internally
developed or in-licensed, and its research and development activities in
general, are subject to extensive regulation in the United States by the
federal government, principally by the FDA, and in other countries by similar
health and regulatory authorities. The Federal Food, Drug and Cosmetic Act
and the regulations promulgated thereunder, and other federal and state
statutes govern, among other things, the testing, manufacture, safety,
labeling, storage, recordkeeping, advertising and promotion of pharmaceutical
products and medical devices. Product development and approval or clearance
within the regulatory framework requires a number of years and involves the
expenditure of substantial resources.
In order to obtain FDA clearance to market a new drug or device in the
United States for use in humans, it is necessary to proceed through several
stages of product testing, including research and development, clinical
trials, and the filing of a product registration dossier such as a new drug
application or 510(k) application with the FDA to obtain authorization to
market a product. The Company's product candidates may be regulated by any of
a number of divisions of the FDA.
Before human testing of a therapeutic product candidate may commence, the
FDA, and like agencies in other countries, generally require certain
preclinical testing, such as toxicology studies in animals, to begin to
establish product safety. Results of such studies are submitted as part of
the application to the regulatory agency. Preclinical testing is not
necessarily indicative of the safety or effectiveness of a product candidate
for human use.
-5-
<PAGE>
Human clinical trials of an investigational therapeutic compound in the
United States typically involve a three-phase process. Following the
investigational new drug ("IND") submission period, Phase I trials may be
conducted with a small group of healthy volunteers or, in some instances,
patients, to determine the early safety profile and the pattern of drug
absorption, distribution and metabolism. Phase II trials are conducted with
groups of patients afflicted with a specific disease or specific element of a
disease to determine preliminary effectiveness, optimal dosage and treatment
regimens and expanded evidence of safety. Phase III comparative trials are
conducted with a larger number of patients at multiple test sites to gather
information about safety and effectiveness that is needed to evaluate the
overall benefit-risk relationship of the compound and to provide an adequate
basis for proposed product labeling.
The results of clinical trials are submitted to the FDA, and to similar
agencies in other countries, in the form of a new drug application ("NDA") or
like submission, for approval to commence commercial distribution of the
product. The regulatory agencies may take one to two years or more to act on
an NDA or like submission, if they elect to act at all. The final decision
rests with the regulatory agency as to whether or not approval will be
granted. The regulatory agencies, at their discretion, may request further
testing, additional data, or may deny approval if the agency determines that
regulatory approval criteria are not sufficiently satisfied. Therefore,
there can be no assurance that any approvals of the Company's proposed
candidates would be granted on a timely basis, if at all, following
completion of clinical testing.
In the United States, products that do not seek to make effectiveness
claims based on human clinical evaluation, may be subject to review and
regulation under the FDA's cosmetic or 510(k) medical device guidelines.
Similar guidelines exist for such products in other countries. Such
products, which include wound care dressings, ointments and gels, must show
safety and substantial equivalency with predicate products already cleared to
be marketed by the FDA. There can be no assurance that such product
pre-market notification applications submitted to the FDA or similar agencies
in other countries will receive clearance to be marketed, or that the
labeling claims sought will be approved, or that, if cleared, such products
will be commercially successful.
In addition to obtaining FDA or other countries' approval or clearance to
market a product, the prospective manufacturer's quality control and
manufacturing procedures must conform to current good manufacturing practices
("cGMPs") guidelines, or ISO 9000 standards, when appropriate. In complying
with standards set forth in these regulations, which are subject to change at
any time without notice to the Company, manufacturers must continue to expend
time, monies and effort in production and quality control. Manufacturing
establishments, such as ProCyte's manufacturing plant, are also subject to
regulations from and inspections by other foreign, federal, state or local
agencies, such as the Drug Enforcement Agency, the city water and waste
treatment agencies, and state and federal safety and health regulations.
There can be no assurance that the Company's manufacturing facility or its
operations for the manufacture of its own product candidates or the bulk
products manufactured and processes followed by the Company on behalf of its
clients will be able to meet all appropriate guidelines or to pass
inspections by any government agency. If the Company's manufacturing
operations should fail to pass an inspection, for any reason, the possible
resultant outcome on the plant's continuing operations, and the impact on the
Company's overall reputation, operations and financial condition could be
severe.
The Company also is or may become subject to various other foreign, U.S.,
state and local laws, regulations and policies relating to, among other
things, safe working conditions, good laboratory practices, animal welfare,
and the use and disposal of hazardous or potentially hazardous substances
used in connection with research, development and/or manufacturing.
-6-
<PAGE>
Existing Corporate License Agreements
Hymedix International, Inc.
In November 1995, ProCyte entered into a license agreement with Hymedix
International Inc. ("Hymedix") in which the Company acquired the exclusive
worldwide rights, outside of Asia, to five FDA-cleared wound care products
developed by Hymedix, as well as exclusive rights to the use of the
underlying technology in the territory for future wound care products.
Additionally, the Company acquired, on a non-exclusive basis, the rights to a
sixth FDA-cleared wound care product in the same territory. The Company
shares marketing rights to the sixth product with B. Braun Medical, Inc. At
Present, the Company does not plan to commercialize the specific
510(k)-cleared products licensed from Hymedix. The Company also acquired
exclusive worldwide rights to the drug delivery application of Hymedix's
polymer-based technology for wound healing applications.
Under the terms of the agreement with Hymedix, the Company is obligated
to pay certain upfront, milestone and royalty payments. The Company's
upfront payment included 200,000 shares of the Company's common stock,
releasable over a two-year period in four equal assignments of 50,000 shares
each, unless Hymedix has materially breached the license agreement or the
Company has terminated the license agreement. The stock is subject to SEC
Rule 144 restrictions and has piggyback registration rights for a limited
period of time. The Company may terminate the agreement at any time upon
sixty days' written notice.
Kissei Pharmaceutical Co., Ltd.
In November 1993, the Company entered into a license agreement with
Kissei Pharmaceutical Co., Ltd. ("Kissei"). Under the terms of the
agreement, the Company granted to Kissei an exclusive license to make, have
made, use and sell the Company's Iamin-Registered Trademark- compound in
Japan, China, Taiwan, and Korea for topical wound healing applications,
including chronic human dermal wounds such as diabetic ulcers, venous stasis
ulcers, pressure sores, surgical wounds and burns.
On March 7, 1997, the Company received notice from Kissei that it intends
to terminate the license agreement subject to a ninety day notice period.
The termination came about in large part because the Iamin-Registered
Trademark-compound was cleared to be marketed in the U.S. as a device and is
not presently being developed in the U.S. as a drug, which makes it difficult
for Kissei to pursue drug registration in Japan. As a result of the license
termination, ProCyte will regain all rights to the use of its technology for
wound care and healing in Asia. No monies paid by Kissei to the Company
during the period of the agreement are refundable to Kissei.
Pursuant to the terms of the agreement, as of third quarter 1995, Kissei
had satisfied all of its research and development payment requirements which
it was obligated under the agreement to pay to the Company. In January 1996,
Kissei paid the Company a $1.0 million milestone payment owing under the
agreement.
ProCyte intends to seek to establish corporate distribution or other
alliances with others who are capable of pursuing device registrations of the
Company's copper-based wound care products and technology in Asia and
elsewhere. There can be no assurance that the Company will be successful in
securing, attracting or retaining distribution or other corporate alliances
on terms favorable to the Company, whether for the Company's wound care
technology or otherwise, that the interests and motivations of any corporate
partner or licensee would be or remain consistent with those of the Company,
or that such partners or licensees would successfully perform the necessary
technology transfer, clinical development, regulatory compliance,
manufacturing, marketing or other obligations. Suspension or termination of
agreements with the Company's current or future partners or licensees could
have a material adverse affect on the development of the Company's proposed
products and could materially adversely affect the Company's financial
position.
Employees
-7-
<PAGE>
At December 31, 1996, the Company had 44 full-time employees, of whom
five hold Ph.D. degrees. At year end, 12 employees were engaged in research
and development, ten in manufacturing, five in regulatory and clinical
affairs, ten in sales and marketing, and seven in accounting, finance and
administration. The Company expects to add sales and marketing staff in 1997
and to recruit additional plant operations and related personnel for the
manufacturing facility. The Company will need to compete with companies that
have established product lines, sales and marketing organizations and bonus
and commission schedules in recruiting for its planned sales staff. With
regard to recruitment of manufacturing personnel, the Company will need to
search for candidates on a nationwide basis, and attract and retain staff
from profitable plants with established clients. There can be no assurance
that the Company will be able to compete successfully against other companies
in recruiting such personnel. The Company believes that its relations with
its employees are good.
Factors Affecting Stock Price
The market prices for healthcare, medical devices, pharmaceutical and
biotechnology companies are subject to volatility, and the market has from
time to time experienced significant fluctuations that are unrelated to the
operations of the Company.
ProCyte's market price has fluctuated over a wide range since the
Company's initial public offering in 1989. Announcements concerning the
Company or its competitors, including changes in research and development
program direction, results of clinical trials, addition or deletion of
corporate partnerships, technology licenses, clearance or approval to market
products, government regulations, healthcare reform, litigation concerning
business operations or intellectual property, or public concern as to safety
of products, as well as changes in general market conditions, may have a
significant effect on the market price of ProCyte's common stock.
Directors and Executive Officers of the Company
The directors and executive officers of the Company are as follows:
Name Age Position
---- --- --------
Joseph Ashley (3) 69 Chairman of the Board
Jules Blake, Ph.D. (1) 72 Director
John F. Clifford 53 Chief Executive Officer, President,
Director, and Treasurer
Kenneth S. Green 53 Vice President, Sales
Karen L. Hedine 43 Vice President, Business
Development & Administration;
Secretary
Robert MacDonald 48 Director of Finance
Robert E. Patterson(1)(2)(3) 55 Director
William M. Sullivan(1)(2) 62 Director
Thomas E. Tierney(1)(2)(3) 69 Director
John Young 47 Vice President, Manufacturing
Operations
- ------------------------
(1) Member of the Audit Committee
(2) Member of the Compensation Committee
(3) Member of the Nominating Committee
-8-
<PAGE>
Joseph Ashley, age 69, Chairman of the Board, January 1991 to present;
President, Chief Executive Officer, and Treasurer, January 1987-August 1996.
He served as president and chief operating officer of Genetic Systems
Corporation, a biotechnology company, from 1984-1986, and in various
management capacities with Beckman Instruments, Division of SmithKline
Beckman Corporation, a diversified healthcare and life sciences company, from
1954-1984, including group vice president of Diagnostics, from 1981-84. He
chairs the Company's Nominating Committee. Mr. Ashley received a Certificate
of Executive Management from the University of California at Los Angeles
Graduate School of Business and a B.A. in Mechanical Engineering from City
College, New York.
Jules Blake, Ph.D., age 72, was elected a Director of the Company in
1991. He served as vice president of corporate scientific affairs (1987-1989)
and vice president of research and development (1973-1987) for
Colgate-Palmolive, a consumer products company. He has been a director of
Martek Biosciences Corporation, a biotechnology company, since 1990; a
director of GeneLogic, a biotechnology company, since 1996; a trustee of the
Allegheny University of the Health Sciences since 1992, and is a member of
the Audit Committee. Dr. Blake received his Ph.D. in Organic Chemistry and
his M.S. and B.S. in Chemistry from the University of Pennsylvania.
John F. "Jack" Clifford, age 53, joined the Company in August 1996 as
President, Chief Executive Officer, a Director of the Company and Treasurer.
Before joining ProCyte, Mr. Clifford was the president of Orthofix, Inc.,
from 1995-1996, a Dallas-area healthcare company in the managed care market.
Orthofix acquired American Medical Electronics, a medical device company, of
which Mr. Clifford was president and chief executive officer from 1994-1995.
From 1989-1994, Mr. Clifford served as division vice president and prior to
that as vice president of sales and marketing for American Cyanamid's Davis
and Geck Division, in the surgical sutures market. Prior to Davis and Geck,
he served from 1988-1989 as the president and chief executive officer for
Lukens Medical Corporation, a medical device company, and spent twenty years
in various sales and marketing positions with Johnson & Johnson, Inc.,
including as the vice president of marketing for that company's IOLAB
Corporation from 1981-1987. Mr. Clifford holds a B.S. in economics from
Villanova University and an MBA in finance from Drexel University. He has
participated in the Harvard University Graduate School of Business
Administration management development program.
Kenneth S. Green, age 53, joined ProCyte as Vice President of Sales in
December 1996. Prior to joining the Company, Mr. Green was the vice
president of marketing and sales for Glenwood Inc., a wound care products
company (August-September, 1996). From 1984-1996 he served for twelve years
as vice president of sales for Acme United Corporation, a wound care products
company. Mr. Green's career experience also includes serving as vice
president and general manager of Health and Medical Techniques (1983-1984), a
medical products company, vice president of sales and marketing for the
contract packaging division of Nice-Pak Corporation, a packaging company,
(1981-1983), and for the U.S. medical products division of Beirsdorf, Inc. an
international medical products company (1975-1981). Mr. Green holds a B.A.
in liberal arts from the California University at Los Angeles.
Karen L. Hedine, age 43, has been Vice President, Business Development
and Administration of the Company since October 1989, and became the
corporate secretary in 1996, having served as a management consultant to the
Company, from 1987-1989. She is responsible for general corporate
operations, including corporate governance, government liaison, business
development, legal, investor/public relations, and human resources. From
1986-1988, she was vice president of administration and human resources of
Ecova Corporation, a hazardous waste remediation company. From 1984-1986,
Ms. Hedine was director of human resources for Genetic Systems, a
biotechnology company. She is past chairperson, vice president and a member
of the Board of the Washington State Biotechnology and Biomedical
Association. Ms. Hedine received an M.A. in Personnel Administration from
Indiana University and a B.A. in English from the University of Washington.
-9-
<PAGE>
Robert MacDonald, age 48, joined ProCyte as Controller in February 1996,
and was promoted to Director of Finance in January 1997. Before joining
ProCyte, Mr. MacDonald served as the project finance manager (1972-1996) and
northwest region accounting manager (1987-1992) for Digital Equipment
Corporation, a provider of computers, services and systems consulting. From
1985-1987, he was the finance manager for Fairchild Semiconductor
Corporation, a provider of semiconductors, and from 1984-1985 served as that
company's financial analyst. Mr. MacDonald holds a B.S. in accounting from
Central Washington University, was awarded the CPA certificate in 1984, and
is presently pursuing courses toward an MBA degree at City University.
Robert E. Patterson, J.D., age 55, was elected a Director of the Company
in 1994. He serves as a managing director of Thompson Clive, Inc., a
U.K.-based venture capital firm (1983 - present), and is a partner in the
legal services firm of Graham & James (1972 - present). Mr. Patterson
currently serves on the board of several private businesses, including
QuestGen Corporation, a biotechnology company. He is a member of the
Compensation and Nominating Committees and has served as chairman of the
Audit Committee of the Board, since 1995. Mr. Patterson completed the
Executive Program at the Stanford Graduate School of Business in 1986; he
obtained his law degree from Stanford Law School and holds a B.A. in Physics
from the University of California at Los Angeles.
William M. Sullivan, J.D., age 62, was elected a Director of the Company
in 1991. He served as chairman, president and CEO of Burroughs Wellcome Co.,
a pharmaceutical and consumer products company from 1981-1986 and in various
other management and corporate legal positions from 1974-1980. He served as
president and CEO of Sparta Pharmaceuticals, Inc., a publicly-traded
development stage pharmaceutical company ("Sparta"), from 1991 to March 1996,
and Sparta's chairman of the board since 1991. He served as chairman of the
board, The Immune Response Corporation, a biotechnology company, from
1987-1994 and a director of that company since 1994-present; a Director of
BioVentures, Inc., a diagnostic company, since 1989; and a director of
Research Corporation Technologies, a technology transfer company, since 1995.
Mr. Sullivan is a member of the Audit and Compensation Committees. Mr.
Sullivan holds a J.D. from Harvard Law School and an A.B. from the University
of Notre Dame.
Thomas E. Tierney, age 69, was elected a Director of the Company in 1996.
From 1951-1988, he served in various sales, marketing and general management
positions for the Kendall Company, including vice president and general
manager, Hospital Products Business, group vice president, Healthcare
Business and executive vice president of Kendall Company and Group Executive,
Worldwide Healthcare, until his retirement in 1988. He has been chairman of
TET Associates, a healthcare consulting company since 1998; a director of
Uromed, a development-stage healthcare company since 1996. Mr. Tierney is a
member of the Nominating and Audit Committees of ProCyte's Board of
Directors, and has served as chairman of the Compensation Committee since
1996. Mr. Tierney received a B.A. in General Sciences from Colgate
University in 1951 and attended the Harvard Business School Advanced
Management Program.
John Young, age 47, became the Company's Vice President of Manufacturing
Operations in July 1996. From 1994-1995, he was president and CEO of
Biotrans, Inc., a biomedical transfer company. He served from 1988-1994 as
vice president of operations and director of operations for Molecular
Biosystems, Inc., a biotechnology company. From 1977-1988, Mr. Young was the
therapeutic program manager at the Baxter Healthcare Hyland Division, a
medical products company, and served in plant production roles from ICI Inc.,
a pharmaceutical company (1976-1977) and AHS, McGraw Laboratories
(1973-1976). Mr. Young holds a B.S. in Biological Sciences from California
State University at Los Angeles.
-10-
<PAGE>
ITEM 2. PROPERTIES
The Company presently leases approximately 28,000 square feet of
laboratory and office space at its corporate offices in Kirkland, Washington,
and approximately 16,000 square feet of manufacturing and expansion space in
Redmond, Washington. The Company is presently using this space for its
commercial-scale bulk substance manufacturing for its own commercial needs,
as well as for toll manufacturing operations for clients in the
pharmaceutical and biotechnology industries. In February 1997, the Company
executed a ten year lease for approximately 32,000 square feet at the Redmond
location, including the existing plant, for relocation of the corporate
offices, and terminated its lease for its Kirkland offices, effective July 1,
1997. Delays in obtaining building permits, cost overruns in the facility
expansion and construction delays could adversely affect the Company's
business operations and significantly delay product launch plans.
ITEM 3. LEGAL PROCEEDINGS
On March 5, 1996, the Company announced that it had elected to settle the
shareholder lawsuit filed in October 1994 against the Company and certain of
its officers and directors rather than continue to pursue costly litigation
expenses. The Company continues to believe that there was no wrongdoing on
the part of the Company and/or any of its officers and directors, but reached
the settlement agreement in an effort to focus management's attention and
corporate financial resources on the important business of building long-term
shareholder value in the Company.
The settlement, which was for $7.75 million, received court approval on
September 12, 1996. On October 22, 1996, the Company paid, in cash, the
$5.25 million balance owing of the settlement. ProCyte and one of its
insurance carriers had previously paid $2.5 million of the settlement in June
1996. Two other carriers have declined coverage, one with respect to $1
million, and the other with respect to $2 million. The Company is in
settlement discussions with regard to the $1 million, and does not plan to
take further action with regard to the $2 million.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITYHOLDERS
No matters were submitted to the shareholders for vote during fourth
quarter 1996.
PART II
ITEM 5. MARKET FOR COMPANY'S COMMON STOCK AND RELATED SHAREHOLDER MATTERS
Certain information required by this Item is incorporated by reference to
the information contained under the caption, "Price Range of Common Stock,"
located on page 14 of the Registrant's 1996 Annual Report to Shareholders.
The Company's common stock trades on the Nasdaq Stock Market under the
symbol "PRCY." At the close of business on March 7, 1997, there were 485
shareholders of record.
ProCyte has not paid any cash dividends on its common stock and does not
intend to pay cash dividends in the foreseeable future.
On each of June 19 and November 18, 1996, the Company issued 50,000
shares of its common stock to Hymedix International, Inc. pursuant to the
terms of the stock acquisition agreement described in Item 1. Such shares
were issued in a transaction not involving a public offering and are
therefore exempt pursuant to Section 4(2) of the Securities Act of 1933, as
amended.
-11-
<PAGE>
ITEM 6. SELECTED FINANCIAL DATA
The information required by this Item is incorporated by reference to the
information contained under the caption, "Financial Highlights," located on
the inside front cover page of the Registrant's 1996 Annual Report to
Shareholders.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The information required by this Item is incorporated by reference to the
information under the caption, "Management's Discussion and Analysis of
Financial Condition and Results of Operations" located on pages 10-14 of the
Registrant's 1996 Annual Report to Shareholders.
ITEM 8. FINANCIAL STATEMENTS
See Item 14 for an Index to Financial Statements and Financial Statement
Schedules. Such Financial Statements are incorporated herein by reference to
pages 15-28 of the Company's 1996 Annual Report to Shareholders.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
None.
PART III
See "Directors and Executive Officers of the Registrant" under Item I
- -Part I above. The remaining information called for by Items 10, 11, 12 and
13 is included in the Company's Proxy Statement relating to the Company's
annual meeting of shareholders, and is incorporated herein by reference. The
information appears in the Proxy Statement under the captions "Election of
Directors," "Executive Compensation," and "Security Ownership of Certain
Beneficial Owners and Management." Such Proxy Statement will be filed with
the Securities and Exchange Commission within 120 days of the Company's last
fiscal year end, December 31, 1996.
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
a. (1) and (2) Index to Financial Statements and Financial Statement
Schedules
(1) Financial Statements
The following financial statements and Independent Auditors'
Report are incorporated by reference to pages 15-28 of the
Registrant's 1996 Annual Report to Shareholders.
Balance Sheets as of December 31, 1996 and 1995.
Statements of Operations for the years ended December 31, 1996,
1995, and 1994, and the period January 1, 1985 (Predecessor
inception) to December 31, 1996.
Statements of Cash Flows for the years ended December 31, 1996,
1995, and 1994, and the period January 1, 1985 (Predecessor
inception) to December 31, 1996.
Statements of Stockholders' Equity for the years ended
December 31, 1996, 1995, and 1994, and the period
January 1, 1985 (Predecessor inception) to December 31, 1996.
Notes to Financial Statements
-12-
<PAGE>
Independent Auditors' Report
(2) Financial Statement Schedules
Financial Statement Schedules have been omitted because of the
absence of conditions under which they are required or because
the required information is included in the Financial Statements
or notes thereto.
With the exception of the pages listed in the above Index to Financial
Statements and Financial Statements Schedules and the portion of such
report referred to in Items 5, 6 and 7 of the Annual Report on
Form 10-K, the 1996 Annual Report to Shareholders is not deemed filed
as part of this report.
(3) Index to Exhibits
Exhibit Description Note
3.1 Restated Articles of Incorporation of the
Registrant (A)
3.2 Restated Bylaws of the Registrant (A)
10.1* 1987 Stock Benefit Plan of ProCyte Corporation (A)
10.2* ProCyte Corporation 1989 Restated Stock Option Plan. (B)
10.3* ProCyte Corporation 1991 Restated Stock Option Plan
for Nonemployee Directors and amendments thereto (G)
10.4 Kirkland Limited Partnership IV Lease dated as of
January 15, 1990 (C)
10.5 Teachers Insurance & Annuity Association Lease
dated as of October 1, 1993 and second amendment
thereto dated February 28, 1997 (1) (G)
10.6 License Agreement dated as of November 15, 1995
between ProCyte Corporation and Hymedix
International, Inc., containing an exhibit within,
of the Stock Acquisition Agreement dated as of
November 15, 1995 between ProCyte Corporation and
Hymedix International, Inc.(1) (F)
10.7* 1996 Stock Option Plan (G)
10.9* Consulting and Separation Agreement for
Mr. Joseph Ashley (G)
10.10* Change of Control Agreement for
Ms. Karen L. Hedine (E)
10.11* Change of Control Agreement for
Mr. John F. Clifford (G)
10.12* Form of Indemnity Agreement dated
February 23, 1995 between the Registrant and each
of Mr. Ashley, Dr. Blake, Ms. Hedine,
Mr. Patterson,Mr. Tierney, Mr. Clifford, Mr. Green
and Mr. Sullivan (E)
10.13* Form of Severance Agreement for Ms. Karen Hedine,
Mr. Kenneth Green and Mr. John Clifford (G)
13.1 1996 Annual Report to Shareholders (G)
23.1 Consent of Deloitte & Touche LLP (G)
27.1 Financial Data Schedule (G)
- --------------------------------------------------------------------------------
* Management contract or compensatory plan or arrangement
(A) Incorporated by reference to the Registrant's Registration Statement of
Form S-1 (No. 33-31353).
(B) Incorporated by reference to the Registrant's Registration Statement of
Form S-1 (No. 33-46364).
(C) Incorporated by reference to the Registrant's Annual Report on Form 10-K
for the year ended December 31, 1990.
(D) Incorporated by reference to the Registrant's Annual Report on Form 10-K
for the year ended December 31, 1993.
(E) Incorporated by reference to the Registrant's Annual Report on Form 10-K
for the year ended December 31, 1994.
(F) Incorporated by reference to the Registrant's Annual Report on Form 10-K
for the year ended December 31, 1995.
(G) Filed herewith.
-13-
<PAGE>
(1) Confidential treatment has been granted or requested with respect to
portions of this exhibit.
b. Reports on Form 8-K
None
-14-
<PAGE>
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
PROCYTE CORPORATION
(REGISTRANT)
By: /s/ John F. Clifford
-------------------------------------
Date:March 26, 1997 John F. Clifford
President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
Name Title Date
/s/ Joseph Ashley Chairman of the Board March 26, 1997
- -----------------------------
Joseph Ashley
/s/ Jules Blake Director March 26, 1997
- -----------------------------
Jules Blake, Ph.D.
/s/ John F. Clifford President and Chief Executive March 26, 1997
- ----------------------------- Officer (Principal Executive
John F. Clifford Officer and Principal
Financial Officer)
/s/ Robert E. Patterson Director March 26, 1997
- -----------------------------
Robert E. Patterson
/s/ William M. Sullivan Director March 26, 1997
- -----------------------------
William M. Sullivan
/s/ Thomas E. Tierney Director March 26, 1997
- -----------------------------
Thomas E. Tierney
/s/ Robert MacDonald Director of Finance March 26, 1997
- -----------------------------(Principal Accounting
Robert MacDonald Officer)
-15-
<PAGE>
EXHIBIT 10.3
PROCYTE CORPORATION
1991 RESTATED STOCK OPTION PLAN FOR NONEMPLOYEE DIRECTORS
ARTICLE I - PURPOSE
The purpose of the ProCyte Corporation 1991 Restated Stock Option Plan for
Nonemployee Directors (the "Plan") are to attract and retain the services of
experienced and knowledgeable nonemployee directors of ProCyte Corporation (the
"Corporation") and to provide an incentive for such directors to increase their
proprietary interest in the Corporation's long-term success and progress.
ARTICLE II - SHARES SUBJECT TO THE PLAN
The total number of shares of common stock (the "Shares") of the Corporation for
which options may be granted under the Plan is 200,000, subject to adjustment in
accordance with Article IV hereof. Such Shares shall be shares presently
authorized but unissued or subsequently acquired by the Corporation and shall
include shares representing the unexercised portion of any option granted under
the Plan which expires or terminates without being exercised in full.
ARTICLE III - ADMINISTRATION OF THE PLAN
The administrator of the Plan (the "Plan Administrator") shall consist of a
committee appointed by the Board of Directors of the Corporation (the "Board").
Subject to the terms of the Plan, the Plan Administrator shall have the power to
construe the provisions of the Plan, to determine all questions arising
thereunder and to adopt and amend such rules and regulations for the
administration of the Plan as it may deem desirable.
ARTICLE IV - PARTICIPATION IN THE PLAN
Each Director of the Corporation elected or appointed who is not otherwise an
employee of the Corporation or any subsidiary (an "Eligible Director") shall be
eligible to receive the following option grants under the Plan:
1. Initial Grants
An option to purchase 25,000 Shares (if granted prior to September 4, 1996) or
12,000 Shares (if granted on or after September 4, 1996) (as adjusted pursuant
to Article VI hereof) (an "Initial Grant") shall be granted to
(a) each Eligible Director immediately following the Board's approval of the
Plan, and
(b) each Eligible Director upon the earlier of such Eligible Director's initial
election or appointment.
2. Additional and Supplemental Grants
Once an Eligible Director's Initial Grant for 25,000 Shares becomes fully
vested, provided such vesting occurs prior to September 4, 1996, such Eligible
Director shall automatically receive an additional grant (an "Additional Grant")
of an option for the acquisition of 18,000 Shares immediately following the
annual meeting of shareholders of the Corporation as specified in the
Corporation's Bylaws (an "Annual Meeting") at which an option previously granted
thereunder becomes fully vested.
Each Eligible Director in office on September 4, 1996 who will have continuously
served as an Eligible Director for at least five years as of September 30, 1996,
shall automatically receive the grant of an option to purchase 6,000 Shares (a
"Supplemental Grant") on September 4, 1996.
3. Annual Grants
Commencing with the 1997 Annual Meeting, each Eligible Director shall
automatically receive an option to purchase 6,000 Shares immediately following
each year's Annual Meeting (each an "Annual Grant"); provided that any Eligible
Director who received an Initial Grant for 25,000 Shares, or who received an
Initial Grant for 12,000 Shares within four months of an Annual Meeting, shall
not receive an Annual Grant until immediately following the Annual Meeting at
which such Initial Grant becomes fully vested.
-16-
<PAGE>
ARTICLE V - OPTIONS TERMS
Each option granted under the Plan and the issuance of Shares thereunder shall
be subject to the following terms:
1. Option Agreement
Each option granted under the Plan shall be evidenced by an option agreement (an
"Agreement") duly executed on behalf of the Corporation and by the Eligible
Director to whom such option is granted. Each Agreement shall comply with and
be subject to the terms and conditions of the Plan. Any Agreement may contain
such other terms, provisions and conditions not inconsistent with the Plan as
may be determined by the Plan Administrator.
2. Option Exercise Price
The option exercise price for an option granted under the Plan shall be the fair
market value of the Shares covered by the option at the time the option is
granted. For purposes of the Plan, "fair market value" shall mean the average
between the high and low sale prices quoted on the day of grant on the National
Association of Securities Dealers Automated Quotation System or the closing
price on the principal exchange on which such Shares are then traded.
3. Time and Manner of Exercise of Option
Each Initial Grant for 25,000 Shares and each Additional Grant shall vest and
become exercisable in accordance with the following schedule and vested portions
may be exercised in full at one time or in part from time to time:
Period of Optionee's Continuous Service
as a Director With the Corporation From Portion of Grant That Is
the Date the Option Is Granted Exercisable
- -------------------------------------------- ------------------------
First Subsequent Annual Meeting After Grant 33-1/3%
Second Subsequent Annual Meeting After Grant 66-2/3%
Third Subsequent Annual Meeting After Grant 100%;
provided that if such Initial Grant is made within four months of an Annual
Meeting, the Initial Grant shall not begin to vest until the second subsequent
Annual Meeting after grant and shall vest ratably upon the second, third and
fourth subsequent Annual Meetings after grant.
Subject to shareholder approval of the Plan as amended on September 4, 1996,
each Initial Grant for 12,000 Shares and each Supplemental Grant and Annual
Grant shall vest and become exercisable upon the first subsequent Annual Meeting
after grant; provided that if such Initial Grant is made within four months of
an Annual Meeting, the Initial Grant shall vest and become exercisable upon the
second Annual Meeting after grant.
If the shareholders of the Corporation fail to approve the Plan at the next
Annual Meeting, all options granted hereunder shall be deemed null and void.
Any option may be exercised by giving written notice, signed by the person
exercising the option, to the Corporation stating the number of Shares with
respect to which the option is being exercised, accompanied by payment in full
for such Shares, which payment may be in whole or in part in cash, check or
(i) shares of the Common Stock of the Corporation already owned for at least six
(6) months by the person exercising the option, valued at fair market value at
the time of such exercise, or (ii) delivery of a properly executed exercise
notice, together with irrevocable instructions to a broker, all in accordance
with the regulations of the Federal Reserve Board, to properly deliver to the
Corporation the amount of sale or loan proceeds to pay the exercise price and
any federal, state or local withholding tax obligations that may arise in
connection with the exercise.
-17-
<PAGE>
4. Term of Options
Each option shall expire not more than ten (10) years from the date of the
granting thereof, but shall be subject to earlier termination as follows:
(a) In the event of the death of an optionee, the unvested portion of the
option granted to such optionee shall terminate immediately and the vested
portion of the option granted to such optionee may be exercised only within one
(1) year after the date of death of such optionee or prior to the date on which
the option expires by its terms, whichever is earlier, by the estate of such
optionee, or by any person or persons whom the optionee shall have designated in
writing on forms prescribed by and filed with the Corporation, or if no such
designation has been made by the person or persons to whom the optionee's rights
have passed, by will or the laws of descent and distribution.
(b) In the event that an optionee has ceased to be a Director of the
Corporation, the unvested portion of the option granted to such optionee shall
terminate immediately and the vested portion of the option granted to such
optionee may be exercised by him or her only within one (1) year after the date
such optionee ceased to be a Director of the Corporation or prior to the date on
which the option expires by its terms, whichever is earlier.
5. Transferability
The right of any optionee to exercise an option granted to him or her under the
Plan may not be assigned, pledged or transferred by any such optionee otherwise
than (a) by will or the laws of descent and distribution, (b) in accordance with
the terms of a domestic relations order as defined in the Internal Revenue Code
of 1986, as amended, or (c) by gift or other transfer to either (i) a spouse or
other immediate family member or (ii) any trust, partnership or other entity in
which the original optionee or such person's spouse or other immediate family
member has a substantial beneficial interest; provided that any option so
assigned or transferred shall be subject to all the same terms and conditions
contained in the Plan. Any option granted under the Plan shall be exercisable
during the lifetime of the optionee only by the optionee or a permitted
transferee or assignee. Any attempt to assign, pledge, transfer, hypothecate or
otherwise dispose of any option under this Plan or of any right or privilege
conferred thereby, contrary to the provisions of this Plan, or the sale or levy
or any attachment or any similar process upon the rights and privileges
conferred hereby, shall be null and void.
6. Holding Period
If an individual subject to Section 16 of the Securities Exchange Act of 1934,
as amended (the "Exchange Act") sells shares of Common Stock obtained upon the
exercise of any option granted under this Plan within six (6) months after the
date the option was granted, such sale may result in short-swing profit recovery
under Section 16(b) of the Exchange Act.
7. Participant's or Successor's Rights as Shareholder
Neither the recipient of an option under the Plan nor his or her successor(s) in
interest shall have any rights as a shareholder of the Corporation with respect
to any Shares subject to an option granted to such person until such person
becomes a holder of record of such Shares.
8. Regulatory Approval and Compliance
The Corporation shall not be required to issue any certificate or certificates
for Shares upon the exercise of an option granted under the Plan, or record as a
holder of record of Shares the name of the individual exercising an option under
the Plan, without obtaining to the complete satisfaction of the Plan
Administrator the approval of all regulatory bodies deemed necessary by the Plan
Administrator, and without complying, to the Plan Administrator's complete
satisfaction, with all rules and regulations under federal, state or local law
deemed applicable by the Plan Administrator.
-18-
<PAGE>
ARTICLE VI - CAPITAL ADJUSTMENTS
The aggregate number of Shares with respect to which options may be granted
under the Plan, as provided in Article II, the additional aggregate number of
Shares with respect to which an option may be granted under the Plan as provided
in Article IV, the number of Shares subject to each outstanding option and the
price per share specified in each such option shall all be proportionally
adjusted for any increases or decreases in the number of issued shares of the
Corporation's common stock resulting from a subdivision or consolidation of
shares or any other similar capital adjustments, the payment of a stock
dividend, or other increase or decrease in such shares effected without receipt
of consideration by, or a merger or consolidation of, the Corporation, or the
sale of all or substantially all of the assets of, or the liquidation of, the
Corporation.
ARTICLE VII - EXPENSES OF THE PLAN
All costs and expenses of the adoption and administration of the Plan shall be
borne by the Corporation, and none of such expenses shall be charged to any
optionee.
ARTICLE VIII - APPROVAL OF SHAREHOLDER
The Plan shall be effective upon adoption by the Board so long as it receives
any required approval by the holders of a majority of the Corporation's
outstanding shares of voting capital stock at the next Annual Meeting.
ARTICLE IX - COMPLIANCE WITH RULE 16b-3
It is the intention of the Corporation that the Plan comply in all respects with
the requirements for a "formula plan" within the meaning attributed to that term
for purposes of Rule 16b-3 promulgated under Section 16(b) of the Exchange Act.
Therefore, if any Plan provision is later found not to be in compliance with
such requirements, that provision shall be deemed null and void, and in all
events the Plan shall be construed in favor of its meeting such requirements.
ARTICLE X - TERMINATION AND AMENDMENT OF THE PLAN
The Board may amend, terminate or suspend the Plan at any time, in its sole and
absolute discretion; provided, however, that if required to qualify the Plan as
a formula plan for purposes of Rule 16b-3 promulgated under Section 16 of the
Exchange Act, no amendment may be made more than once every six months that
would change the amount, price or timing of any option granted under the Plan,
other than to comport with changes in the Internal Revenue Code of 1986, as
amended, or the rules and regulations promulgated thereunder; and provided,
further, that if required by any applicable law or regulation, no amendment that
would
(a) materially increase the number of Shares that may be issued under the Plan,
or
(b) otherwise require approval under any applicable law or regulation
shall be made without the approval of the Corporation's shareholders.
Adopted by the Board of Directors on September 27, 1991 and approved by the
shareholders on May 8, 1992. Plan amended and restated by the Board of
Directors on February 24, 1994 and approved by the shareholders on May 10, 1994.
Plan amended and restated by the Board of Directors on September 4, 1996 and
approved by the shareholders on ______________.
-19-
<PAGE>
EXHIBIT 10.5
TEACHER'S INSURANCE AND ANNUITY ASSOCIATION LEASE DATED AS OF OCTOBER 1, 1993
AND SECOND AMENDMENT THERETO DATED FEBRUARY 28, 1997
This Second Amendment to Lease (the "Second Amendment") is made this 28th day of
February, 1997, by and between Teachers Insurance & Annuity Association
("Landlord") and ProCyte Corporation ("Tenant").
RECITALS
Landlord and Tenant are parties to that certain Lease dated August 30, 1993, as
amended by First Amendment dated January 17, 1994, (collectively, the "Lease")
for certain premises located at 8511 154th Avenue NE, Redmond, WA 98052 (the
"Premises").
The parties wish to amend the Lease all as more fully set forth herein.
AGREEMENT
Now, therefore, for good and valuable consideration the parties hereto agree as
follows:
1. As used herein the "Second Amendment Effective Date" shall be March 1,
1997.
2. On the Second Amendment Effective Date, Section 1.04 of the Lease shall be
deemed amended to include therein that property shown in cross-hatching on
Exhibit A hereto, for a total rentable square footage of the Property of
32,750 rentable square feet which constitutes 90% of the Project.
3. The Lease term as set forth in Section 1.05 of the Lease is hereby extended
to and including June 30, 2007. Additional Rent as defined in Section 4.01
of the Lease shall be applied to the additional 16,097 sf expansion space
effective July l, 1997.
4. In reference to Section 1.09 of the Lease, each party represents and
warrants that there is no broker involved in the Second Amendment.
5. On or before the Expiration Date of the Letter of Credit, Tenant shall
deposit such additional funds as are necessary to make the cash security
deposit held by Landlord pursuant to Section l.ll of the Lease total
$35,782.
6. The Base Rent as set forth in Section 1.13 of the Lease is hereby amended
to be that Base Rent set forth in Exhibit B hereto.
7. Section 4.05 (c) is hereby superseded and extinguished. Landlord grants to
Tenant and Tenant's customers, suppliers, employees and invitees, a
non-exclusive license to use the designated parking areas in the Project on
a pro-rata basis for the use of motor vehicles during the term of this
Lease. Landlord reserves the right at any time to grant similar
non-exclusive use to other tenants, to promulgate rules and regulations
relating to the use of such parking areas, including reasonable
restrictions on parking by tenants and employees, to designate specific
spaces for the use of any tenant, to make changes in the parking layout
from time to time, and to establish reasonable time limits on parking.
Overnight parking is prohibited and any vehicle violating this or any other
vehicle regulation adopted by Landlord is subject to removal at the owner's
expense.
8. Landlord shall make up to Six Hundred Thousand Dollars ($600,000) (the
"Second Amendment Allowance") available to reimburse Tenant for actual
out-of-pocket costs paid to third parties for designing, permitting,
coordinating, and constructing Tenant improvements to the Premises between
the Second Amendment Effective Date and September l, 1997. From the Second
Amendment Allowance, up to $10,000 shall be deducted for Landlord's
consultant's review of Tenant's plans and specifications and for Landlord's
coordination of Tenant improvements. Such tenant improvements
-20-
<PAGE>
shall be constructed pursuant to the standards and procedures of Rider 1
to the Lease provided that the delivery of proposed contract documents to
Landlord pursuant to the first sentence of Section 3.3.1 of Rider 1 shall
be at such time as Tenant determines in its discretion and provided further
that Section 7 of Rider 1 is deleted and replaced by this Second Amendment,
and reimbursement to Tenant for actual out-of-pocket costs paid to third
parties shall be made within thirty (30) days after submission by Tenant of
applicable invoices and certification by Tenant that it has accepted the
applicable work.
9. Rider 2 to the Lease is deleted and substituted therefore is "Rider
2/Second Amendment" attached as Exhibit C hereto.
10. Rider 4 of the Lease and Section 17.01 of the First Amendment and its
attached Option Agreement are hereby superseded and extinguished. There is
hereby created a new Rider 5 to the Lease "Right of First Opportunity"
attached as Exhibit D hereto.
11. As a condition of Landlord's reimbursement obligations under Section 7,
Tenant shall procure an "irrevocable" letter of credit in favor of Landlord
in the amount of $225,000, securing Tenant's full and timely performance of
all of Tenant's obligations under the Lease to the same extent and in the
same manner as Security Deposits pursuant to Section 13.03 of the Lease.
The amount of the letter of credit shall decline on every anniversary of its
issuance by $45,000 and it shall expire on the fifth anniversary of its
issuance, and Tenant may take such steps as may be appropriate to amend or
cancel and reissue such letter of credit to reflect such declining balance and
expiration. Such letter of credit shall be in such form as will allow the
"confirming bank" to issue a confirmation advice in the form attached hereto as
Exhibit E. Landlord represents to Tenant that this form is commercially
available, and if such form of confirmation advice (or irrevocable letter of
credit) is commercially unavailable, Tenant may substitute the closest
practicable form of "Irrevocable Letter of Credit" acceptable to Landlord in its
reasonable discretion. Landlord shall be entitled to draw upon the Letter of
Credit in the same manner and with the same procedures as draws upon Security
Deposits pursuant to Section 13.03 of the Lease.
TEACHERS INSURANCE & ANNUITY ASSOCIATION PROCYTE CORPORATION
By: By:
------------------------------------- ------------------------------------
Its: Its: President & CEO
STATE OF COUNTY OF
--------------------------- ---------------------------
I certify that I know or have satisfactory evidence that signed this instrument,
on oath stated that (he/she) was authorized to execute the instrument and
acknowledged it in (his/her) capacity as of TEACHERS INSURANCE & ANNUITY
ASSOCIATION to be the free and voluntary act of such party for the uses and
purposes mentioned in the instrument. Dated this day of , 1997.
---- --------------
- -------------------------------------------
(Signature)
- -------------------------------------------
(Print Name) Notary Public, in and for the State of , residing at My Commission
Expires
-21-
<PAGE>
STATE OF COUNTY OF
-------------------------- ----------------------
I certify that I know or have satisfactory evidence that signed this instrument,
on oath stated that (he/she) was authorized to execute the instrument and
acknowledged it in (his/her) capacity as of TEACHERS INSURANCE & ANNUITY
ASSOCIATION to be the free and voluntary act of such party for the uses and
purposes mentioned in the instrument. Dated this day of , 1997.
---- --------------
- -------------------------------------------
(Signature)
- -------------------------------------------
(Print Name) Notary Public, in and for the State of , residing at My Commission
Expires
-22-
<PAGE>
EXHIBIT A
DIAGRAM OF THE PROPERTY
-23-
<PAGE>
EXHIBIT A-1
EXPANSION SPACE
-24-
<PAGE>
EXHIBIT B
BASE RENT
- -----------------------------------------------------------------------------
Month Rent
- -----------------------------------------------------------------------------
March 1997 $10,650.00
- -----------------------------------------------------------------------------
April '97 - June '97 $10,914.00
- -----------------------------------------------------------------------------
July'97-December'97 $30,341.00
- -----------------------------------------------------------------------------
January '98 - March '98 $5,139.00
- -----------------------------------------------------------------------------
April '98 - December '98 $31,513.00
- -----------------------------------------------------------------------------
January '99 - March '99 $32,109.00
- -----------------------------------------------------------------------------
April'99- July'00 $32,339.00
- -----------------------------------------------------------------------------
August'00- June'02 $34,936.00
- -----------------------------------------------------------------------------
July ;02 - June '05 $32,828.00
- -----------------------------------------------------------------------------
July'05-July'07 $35,782.00
- -----------------------------------------------------------------------------
-25-
<PAGE>
EXHIBIT C
RIDER 2 - SECOND AMENDMENT
The terms used in this Rider shall have the same definitions as set forth in
the Lease. The provisions of this Rider shall prevail over any inconsistent
or conflicting provisions of the Lease.
1. Tenant is granted the right to extend the term of this Lease beyond the
expiration date of the initial Lease Term for one (I) period of sixty (60)
months (each an "Extended Term"). If Tenant has defaulted in its
obligations under this Lease, and failed to cure such defaults within any
applicable cure period, then Tenant's right to extend the Lease for the
Extended Terms shall automatically terminate. Tenant's rights to extend the
Lease are personal to Tenant and may not be exercised by any subtenant or
assignee of Tenant. Tenant's extension rights shall apply to all of the
Property under lease to Tenant at the time. From and after the commencement
of an Extended Term, all of the terms, covenants, and conditions of the
Lease shall continue in full force and effect as written, except that Base
Rent for the Extended Term shall be equal to equal to the market rate
(referencing comparable terms such as comparable pass-through and
concessions) for a sixty (60) month term for comparably improved space in
the Willows/Marymoor HighTech/Office Park market which space shall be
presumed to be improved only with office and warehouse tenant improvements
similar to those provided by Landlord in WestPark for similarly situated
office and warehouse space, and further assuming that the Premises are
improved as thirty five percent (35%) office and sixty-five (65%)
warehouse; provided that in no event shall the monthly Base Rent plus pass
through for an Extended Term be less than the monthly Base Rent plus pass
through for the last month of the term immediately preceding the Extended
Term. Fair Market Rent shall be determined as set forth below.
2. To preserve its option to extend the Lease Term, Tenant shall give Landlord
written notice of its election to commence extension proceedings (the
"Extension Election") not less than eight (8) months prior to the first day
of the applicable Extended Term.
3. If Tenant makes an Extension Election, the parties shall promptly meet to
attempt to agree on Fair Market Rent. If they are unable to reach agreement
within sixty (60) days after Tenant's Extension Election, then Tenant shall
give Landlord written notice, within ten(l0) days after expiration of the
sixty (60) day period, electing either to rescind its Extension election or
to arbitrate the Fair market Rent as provided below, Failure of Tenant to
give notice shall be deemed an election to rescind.
4. If the parties are unable to reach agreement on Fair Market Rent during the
period specified in Section 3 of this Rider and Tenant elects arbitration
as provided therein, then within ten (10) days after Tenant's election,
each party shall advise the other in writing of the name and address of its
arbitrator. The arbitrator shall be qualified as a real estate appraiser
with at least ten (10) years experience with rental rates in
Willows/Marymoor High-Tech/Office Park market who would qualify as an
expert witness. Within ten (10) days after receipt of such notice from the
initiating party (the "Instigator") designating its arbitrator, the other
party (the "Recipient") shall give notice to Instigator, specifying the
name and address of the person designated by Recipient to act as arbitrator
on its behalf who shall be similarly qualified. If Recipient fails to
notify Instigator of the appointment of its arbitrator, within or by the
time above specified, then the arbitrator appointed by Instigator shall be
the arbitrator or determine the issue. The duty of the arbitrator(s) shall
be to determine the Fair Market Rent based solely on rental rates in the
Willows/Marymoor High-Tech/Office market. If the two (2) arbitrators are so
chosen the arbitrators so chosen shall meet within ten (10) days after the
second arbitrator is appointed and, if within ten (10) days after such
first meeting the two arbitrators shall be unable to agree promptly upon a
determination of Fair Market Rent, they, themselves, shall appoint a third
arbitrator, who shall be a competent and impartial person with
qualifications similar to those required of the first two arbitrators. If
they are unable to agree upon such appointment within five (5) days after
expiration of said ten (10) day period, then either party, on behalf of
both, may request appointment of such a qualified person by the then
presiding judge of King County Superior Court acting in his/her private
nonjudicial capacity, and the other party shall not raise any question as
to such Judge's full power and jurisdiction to entertain the application
for and make the
-26-
<PAGE>
appointment, and the parties agree to indemnify and hold the presiding judge
fully and completely harmless from and against all claims arising out of the
presiding judge's appointment of an arbitrator.
The three (3) arbitrators shall decide the dispute, if it has not been
previously resolved, by following the procedure set forth in this Rider. The
arbitrator selected by each of the parties shall state in writing his/her
determination of the Fair Market Rent supported by the reasons therefore with
counterpart copies to each party. The arbitrators shall arrange for a
simultaneous exchange of such proposed resolutions. The role of the third
arbitrator shall be to select which of the two proposed resolutions most closely
approximates his/her determination of Fair Market Rent. The third arbitrator
shall have no right to propose a middle ground or any modification of either of
the two proposed resolutions. The resolution he/she chooses as most closely
approximating his/her determination shall constitute the decision of the
arbitrators and be final and binding upon the parties. The arbitrators shall
attempt to decide the issue within thirty (30) days after the appointment of the
third arbitrator. Any decision in which the arbitrator appointed by Landlord and
the arbitrator appointed by Tenant concur shall be binding and conclusive upon
the parties. Each party shall pay the fee and expenses of its respective
arbitrator and both shall share equally the fee and expenses of the third
arbitrator, if any, and the attorneys' fees and expenses of counsel for the
respective parties and of witnesses shall be paid by the respective party
engaging such counsel or calling such witnesses. The arbitrators shall render
their decision and award in writing with counterpart copies to each party. The
arbitrators shall have no power to modify the provisions of this Lease. Time is
of the essence in this Rider.
-27-
<PAGE>
EXHIBIT D
FIRST RIGHT OF OPPORTUNITY
The terms used in this Rider shall have the same definitions as set forth in the
Lease. The provisions of this Rider shall prevail over any inconsistent or
conflicting provisions of the Lease.
This Right of First Opportunity shall apply to the area shown in crosshatching
on Exhibit A-1 hereto and labeled "Expansion Space." At such time as Landlord
intends to offer all or part of the Expansion Space for lease, Landlord shall so
notify Tenant, which notice shall include the terms (rate, term, etc.) on which
Landlord intends to offer the Expansion Space or part thereof (the "offered
Space"). If Landlord is offering a portion of the Expansion Space in conjunction
with other, adjacent space, Landlord may designate the entirety of such offered
space as the Offered Space. Tenant shall have five (5) days from receipt of such
notice to notify Landlord that Tenant agrees to enter into a lease for the
Offered Space on the terms stated in Landlord's notice or to enter into a lease
for the Offered Space on such other terms as may be mutually agreeable to
Landlord and Tenant in their sole discretion. The Right of First Opportunity
shall be exercisable by Tenant only if Tenant is in possession of the Premises
under this Lease and is not then nor has ever been in default under this Lease.
Notwithstanding any other provision of this Section, this Right of First
Opportunity shall expire on the 1 24th monthly anniversary of the extended Lease
Term.
-28-
<PAGE>
EXHIBIT E
CONFIRMATION ADVICE FORM
Confirmation Advice
(Draft for Discussion Purposes Only)
Date:
Confirming Bank: (Insert Name and Address)
Issuing Bank: (Insert Name and Address)
Teachers Insurance & Annuity Association (or Subsidiary Owner)
730 Third Avenue
New York, NY 10017
Dear Sirs:
At the request of the Issuing Bank indicated above, we quote below their
Irrevocable Letter of Credit established in your favor.
QUOTE
We hereby establish our Irrevocable Letter of Credit No. (the "Letter of Credit"
in your favor for the account of (Tenant) of for up to an aggregate amount of US
$ ( U.S. Dollars) available by your sight draft(s) drawn on Specify Name of
Issuing Bank accompanied by this original Letter of Credit.
Partial draw downs are permitted.
This Letter of Credit is subject to the Uniform Customs and Practice for
Documentary Credits (1995 Revision) international Chamber of Commerce
Publication No. 500.
We hereby agree that drafts drawn in accordance with the terms stipulated herein
will be duly honored upon presentation and delivery of this original Letter of
Credit and your sight draft if presented to (Specify bank department and address
of Confirming New York City bank) on or before (Enter expiration date) on which
date this Letter of Credit expires.
This Letter of Credit shall be automatically extended without amendment for an
additional period of one year from the present and each future expiration date,
unless at least 90 days prior to that date (specify name of Issuing Bank)
provides written notice by hand delivery to:
Teachers Insurance and Annuity Association (or Subsidiary Owner)
Managing Director
Mortgage & Real Estate
and a copy to:
Vice President and Chief Counsel
Mortgage & Real Estate at the above address that (Specify Name of Issuing Bank)
elects not to renew their Letter of Credit.
(Specify name of Issuing Bank) Letter of Credit No. and
(specify name of confirming Bank) Confirmation No. must be quoted on all drafts
presented under this Letter of Credit. UNQUOTE
-29-
<PAGE>
EXHIBIT E (Cont.)
We hereby irrevocably confirm the above referenced Letter of Credit and thereby
undertake to pay on sight all drafts drawn and presented as specified therein on
or before (Specify expiration date on which Letter of Credit expires) and any
automatically extended date of the letter of Credit.
This confirmation shall be deemed automatically extended without amendment for
one year from the expiration date or any future expiration date of the above
referenced letter of Credit, unless we shall notify you at least 90 days prior
to the expiration of this Confirmation by hand delivery to:
Teachers Insurance and Annuity Association (or Subsidiary Owner) Managing
Director Mortgage & Real Estate and a copy to:
Vice President and Chief Counsel
Mortgage & Real Estate
that we have elected not to renew this Confirmation for such an additional
period and that (Specify name of Issuing Bank) does not intend to renew the
Letter of Credit as stipulated under the terms of the Letter of Credit.
Very Truly yours,
- ----------------------------------
Authorized Signature
Confirming Bank
-30-
<PAGE>
EXHIBIT 10.7
PROCYTE CORPORATION
1996 STOCK OPTION PLAN
SECTION 1. PURPOSE
The purpose of the ProCyte Corporation 1996 Stock Option Plan (the "Plan") is
to enhance the long-term shareholder value of ProCyte Corporation, a
Washington corporation (the "Company"), by offering opportunities to
employees, directors, officers, consultants, agents, advisors and independent
contractors of the Company and its Subsidiaries (as defined in Section 2) to
participate in the Company's growth and success, and to encourage them to
remain in the service of the Company and its Subsidiaries and to acquire and
maintain stock ownership in the Company.
SECTION 2. DEFINITIONS
For purposes of the Plan, the following terms shall be defined as set forth
below:
2.1 Award
"Award" means an award or grant made to a Participant pursuant to the Plan,
including awards or grants of Incentive Stock Options and Nonqualified Stock
Options or any combination of the foregoing.
2.2 Board
"Board" means the Board of Directors of the Company.
2.3 Cause
"Cause" means dishonesty, fraud, misconduct, unauthorized use or disclosure
of confidential information or trade secrets, or conviction or confession of
a crime punishable by law (except minor violations), in each case as
determined by the Plan Administrator, and its determination shall be
conclusive and binding.
2.4 Code
"Code" means the Internal Revenue Code of 1986, as amended from time to time.
2.5 Common Stock
"Common Stock" means the common stock of the Company.
2.6 Corporate Transaction
"Corporate Transaction" means any of the following events:
(a) Consummation of any merger or consolidation of the Company in which
the Company is not the continuing or surviving corporation, or pursuant to
which shares of the Common Stock are converted into cash, securities or other
property, if following such merger or consolidation the holders of the
Company's outstanding voting securities immediately prior to such merger or
consolidation own less than 66-2/3% of the outstanding voting securities of
the surviving corporation;
(b) Consummation of any sale, lease, exchange or other transfer in one
transaction or a series of related transactions of all or substantially all
of the Company's assets other than a transfer of the Company's assets to a
majority-owned subsidiary corporation (as the term "subsidiary corporation"
is defined in Section 8.3) of the Company;
(c) Approval by the holders of the Common Stock of any plan or proposal
for the liquidation or dissolution of the Company; or
(d) Acquisition by a person, within the meaning of Section 3(a)(9) or of
Section 13(d)(3) (as in effect on the date of adoption of the Plan) of the
Exchange Act of a majority or more of the Company's outstanding voting
securities (whether directly or indirectly, beneficially or of record).
-31-
<PAGE>
Ownership of voting securities shall take into account and shall include
ownership as determined by applying Rule 13d-3(d)(1)(i) (as in effect on the
date of adoption of the Plan) pursuant to the Exchange Act.
2.7 Disability
"Disability" means "disability" as that term is defined for purposes of
Section 22(e)(3) of the Code.
2.8 Exchange Act
"Exchange Act" means the Securities Exchange Act of 1934, as amended.
2.9 Fair Market Value
"Fair Market Value" shall be as established in good faith by the Plan
Administrator or (a) if the Common Stock is listed on the Nasdaq National
Market, the closing selling price for the Common Stock as reported by the
Nasdaq National Market for a single trading day or (b) if the Common Stock is
listed on the New York Stock Exchange or the American Stock Exchange, the
closing selling price for the Common Stock as such price is officially quoted
in the composite tape of transactions on such exchange for a single trading
day. If there is no such reported price for the Common Stock for the date in
question, then such price on the last preceding date for which such price
exists shall be determinative of Fair Market Value.
2.10 Good Reason
"Good Reason" means the occurrence of any of the following events or
conditions and the failure of the Successor Corporation to cure such event or
condition within 30 days after receipt of written notice by the Holder:
(a) a change in the Holder's status, title, position or
responsibilities (including reporting responsibilities) that, in the Holder's
reasonable judgment, represents a substantial reduction in the status, title,
position or responsibilities as in effect immediately prior thereto; the
assignment to the Holder of any duties or responsibilities that, in the
Holder's reasonable judgment, are materially inconsistent with such status,
title, position or responsibilities; or any removal of the Holder from or
failure to reappoint or reelect the Holder to any of such positions, except
in connection with the termination of the Holder's employment for Cause, for
Disability or as a result of his or her death, or by the Holder other than
for Good Reason;
(b) a reduction in the Holder's annual base salary;
(c) the Successor Corporation's requiring the Holder (without the
Holder's consent) to be based at any place outside a 35-mile radius of his or
her place of employment prior to a Corporate Transaction, except for
reasonably required travel on the Successor Corporation's business that is
not materially greater than such travel requirements prior to the Corporate
Transaction;
(d) the Successor Corporation's failure to (i) continue in effect any
material compensation or benefit plan (or the substantial equivalent thereof)
in which the Holder was participating at the time of a Corporate Transaction,
including, but not limited to, the Plan, or (ii) provide the Holder with
compensation and benefits substantially equivalent (in terms of benefit
levels and/or reward opportunities) to those provided for under each material
employee benefit plan, program and practice as in effect immediately prior to
the Corporate Transaction;
(e) any material breach by the Successor Corporation of its obligations
to the Holder under the Plan or any substantially equivalent plan of the
Successor Corporation; or
(f) any purported termination of the Holder's employment or service for
Cause by the Successor Corporation that does not comply with the terms of the
Plan or any substantially equivalent plan of the Successor Corporation.
-32-
<PAGE>
2.11 Grant Date
"Grant Date" means the date the Plan Administrator adopted the granting
resolution or a later date designated in a resolution of the Plan
Administrator as the date an Award is to be granted.
2.12 Holder
"Holder" means the Participant to whom an Award is granted or, for a Holder
who has died, the personal representative of the Holder's estate, the
person(s) to whom the Holder's rights under the Award have passed by will or
the applicable laws of descent and distribution or the beneficiary designated
pursuant to Section 10.
2.13 Incentive Stock Option
"Incentive Stock Option" means an Option to purchase Common Stock granted
under Section 7 with the intention that it qualify as an "incentive stock
option" as that term is defined in Section 422 of the Code.
2.14 Nonqualified Stock Option
"Nonqualified Stock Option" means an Option to purchase Common Stock granted
under Section 7 other than an Incentive Stock Option.
2.15 Option
"Option" means the right to purchase Common Stock granted under Section 7.
2.16 Participant
"Participant" means an individual who is a Holder of an Award or, as the
context may require, any employee, director, officer, consultant, agent,
advisor or independent contractor of the Company or a Subsidiary who has been
designated by the Plan Administrator as eligible to participate in the Plan.
2.17 Plan Administrator
"Plan Administrator" means the Board or any committee of the Board designated
to administer the Plan under Section 3.1.
2.18 Securities Act
"Securities Act" means the Securities Act of 1933, as amended.
2.19 Subsidiary
"Subsidiary," except as provided in Section 8.3 in connection with Incentive
Stock Options, means any entity that is directly or indirectly controlled by
the Company or in which the Company has a significant ownership interest, as
determined by the Plan Administrator, and any entity that may become a direct
or indirect parent of the Company.
2.20 Successor Corporation
"Successor Corporation" has the meaning set forth under Section 11.2.
SECTION 3. ADMINISTRATION
3.1 Plan Administrator
The Plan shall be administered by the Board or a committee or committees
(which term includes subcommittees) appointed by, and consisting of two or
more members of, the Board. If and so long as the Common Stock is registered
under Section 12(b) or 12(g) of the Exchange Act, the Board shall consider in
selecting the Plan Administrator and the membership of any committee acting
as Plan Administrator for any persons subject or likely to become subject to
Section 16 under the Exchange Act the provisions regarding (a) "outside
directors" as contemplated by Section 162(m) of the Code and (b) "nonemployee
directors" as contemplated by Rule 16b-3 under the Exchange Act. The Board
may delegate the responsibility for administering the Plan with respect to
designated classes of eligible Participants to different committees, subject
to such limitations as the Board deems appropriate. Committee members shall
serve for such term as the Board may determine, subject to removal by the
Board at any time.
-33-
<PAGE>
3.2 Administration and Interpretation by the Plan Administrator
Except for the terms and conditions explicitly set forth in the Plan, the
Plan Administrator shall have exclusive authority, in its discretion, to
determine all matters relating to Awards under the Plan, including the
selection of individuals to be granted Awards, the type of Awards, the number
of shares of Common Stock subject to an Award, all terms, conditions,
restrictions and limitations, if any, of an Award and the terms of any
instrument that evidences the Award. The Plan Administrator shall also have
exclusive authority to interpret the Plan and may from time to time adopt,
and change, rules and regulations of general application for the Plan's
administration. The Plan Administrator's interpretation of the Plan and its
rules and regulations, and all actions taken and determinations made by the
Plan Administrator pursuant to the Plan, shall be conclusive and binding on
all parties involved or affected. The Plan Administrator may delegate
administrative duties to such of the Company's officers as it so determines.
SECTION 4. STOCK SUBJECT TO THE PLAN
4.1 Authorized Number of Shares
Subject to adjustment from time to time as provided in Section 11.1, a
maximum of 550,000 shares of Common Stock shall be available for issuance
under the Plan. Shares issued under the Plan shall be drawn from authorized
and unissued shares.
4.2 Limitations
Subject to adjustment from time to time as provided in Section 11.1, not more
than 150,000 shares of Common Stock may be made subject to Awards under the
Plan to any individual Participant in the aggregate in any one fiscal year of
the Company; except that the Company may make additional one-time grants of
up to 300,000 shares to newly hired Participants such limitation shall be
applied in a manner consistent with the requirements of, and only to the
extent required for compliance with, the exclusion from the limitation on
deductibility of compensation under Section 162(m) of the Code.
4.3 Reuse of Shares
Any shares of Common Stock that have been made subject to an Award that cease
to be subject to the Award (other than by reason of exercise or payment of
the Award to the extent it is exercised for in shares), shall again be
available for issuance in connection with future grants of Awards under the
Plan; provided, however, that any such shares shall be counted in accordance
with the requirements of Section 162(m) of the Code.
SECTION 5. ELIGIBILITY
Awards may be granted under the Plan to those officers, directors and key
employees of the Company and its Subsidiaries as the Plan Administrator from
time to time selects. Awards may also be made to consultants, agents,
advisors and independent contractors who provide services to the Company and
its Subsidiaries.
SECTION 6. AWARDS
6.1 Form and Grant of Awards
The Plan Administrator shall have the authority, in its sole discretion, to
determine the type or types of Awards to be made under the Plan. Such Awards
may consist of Incentive Stock Options and/or Nonqualified Stock Options.
Awards may be granted singly or in combination.
6.2 Acquired Company Awards
Notwithstanding anything in the Plan to the contrary, the Plan Administrator
may grant Awards under the Plan in substitution for awards issued under other
plans, or assume under the Plan awards issued under other plans, if the other
plans are or were plans of other acquired entities ("Acquired Entities") (or
the parent of the Acquired Entity) and the new Award is substituted, or the
old award is assumed, by reason of a merger, consolidation, acquisition of
property or of stock, reorganization or liquidation (the "Acquisition
Transaction"). In the event that a written agreement pursuant to which the
Acquisition Transaction is completed is approved by the Board and said
agreement sets forth the terms and conditions of the substitution for or
-34-
<PAGE>
assumption of outstanding awards of the Acquired Entity, said terms and
conditions shall be deemed to be the action of the Plan Administrator without
any further action by the Plan Administrator, except as may be required for
compliance with Rule 16b-3 under the Exchange Act, and the persons holding
such Awards shall be deemed to be Participants and Holders.
SECTION 7. AWARDS OF OPTIONS
7.1 Grant of Options
The Plan Administrator is authorized under the Plan, in its sole discretion,
to issue Options as Incentive Stock Options or as Nonqualified Stock Options,
which shall be appropriately designated.
7.2 Option Exercise Price
The exercise price for shares purchased under an Option shall be as
determined by the Plan Administrator, but shall not be less than 100% of the
Fair Market Value of the Common Stock on the Grant Date with respect to
Incentive Stock Options and not less than 85% of the Fair Market Value of the
Common Stock on the Grant Date with respect to Nonqualified Stock Options.
7.3 Term of Options
The term of each Option shall be as established by the Plan Administrator or,
if not so established, shall be 10 years from the Grant Date.
7.4 Exercise of Options
The Plan Administrator shall establish and set forth in each instrument that
evidences an Option the time at which or the installments in which the Option
shall become exercisable, which provisions may be waived or modified by the
Plan Administrator at any time. If not so established in the instrument
evidencing the Option, the Option will become exercisable according to the
following schedule, which may be waived or modified by the Plan Administrator
at any time:
Period of Holder's Continuous Employment
or Service With the Company or Its Subsidiaries Percent of Total Option
From the Option Grant Date That Is Exercisable
- ----------------------------------------------- -----------------------
After 1 year 1/3
After 2 years 2/3
After 3 years 100%
Unless the Plan Administrator determines otherwise, the vesting schedule of
an Option shall be adjusted proportionately to the extent the Holder works
less than "full time" as that term is defined by the Plan Administrator.
To the extent that the right to purchase shares has accrued thereunder, an
Option may be exercised from time to time by written notice to the Company,
in accordance with procedures established by the Plan Administrator, setting
forth the number of shares with respect to which the Option is being
exercised and accompanied by payment in full as described in Section 7.5.
The Plan Administrator may determine at any time that an Option may not be
exercised as to less than 100 shares at any one time (or the lesser number of
remaining shares covered by the Option).
-35-
<PAGE>
7.5 Payment of Exercise Price
The exercise price for shares purchased under an Option shall be paid in full
to the Company by delivery of consideration equal to the product of the
Option exercise price and the number of shares purchased. Such consideration
must be paid in cash or by check, or a combination of cash and/or check and
one or more of the following alternative forms: (a) tendering (either
actually or, if and so long as the Common Stock is registered under Section
12(b) or 12(g) of the Exchange Act, by attestation) Common Stock already
owned by the Holder for at least six months (or any shorter period necessary
to avoid a charge to the Company's earnings for financial reporting purposes)
having a Fair Market Value on the day prior to the exercise date equal to the
aggregate Option exercise price; (b) if and so long as the Common Stock is
registered under Section 12(b) or 12(g) of the Exchange Act, delivery of a
properly executed exercise notice, together with irrevocable instructions, to
(i) a brokerage firm designated by the Company to deliver promptly to the
Company the aggregate amount of sale or loan proceeds to pay the Option
exercise price and any withholding tax obligations that may arise in
connection with the exercise and (ii) the Company to deliver the certificates
for such purchased shares directly to such brokerage firm, all in accordance
with the regulations of the Federal Reserve Board; if permitted by the Plan
Administrator, in its sole discretion, either at the time the Option is
granted or at any time before it is exercised and subject to such limitations
as the Plan Administrator may determine, (c) a promissory note delivered
pursuant to Section 9; or (d) such other consideration as the Plan
Administrator may permit.
7.6 Post-Termination Exercises
The Plan Administrator shall establish and set forth in each instrument that
evidences an Option whether the Option will continue to be exercisable, and
the terms and conditions of such exercise, if a Holder ceases to be employed
by, or to provide services to, the Company or its Subsidiaries, which
provisions may be waived or modified by the Plan Administrator at any time.
If not so established in the instrument evidencing the Option, the Option
will be exercisable according to the following terms and conditions, which
may be waived or modified by the Plan Administrator at any time.
In case of termination of the Holder's employment or services other than by
reason of death or Cause, the Option shall be exercisable, to the extent of
the number of shares purchasable by the Holder at the date of such
termination, only (a) within three months after the date the Holder ceases to
be an employee, director, officer, consultant, agent, advisor or independent
contractor of the Company or a Subsidiary if termination of the Holder's
employment or services is for any reason other than Disability or (b) within
one year if such termination is because of Disability, but in no event later
than the remaining term of the Option. Any Option exercisable at the time of
the Holder's death may be exercised, at any time or from time to time within
one year after the date of death, but in no event later than the remaining
term of the Option, to the extent of the number of shares purchasable by the
Holder at the date of the Holder's death, by the personal representative of
the Holder's estate the person(s) to whom the Holder's rights under the Award
have passed by will or the applicable laws of descent and distribution or the
beneficiary designated pursuant to Section 10. In case of termination of the
Holder's employment or services for Cause, the Option shall automatically
terminate upon first notification to the Holder of such termination, unless
the Plan Administrator determines otherwise. If a Holder's employment or
services with the Company are suspended pending an investigation of whether
the Holder shall be terminated for Cause, all the Holder's rights under any
Option likewise shall be suspended during the period of investigation.
A transfer of employment or services between or among the Company and its
Subsidiaries shall not be considered a termination of employment or services.
The effect of a Company-approved leave of absence on the terms and conditions
of an option shall be determined by the Plan Administrator, in its sole
discretion.
-36-
<PAGE>
SECTION 8. INCENTIVE STOCK OPTION LIMITATIONS
To the extent required by Section 422 of the Code, Incentive Stock Options
shall be subject to the following additional terms and conditions:
8.1 Dollar Limitation
To the extent the aggregate Fair Market Value (determined as of the Grant
Date) of Common Stock with respect to which Incentive Stock Options are
exercisable for the first time during any calendar year (under the Plan and
all other stock option plans of the Company) exceeds $100,000, such portion
in excess of $100,000 shall be treated as a Nonqualified Stock Option. In
the event the Participant holds two or more such Options that become
exercisable for the first time in the same calendar year, such limitation
shall be applied on the basis of the order in which such Options are granted.
8.2 10% Shareholders
If a Participant owns more than 10% of the total voting power of all classes
of the Company's stock, then the exercise price per share of an Incentive
Stock Option shall not be less than 110% of the Fair Market Value of the
Common Stock on the Grant Date and the Option term shall not exceed five
years. The determination of 10% ownership shall be made in accordance with
Section 422 of the Code.
8.3 Eligible Employees
Individuals who are not employees of the Company or one of its parent
corporations or subsidiary corporations may not be granted Incentive Stock
Options. For purposes of this Section 8.3, "parent corporation" and
"subsidiary corporation" shall have the meanings attributed to those terms
for purposes of Section 422 of the Code.
8.4 Term
The term of an Incentive Stock Option shall not exceed 10 years.
8.5 Exercisability
To qualify for Incentive Stock Option tax treatment, an Option designated as
an Incentive Stock Option must be exercised within three months after
termination of employment for reasons other than death, except that, in the
case of termination of employment due to total disability, such Option must
be exercised within one year after such termination. Employment shall not be
deemed to continue beyond the first 90 days of a leave of absence unless the
Participant's reemployment rights are guaranteed by statute or contract. For
purposes of this Section 8.5, "total disability" shall mean a mental or
physical impairment of the Participant which is expected to result in death
or which has lasted or is expected to last for a continuous period of 12
months or more and which causes the Participant to be unable, in the opinion
of the Company and two independent physicians, to perform his or her duties
for the Company and to be engaged in any substantial gainful activity. Total
disability shall be deemed to have occurred on the first day after the
Company and the two independent physicians have furnished their opinion of
total disability to the Plan Administrator.
8.6 Taxation of Incentive Stock Options
In order to obtain certain tax benefits afforded to Incentive Stock Options
under Section 422 of the Code, the Participant must hold the shares issued
upon the exercise of an Incentive Stock Option for two years after the Grant
Date of the Incentive Stock Option and one year from the date of exercise. A
Participant may be subject to the alternative minimum tax at the time of
exercise of an Incentive Stock Option. The Plan Administrator may require a
Participant to give the Company prompt notice of any disposition of shares
acquired by the exercise of an Incentive Stock Option prior to the expiration
of such holding periods.
8.7 Promissory Notes
The amount of any promissory note delivered pursuant to Section 9 in
connection with an Incentive Stock Option shall bear interest at a rate
specified by the Plan Administrator but in no case less than the rate
required to avoid imputation of interest (taking into account any exceptions
to the imputed interest rules) for federal income tax purposes.
-37-
<PAGE>
SECTION 9. LOANS, INSTALLMENT PAYMENTS AND LOAN GUARANTEES
To assist a Holder (including a Holder who is an officer or director of the
Company) in acquiring shares of Common Stock pursuant to an Award granted
under the Plan, the Plan Administrator, in its sole discretion, may
authorize, either at the Grant Date or at any time before the acquisition of
Common Stock pursuant to the Award, (a) the extension of a loan to the Holder
by the Company, (b) the payment by the Holder of the purchase price, if any,
of the Common Stock in installments, or (c) the guarantee by the Company of a
loan obtained by the grantee from a third party. The terms of any loans,
installment payments or loan guarantees, including the interest rate and
terms of repayment, will be subject to the Plan Administrator's discretion.
Loans, installment payments and loan guarantees may be granted with or
without security. The maximum credit available is the purchase price, if
any, of the Common Stock acquired, plus the maximum federal and state income
and employment tax liability that may be incurred in connection with the
acquisition.
SECTION 10. ASSIGNABILITY
No Award granted under the Plan may be assigned, pledged or transferred by
the Holder other than by will or by the laws of descent and distribution, and
during the Holder's lifetime, such Awards may be exercised only by the
Holder. Notwithstanding the foregoing, and to the extent permitted by Section
422 of the Code, the Plan Administrator, in its sole discretion, may permit
such assignment, transfer and exercisability and may permit a Holder of such
Awards to designate a beneficiary who may exercise the Award or receive
compensation under the Award after the Holder's death; provided, however,
that any Award so assigned or transferred shall be subject to all the same
terms and conditions contained in the instrument evidencing the Award.
SECTION 11. ADJUSTMENTS
11.1 Adjustment of Shares
In the event that, at any time or from time to time, a stock dividend, stock
split, spin-off, combination or exchange of shares, recapitalization, merger,
consolidation, distribution to shareholders other than a normal cash
dividend, or other change in the Company's corporate or capital structure
results in (a) the outstanding shares, or any securities exchanged therefor
or received in their place, being exchanged for a different number or class
of securities of the Company or of any other corporation or (b) new,
different or additional securities of the Company or of any other corporation
being received by the holders of shares of Common Stock of the Company, then
the Plan Administrator, in its sole discretion, shall make such equitable
adjustments as it shall deem appropriate in the circumstances in (i) the
maximum number and class of securities subject to the Plan as set forth in
Section 4.1, (ii) the maximum number and class of securities that may be made
subject to Awards to any individual Participant as set forth in Section 4.2,
and (iii) the number and class of securities that are subject to any
outstanding Award and the per share price of such securities, without any
change in the aggregate price to be paid therefor. The determination by the
Plan Administrator as to the terms of any of the foregoing adjustments shall
be conclusive and binding.
11.2 Corporate Transaction
Except as otherwise provided in the instrument that evidences the Award, in
the event of any Corporate Transaction, each Award that is at the time
outstanding shall automatically accelerate so that each such Award shall,
immediately prior to the specified effective date for the Corporate
Transaction, become 100% vested, except that such acceleration will not
occur, if in the opinion of the Company's accountants, it would render
unavailable "pooling of interest" accounting for a Corporate Transaction that
would otherwise qualify for such accounting treatment. Such Award shall not
so accelerate, however, if and to the extent that (a) such Award is, in
connection with the Corporate Transaction, either to be assumed by the
successor corporation or parent thereof (the "Successor Corporation") or to
be replaced with a comparable award for the purchase of shares of the capital
stock of the Successor Corporation or (b) such Award is to be replaced with a
cash incentive program of the Successor Corporation that preserves the spread
existing at the time of the Corporate Transaction and provides for subsequent
payout in accordance with the same vesting schedule applicable to such Award.
The determination of Award comparability under clause (a) above shall be
made by the Plan
-38-
<PAGE>
Administrator, and its determination shall be conclusive and binding. All
such Awards shall terminate and cease to remain outstanding immediately
following the consummation of the Corporate Transaction, except to the extent
assumed by the Successor Corporation. Any such Awards that are assumed or
replaced in the Corporate Transaction and do not otherwise accelerate at that
time shall be accelerated in the event the Holder's employment or services
should subsequently terminate within two years following such Corporate
Transaction, unless such employment or services are terminated by the
Successor Corporation for Cause or by the Holder voluntarily without Good
Reason.
11.3 Further Adjustment of Awards
Subject to the preceding Section 11.2, the Plan Administrator shall have the
discretion, exercisable at any time before a sale, merger, consolidation,
reorganization, liquidation or change in control of the Company, as defined
by the Plan Administrator, to take such further action as it determines to be
necessary or advisable, and fair and equitable to Participants, (but shall
not be limited to) establishing, amending or waiving the type, terms,
conditions or duration of, or restrictions on, Awards so as to provide for
earlier, later, extended or additional time for exercise and other
modifications, and the Plan Administrator may take such actions with respect
to all Participants, to certain categories of Participants or only to
individual Participants. The Plan Administrator may take such actions before
or after granting Awards to which the action relates and before or after any
public announcement with respect to such sale, merger, consolidation,
reorganization, liquidation or change in control that is the reason for such
action.
11.4 Limitations
The grant of Awards will in no way affect the Company's right to adjust,
reclassify, reorganize or otherwise change its capital or business structure
or to merge, consolidate, dissolve, liquidate or sell or transfer all or any
part of its business or assets.
SECTION 12. WITHHOLDING
The Company may require the Holder to pay to the Company the amount of any
withholding taxes that the Company is required to withhold with respect to
the grant or exercise of any Award. In such instances, the Plan
Administrator may, in its discretion and subject to the Plan and applicable
law, permit the Holder to satisfy withholding obligations, in whole or in
part, by paying cash, by electing to have the Company withhold shares of
Common Stock or by transferring shares of Common Stock to the Company, in
such amounts as are equivalent to the Fair Market Value of the withholding
obligation. The Company shall have the right to withhold from any shares of
Common Stock issuable pursuant to an Award or from any cash amounts otherwise
due or to become due from the Company to the Participant an amount equal to
such taxes. The Company may also deduct from any Award any other amounts due
from the Participant to the Company or a Subsidiary.
SECTION 13. AMENDMENT AND TERMINATION OF PLAN
13.1 Amendment of Plan
The Plan may be amended by the shareholders of the Company. The Board may
also amend the Plan in such respects as it shall deem advisable; however, to
the extent required for compliance with Section 422 of the Code or any
applicable law or regulation, shareholder approval will be required for any
amendment that will (a) increase the aggregate number of shares as to which
Options may be granted, (b) modify the employees or class of employees
eligible to receive Incentive Stock Options, or (c) otherwise require
shareholder approval under any applicable law or regulation. Amendments made
to the Plan which would constitute "modifications" to Incentive Stock Options
outstanding on the date of such Amendments shall not be applicable to such
outstanding Incentive Stock Options but shall have prospective effect only.
13.2 Termination of Plan
The Company's shareholders or the Board may suspend or terminate the Plan at
any time. The Plan will have no fixed expiration date; provided, however,
that no Incentive Stock Options may be granted more than 10 years after the
earlier of the Plan's adoption by the Board or approval by the shareholders.
-39-
<PAGE>
13.3 Consent of Holder
The amendment or termination of the Plan shall not, without the consent of
the Holder of any Award under the Plan, alter or impair any rights or
obligations under any Award theretofore granted under the Plan.
SECTION 14. GENERAL
14.1 Award Agreements
Awards granted under the Plan shall be evidenced by a written agreement which
shall contain such terms, conditions, limitations and restrictions as the
Plan Administrator shall deem advisable and which are not inconsistent with
the Plan.
14.2 Continued Employment or Services; Rights in Awards
None of the Plan, participation in the Plan as a Participant or any action of
the Plan Administrator taken under the Plan shall be construed as giving any
Participant or employee of the Company any right to be retained in the employ
of the Company or limit the Company's right to terminate the employment or
services of the Participant.
14.3 Registration; Certificates for Shares
The Company shall be under no obligation to any Participant to register for
offering or resale or to qualify for exemption under the Securities Act, or
to register or qualify under state securities laws, any shares of Common
Stock, security or interest in a security paid or issued under, or created
by, the Plan, or to continue in effect any such registrations or
qualifications if made. The Company may issue certificates for shares with
such legends and subject to such restrictions on transfer and stop-transfer
instructions as counsel for the Company deems necessary or desirable for
compliance by the Company with federal and state securities laws.
Inability of the Company to obtain, from any regulatory body having
jurisdiction, the authority deemed by the Company's counsel to be necessary
for the lawful issuance and sale of any shares hereunder or the
unavailability of an exemption from registration for the issuance and sale of
any shares hereunder shall relieve the Company of any liability in respect of
the nonissuance or sale of such shares as to which such requisite authority
shall not have been obtained.
14.4 No Rights as a Shareholder
No Award shall entitle the Holder to any dividend, voting or other right of a
shareholder unless and until the date of issuance under the Plan of the
shares that are the subject of such Award, free of all applicable
restrictions.
14.5 Compliance With Laws and Regulations
Notwithstanding anything in the Plan to the contrary, the Board, in its sole
discretion, may bifurcate the Plan so as to restrict, limit or condition the
use of any provision of the Plan to Participants who are officers or
directors subject to Section 16 of the Exchange Act without so restricting,
limiting or conditioning the Plan with respect to other Participants.
Additionally, in interpreting and applying the provisions of the Plan, any
Option granted as an Incentive Stock Option pursuant to the Plan shall, to
the extent permitted by law, be construed as an "incentive stock option"
within the meaning of Section 422 of the Code.
14.6 No Trust or Fund
The Plan is intended to constitute an "unfunded" plan. Nothing contained
herein shall require the Company to segregate any monies or other property,
or shares of Common Stock, or to create any trusts, or to make any special
deposits for any immediate or deferred amounts payable to any Participant,
and no Participant shall have any rights that are greater than those of a
general unsecured creditor of the Company.
-40-
<PAGE>
14.7 Severability
If any provision of the Plan or any Award is determined to be invalid,
illegal or unenforceable in any jurisdiction, or as to any person, or would
disqualify the Plan or any Award under any law deemed applicable by the Plan
Administrator, such provision shall be construed or deemed amended to conform
to applicable laws, or, if it cannot be so construed or deemed amended
without, in the Plan Administrator's determination, materially altering the
intent of the Plan or the Award, such provision shall be stricken as to such
jurisdiction, person or Award, and the remainder of the Plan and any such
Award shall remain in full force and effect.
SECTION 15. EFFECTIVE DATE
The Plan's effective date is the date on which it is adopted by the Board, so
long as it is approved by the Company's shareholders at any time within 12
months of such adoption or, if earlier, and to the extent required for
compliance with Rule 16b-3 under the Exchange Act, at the next annual meeting
of the Company's shareholders after adoption of the Plan by the Board.
Adopted by the Board on July 23, 1996 and approved by the Company's
shareholders on __________, 199__.
-41-
<PAGE>
EXHIBIT 10.9
CONSULTING AND SEPARATION AGREEMENT FOR MR. JOSEPH ASHLEY
THIS CONSULTING AND SEPARATION AGREEMENT (this "Agreement") dated as of
August 12, 1996 is entered into by and between Joseph Ashley ("Ashley") and
ProCyte Corporation ("ProCyte").
RECITALS
A. Ashley has been employed as Chief Executive Officer and President of
ProCyte and serves as Chairman of ProCyte's Board of Directors (the "Board of
Directors"). Ashley's employment relationship with ProCyte is terminated
effective August 12, 1996.
B. Ashley and ProCyte wish to have Ashley continue as a Director and
Chairman of the Board of Directors and to provide consulting services to
ProCyte, upon the terms and conditions set forth herein.
AGREEMENTS
NOW, THEREFORE, in consideration of the foregoing recitals and the
mutual promises contained below, it is agreed as follows:
1. Employment; Chairman of the Board
Effective August 12, 1996, Ashley's employment with ProCyte is
terminated and he has resigned as Chief Executive Officer and President of
ProCyte. Ashley will continue to serve as a Director and Chairman of the
Board of Directors through the next annual shareholders meeting, his
nomination and election thereafter being at the discretion of the Board of
Directors and/or shareholders, as the case may be.
2. Consulting Services
As and when requested by ProCyte, Ashley shall provide consulting
services to ProCyte until August 11, 1999 (the "Consulting Period");
provided, however, that the consulting services will be provided at mutually
agreed upon times at ProCyte's offices, Kirkland, Washington, or such other
locations reasonably requested by ProCyte and will not exceed an average of
eight (8) hours per week unless otherwise agreed. Ashley shall be reimbursed
for all preapproved, reasonable out-of-pocket business expenses incurred by
him in providing the consulting services upon presentation of an itemized
expense voucher, in a form prescribed by ProCyte, together with receipts or
other reasonable evidence or substantiation of these expenses.
3. Consideration
(a) Cash. In consideration of this Agreement, ProCyte shall pay Ashley
at an annual rate of $107,500 (i.e., approximately 50% of his current gross
base salary) at ProCyte's normal pay periods (currently every two weeks)
during the Consulting Period. In addition, ProCyte shall pay Ashley for a
period of up to eighteen (18) months after his termination of employment the
cost of any health insurance benefits he elects to continue under COBRA for
himself and/or his eligible dependents
(b) Tax Consequences. Because Ashley is an independent contractor, no
withholding of taxes will be made from the amounts paid pursuant to Section
3(a). Ashley assumes any and all tax obligations that may be imposed now or
at any future time with respect to such payments. Ashley shall indemnify and
hold harmless ProCyte and its responsible directors, officers, or managers
against any claims, assessments, liens, penalties, or judgments that may be
asserted against ProCyte or its directors, officers, or managers for
liability for unpaid taxes associated with the payments or treatment or
characterization of the payments to Ashley.
-42-
<PAGE>
(c) Stock Option. The stock option granted to Ashley on January 26, 1995
to purchase One Hundred Fifty Thousand (150,000) shares of ProCyte Common
Stock at $2.94 per share (the "Option") pursuant to ProCyte's 1989 Stock
Option Plan (the "Plan") shall continue to vest and be exercisable during the
term of Ashley's consulting services because his consulting relationship
constitutes a continuing relationship with ProCyte under the Plan, it being
recognized that the Option will become a nonqualified stock option and lose
its status as an incentive stock option. During the Consulting Period, Ashley
shall not be eligible for, and shall rescind, any stock option grants
pursuant to the 1991 Stock Option Plan for Nonemployee Directors or any other
stock option plan for nonemployee directors.
(d) Compensation as Director. During the Consulting Period, Ashley shall
not receive any compensation for his continuing service as a Director or
Chairman of the Board of Directors, other than reimbursement for his expenses.
4. Benefits
Except as expressly provided in this Agreement, all benefits to which
Ashley was entitled as of the date of termination of employment shall cease
as of the date of termination of employment, except Ashley's right to health
insurance benefits under COBRA, if Ashley elects, and his right, in
accordance with federal law, to leave his 401(k) contributions in ProCyte's
401(k) plan.
5. Reaffirmation of Prior Agreements
Ashley and ProCyte expressly reaffirm and incorporate herein as part of
this Agreement the following agreements:
(a) Indemnity Agreement. The Indemnity Agreement that Ashley signed
effective February 23, 1995, shall remain in full force and effect.
(b) Propriety Information and Invention Agreement. The Propriety
Information and Invention Agreement that Ashley signed effective January 29,
1987 shall remain in full force and effect, it being understood and agreed
that the provisions applicable or relating to employment shall also be
applicable or relate to his consulting services during the Consulting Period.
(c) Confidentiality and Computer Systems Agreement. The Confidentiality
and Computer Systems Agreement that Ashley signed effective January 28, 1994
shall remain in full force and effect.
6. Nonsolicitation
Ashley shall not directly or indirectly solicit or entice, or attempt to
solicit or entice, any employee, consultant, customer, research collaborator
or corporate partner of ProCyte to cease his, her, or its relationship with
ProCyte.
7. Cooperation in Ongoing Litigation
Ashley agrees to make himself available for, and to provide whatever
cooperation and assistance may be requested by ProCyte relating to, any
ongoing or future litigation in which ProCyte or any officer, director,
stockholder, manager, agent or representative of ProCyte is a party or has a
direct interest relating to matters occurring before or during Ashley's
employment with ProCyte or service on the Board of Directors, including,
without limitation, In re ProCyte Securities Litigation and any related
cases; provided, however, that Ashley will not be expected to spend time on
such matters in excess of the time he is to be consulting pursuant to Section
2 unless ProCyte has agreed to compensate him at a reasonable consulting fee
plus expenses. Ashley shall execute all documents in connection with such
matters as may be reasonably requested of him.
-43-
<PAGE>
8. No Disparagement
Ashley shall not make any disparaging or negative remarks to anyone,
either inside or outside of ProCyte, about ProCyte or ProCyte's business,
business practices, products, patents, technology, marketing strategy,
services, policies, judgments, decisions, officers, directors, or employees.
ProCyte shall not make any disparaging or negative remarks to anyone, either
inside or outside of ProCyte, about Ashley or Ashley's proposed business,
business practices, services, judgments or decisions.
9. General Release of Claims
Ashley expressly waives any claims against ProCyte and releases ProCyte
(including its officers, directors, shareholders, managers, agents and
representatives) from any claims that Ashley may have in any way arising out
of or connected with Ashley's employment with ProCyte. It is understood that
this release includes, but is not limited to, any claims for wages, bonuses,
employment benefits, or damages of any kind whatsoever, arising out of any
contracts, express or implied, any covenant of good faith and fair dealing,
express or implied, any theory of wrongful discharge, any legal restriction
on ProCyte's right to terminate employees, or any federal, state or other
governmental statute or ordinance, including, without limitation, Title VII
of the Civil Rights Act of 1964, the federal Age Discrimination in Employment
Act, the Americans with Disabilities Act, the Washington Law Against
Discrimination, or any other legal limitation on the employment relationship.
Ashley represents that he has not filed any complaints, charges or
lawsuits against ProCyte with any governmental agency or any court, and
agrees that he shall not initiate, assist or encourage any such actions.
This waiver and release shall not waive or release claims where the
events in dispute first arise after execution of this Agreement, nor shall it
preclude Ashley from filing a lawsuit for the exclusive purpose of enforcing
Ashley's rights under this Agreement.
10. Severability
The provisions of this Agreement are severable, and if any part of it is
found to be unlawful or unenforceable, the other provisions of this Agreement
shall remain fully valid and enforceable to the maximum extent consistent
with applicable law.
11. Knowing and Voluntary Agreement
Ashley represents and agrees that he has read this Agreement,
understands its terms and the fact that it releases any claim he might have
against ProCyte and its agents, understands that he has the right to consult
counsel of choice and has done so, or knowingly waives the right to do so,
and enters into this Agreement without duress or coercion from any source.
12. Entire Agreement
This Agreement sets forth the entire understanding between Ashley and
ProCyte and supersedes and cancels the Key Executive Severance Agreement
dated as of February 23, 1995 and any other prior agreements or
understandings, express or implied, with respect to the subject matter
hereof, including the terms of Ashley's consulting services to be provided to
ProCyte and the termination of his relationship as an employee and officer.
Ashley acknowledges that in executing this Agreement, Ashley does not rely
upon any representation or statement by ProCyte or any representative of
ProCyte concerning the subject matter of this Agreement, except as expressly
set forth in the text of this Agreement.
-44-
<PAGE>
IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first set forth above.
PROCYTE CORPORATION
By: /S/ Thomas E. Tierney
---------------------------------
THOMAS E. TIERNEY
CHAIRMAN, COMPENSATION COMMITTEE
By: /S/ Joseph Ashley
---------------------------------
JOSEPH ASHLEY
-45-
<PAGE>
EXHIBIT 10.11
CHANGE OF CONTROL AGREEMENT BETWEEN
PROCYTE CORPORATION AND JOHN F. CLIFFORD
This Change of Control Agreement (this "Agreement"), dated as of August 12,~,
1996, is between PROCYTE CORPORATION, a Washington corporation (the
"Company"), and JOHN F. CLIFFORD (the "Executive").
The Board of Directors of the Company (the "Board") has determined that it is
in the best interests of the Company and its stockholders to ensure that the
Company will have the continued dedication of the Executive, notwithstanding
the possibility, threat or occurrence of a Change of Control (as defined in
Section 1.1 below) of the Company. The Board believes it is imperative to
diminish the inevitable distraction of the Executive arising from the
personal uncertainties and risks created by a pending or threatened Change of
Control, to encourage the Executive's full attention and dedication to the
Company currently and in the event of any threatened or pending Change of
Control, and to provide the Executive with reasonable compensation and
benefit arrangements upon a Change of Control.
In order to accomplish these objectives, the Board has caused the Company to
enter into this Agreement.
1. DEFINITIONS
1.1 Change of Control
Shall have the definition set forth in Appendix A to this Agreement, which is
hereby incorporated by reference.
1.2 Change of Control Date
Shall mean the first date on which a Change of Control occurs.
1.3 Employment Period
Shall mean the two-year period commencing on the Change of Control Date and
ending on the second anniversary of such date.
2. TERM
The term of this Agreement ("Term") shall be for a period of two (2) years
from the date of this Agreement as first entered above, at which time this
Agreement shall terminate without further action by either the Company or the
Executive; provided, however, that if a Change in Control occurs during the
Term, the Term shall automatically extend for the duration of the Employment
Period.
3. EMPLOYMENT
3.1 Employment Period
During the Employment Period, the Company hereby agrees to continue the
Executive in its employ or in the employ of its affiliated companies, and the
Executive hereby agrees to remain in the employ of the Company or its
affiliated companies, in accordance with the terms and provisions of this
Agreement; provided, however, that either the Company or the Executive may
terminate the employment relationship subject to the terms of this Agreement.
3.2 Position and Duties
During the Employment Period, the Executive's position, authority, duties and
responsibilities shall be at least commensurate in all material respects with
the most significant of those held, exercised and assigned at any time during
the 90-day period immediately preceding the Change of Control Date.
-46-
<PAGE>
3.3 Location
During the Employment Period, the Executive's services shall be performed at
the Company's headquarters on the Change of Control Date or any office which
is subsequently designated as the headquarters of the Company and is less
than 30 miles from such location.
3.4 Employment at Will
The Executive and the Company acknowledge that, except as may otherwise be
provided under any other written agreement between The Executive and the
Company, the employment of the Executive by the Company or its affiliated
companies is "at will" and may be terminated by either the Executive or the
Company or its affiliated companies at any time with or without cause.
Moreover, if prior to the Change of Control Date, the Executive's employment
with the Company or its affiliated companies terminates for any reason, then
the Executive shall have no further rights under this Agreement; provided,
however, that Company may not avoid liability for any termination payments
which would have been required during the Employment Period pursuant to
Section 8 below by terminating the Executive prior to the Employment Period
where such termination is carried out in anticipation of a Change of Control
and the principal motivating purpose is to avoid liability for such
termination payments.
3.5 Board of Directors
The Executive is currently a member of the Board but his continuation as such
shall be subject to the will of the Company's stockholders and the Board, as
provided in the Company's by-laws and certificate of incorporation. Removal
of the-Executive from, or nonelection of the Executive to, the Board by the
Company's stockholders or the Board, as provided in the Company's by-laws and
certificate of incorporation, shall in no event be deemed a breach of this
Agreement by the Company.
4. ATTENTION AND EFFORT
During the Employment Period, and excluding any periods of vacation and sick
leave to which the Executive is entitled, the Executive will devote all of
his productive time, ability, attention and effort to the business and
affairs of the Company and the discharge of the responsibilities assigned to
him hereunder, and will use his reasonable best efforts to perform faithfully
and efficiently such responsibilities. It shall not be a violation of this
Agreement for the Executive to (a) serve on corporate, civic or charitable
boards or committees, (b) deliver lectures, fulfill speaking engagements or
teach at educational institutions, and (c) manage personal investments, so
long as such activities do not significantly interfere with the performance
of the Executive's responsibilities in accordance with this Agreement. It is
expressly understood and agreed that to the extent any such activities have
been conducted by the Executive prior to the Employment Period, the continued
conduct of such activities (or the conduct of activities similar in nature
and scope thereto) during the Employment Period shall not thereafter be
deemed to interfere with the performance of the Executive's responsibilities
to the Company.
5. COMPENSATION
As long as the Executive remains employed by the Company during the
Employment Period, the Company agrees to pay or cause to be paid to the
Executive, and the Executive agrees to accept in exchange for the services
rendered hereunder by him, the following compensation:
5.1 Salary
The Executive shall receive an annual base salary (the "Annual Base Salary"),
at least equal to the annual salary established by the Board or the
Compensation Committee of the Board (the "Compensation Committee") or the
Chief Executive Officer for the fiscal year in which the Change of Control
Date occurs. The Annual Base Salary shall be paid in substantially equal
installments and at the same intervals as the salaries of other executives of
the Company are paid. The Board or the Compensation Committee or the Chief
Executive Officer shall review the Annual Base Salary at least annually and
shall determine in good faith and consistent with any generally applicable
Company policy any increases for future years.
-47-
<PAGE>
5.2 Bonus
In addition to Annual Base Salary, the Executive shall be awarded, for each
fiscal year ending during the Employment Period, an annual bonus (the "Annual
Bonus") in cash at least equal to the average annualized (for any fiscal year
consisting of less than 12 full months) bonus paid or payable, including by
reason of any deferral, to the Executive by the Company and its affiliated
companies in respect of the three fiscal years immediately preceding the
fiscal year in which the Change of Control Date occurs. Each such Annual
Bonus shall be paid no later than 90 days after the end of the fiscal year
for which the Annual Bonus is awarded, unless the Executive shall elect to
defer the receipt of such Annual Bonus.
6. BENEFITS
6.1 Incentive, Retirement and Welfare Benefit Plans; Vacation
During the Employment Period, the Executive shall be entitled to participate,
subject to and in accordance with applicable eligibility requirements, in
such fringe benefit programs as shall be generally made available to other
executives of the Company and its affiliated companies from time to time
during the Employment Period by action of the Board (or any person or
committee appointed by the Board to determine fringe benefit programs and
other emoluments), including, without limitation, paid vacations; any stock
purchase, savings or retirement plan, practice, policy or program; and all
welfare benefit plans, practices, policies or programs (including, without
limitation, medical, prescription, dental, disability, salary continuance,
employee life, group life, accidental death and travel accident insurance
plans or programs).
6.2 Expenses
During the Employment Period, the Executive shall be entitled to receive
prompt reimbursement for all reasonable employment expenses incurred by him
in accordance with the policies, practices and procedures of the Company and
its affiliated companies in effect for the executives of the Company and its
affiliated companies during the Employment Period.
7. TERMINATION
During the Employment Period, employment of the Executive may be terminated
as follows but, in any case, the nondisclosure provisions set forth in
Section 10 hereof shall survive the termination of this Agreement and the
termination of the Executive's employment with the Company:
7.1 By the Company or the Executive
At any time during the Employment Period, the Company may terminate the
employment of the Executive with or without Cause (as defined below), and the
Executive may terminate his employment for Good Reason (as defined below) or
for any reason, upon giving Notice of Termination (as defined below).
7.2 Automatic Termination
This Agreement and the Executive's employment during the Employment Period
shall terminate automatically upon the death or Total Disability of the
Executive. The term "Total Disability" as used herein shall mean the
Executive's inability (with such accommodation as may be required by law and
which places no undue burden on the Company), as determined by a physician
selected by the Company and acceptable to the Executive, to perform the
duties set forth in Section 3.2 hereof for a period or periods aggregating
120 calendar days in any 12-month period as a result of physical or mental
illness, loss of legal capacity or any other cause beyond the Executive's
control, unless the Executive is granted a leave of absence by the Board. The
Executive and the Company hereby acknowledge that the duties specified in
Section 3.2 hereof are essential to Executive's position and that Executive's
ability to perform those duties is the essence of this Agreement.
-48-
<PAGE>
7.3 Notice of Termination
Any termination by the Company or by the Executive during the Employment
Period shall be communicated by Notice of Termination to the other party
given in accordance with Section 12 hereof. The term "Notice of Termination"
shall mean a written notice which (a) indicates the specific termination
provision in this Agreement relied upon and (b) to the extent applicable,
sets forth in reasonable detail the facts and circumstances claimed to
provide a basis for termination of the Executive's employment under the
provision so indicated. The failure by the Executive or the Company to set
forth in the Notice of Termination any fact or circumstance which contributes
to a showing of Good Reason or Cause shall not waive any right of the
Executive or the Company hereunder or preclude the Executive or the Company
from asserting such fact or circumstance in enforcing the Executive's or the
Company's rights hereunder.
7.4 Date of Termination
During the Employment Period, "Date of Termination" means (a) if the
Executive's employment is terminated by reason of death, at the end of the
calendar month in which the Executive's death occurs, (b) if the Executive's
employment is terminated by reason of Total Disability, immediately upon a
determination by the Company of the Executive's Total Disability, and (c) in
all other cases, five days after the date of personal delivery or mailing of
the Notice of Termination. The Executive's employment and performance of
services will continue during such five-day period; provided, however, that
the Company may, upon notice to the Executive and without reducing the
Executive's compensation during such period, excuse the Executive from any or
all of his duties during such period.
8. TERMINATION PAYMENTS
In the event of termination of the Executive's employment during the
Employment Period, all compensation and benefits set forth in this Agreement
shall terminate except as specifically provided in this Section 8.
8.1 Termination by the Company Other Than for Cause or by the Executive for
Good Reason
If during the Employment Period the Company terminates the Executive's
employment other than for Cause or the Executive terminates his employment
for Good Reason, the Executive shall be entitled to:
(a) receive payment of the following accrued obligations (the "Accrued
Obligations"):
(i) the Executive's Annual Base Salary through the Date of Termination
to the extent not theretofore paid;
(ii) the product of (x) the Annual Bonus payable with respect to the
fiscal year in which the Date of Termination occurs and (y) a
fraction, the numerator of which is the number of days in the
current fiscal year through the Date of Termination, and the
denominator of which is 365; and
(iii) any compensation previously deferred by the Executive (together with
accrued interest or earnings thereon, if any) and any accrued
vacation pay which would be payable under the Company's standard
policy, in each case to the extent not theretofore paid;
(b) for one year after the Date of Termination, the Company shall pay the
Executive's premiums for health insurance benefit continuation for
Executive and his family members, if applicable, which the Company
provides to the Executive under the provisions of the federal
Comprehensive Omnibus Budget Reconciliation Act of 1986, as amended
("COBRA") to the extent that the Company would have paid such premiums had
the Executive remained employed by the Company (such continued payment is
hereinafter referred to as "COBRA Continuation"); and
(c) an amount as severance pay equal to two (2) times the Annual Base Salary
for the fiscal year in which the Date of Termination occurs.
-49-
<PAGE>
8.2 Termination for Cause or Other Than for Good Reason
If during the Employment Period the Executive's employment shall be
terminated by the Company for Cause or by the Executive for other than Good
Reason, this Agreement shall terminate without further obligation on the part
of the Company to the Executive, other than the Company's obligation to pay
the Executive (a) his Annual Base Salary through the Date of Termination, (b)
the amount of any compensation previously deferred by the Executive, and (c)
any accrued vacation pay which would be payable under the Company's standard
policy, in each case to the extent theretofore unpaid.
8.3 Expiration of Term
In the case of a termination of the Executive's employment as a result of the
expiration of the Term of this Agreement, this Agreement shall terminate
without further obligation on the part of the Company to the Executive, other
than the Company's obligation to pay the Executive the Accrued Obligations.
8.4 Termination Because of Death or Total Disability
If during the Employment Period the Executive's employment is terminated by
reason of the Executive's death or Total Disability, this Agreement shall
terminate automatically without further obligation on the part of the Company
to the Executive or his legal representatives under this Agreement, other
than the Company's obligation to pay the Executive the Accrued Obligations
(which shall be paid to the Executive's estate or beneficiary, as applicable
in the case of the Executive's death), and to provide COBRA Continuation.
8.5 Payment Schedule
All payments of Accrued Obligations, or any portion thereof payable pursuant
to this Section 8, shall be made to the Executive within ten working days of
the Date of Termination. Any payments payable to the Executive pursuant to
Section 8.1 (c) shall be made to the Executive, at Company option, either (a)
in a lump sum within ten working days of the Date of Termination; or (b) in
two equal payments the first of which is made within ten working days of the
Date of Termination and the second of which is made within six months of the
Date of Termination.
8.6 Cause
For purposes of this Agreement, "Cause" means cause given by the Executive to
the Company and shall include, without limitation, the occurrence of one or
more of the following events:
(a) A clear refusal to carry out any material lawful duties of the Executive
or any directions of the Board or senior management of the Company, all
reasonably consistent with the duties described in Section 3.2 hereof;
(b) Persistent failure to carry out any lawful duties of the Executive
described in Section 3.2 hereof or any directions of the Board or senior
management reasonably consistent with the duties herein set forth to be
performed by the Executive, provided Executive has been given reasonable
notice and opportunity to correct any such failure;
(c) Violation by the Executive of a state or federal criminal law involving
the commission of a crime against the Company or any other criminal act
involving moral turpitude;
(d) Current abuse by the Executive of alcohol or controlled substances;
deception, fraud, misrepresentation or dishonesty by the Executive; any
incident materially compromising the Executive's reputation or ability to
represent the Company with investors, customers or the public; or
(e) Any other material violation of any provision of this Agreement by the
Executive, subject to the notice and opportunity to cure requirements of
Section 1 1.
-50-
<PAGE>
8.7 Good Reason
For purposes of this Agreement, "Good Reason" means
(a) The assignment to the Executive of any duties materially inconsistent with
the Executive's position, authority, duties or responsibilities as
contemplated by Section 3.2 hereof or any other action by the Company
which results in a material diminution in such position, authority, duties
or responsibilities, excluding for this purpose an isolated and
inadvertent action not taken in bad faith and which is remedied by the
Company promptly after receipt of notice thereof given by the Executive;
(b) Any failure by the Company to comply with any of the. provisions of
Section 5 or Section 6 hereof, other than an isolated and inadvertent
failure not taken in bad faith and which is remedied by the Company
promptly after receipt of notice thereof given by the Executive;
(c) The Company's requiring the Executive to be based at any office or
location other than that described in Section 3.3 hereof;
(d) Any failure by the Company to comply with and satisfy Section 13 hereof,
provided that the Company's successor has received at least ten days'
prior written notice from the Company or the Executive of the requirements
of Section 13 hereof; or
(e) Any other material violation of any provision of this Agreement by the
Company, subject to the notice and opportunity to cure requirements of
Section 11.
8.8 Excess Parachute Limitation
If either the Company or the Executive receives confirmation from the
Company's independent tax counsel or its certified public accounting firm, or
such other accounting firm retained as independent certified public
accountants for the Company (the "Tax Advisor"), that any payment by the
Company to the Executive under this Agreement or otherwise would be
considered to be an "excess parachute payment" within the meaning of Section
280G of the Internal Revenue Code of 1986, as amended, or any successor
statute then in effect (the "Code"), then the aggregate payments by the
Company pursuant to this Agreement shall be reduced to the highest amount
that may be paid to the Executive by the Company under this Agreement without
having any portion of any amount payable to the Executive by the Company or a
related entity under this Agreement or otherwise treated as such an "excess
parachute payment", and, if permitted by applicable law and without adverse
tax consequence, such reduction shall be made to the last payment due
hereunder. Any payments made by the Company to the Executive under this
Agreement which are later confirmed by the Tax Advisor to be "excess
parachute payments" shall be considered by all parties to have been a loan by
the Company to the Executive, which loan shall be repaid by the Executive
upon demand together with interest calculated at the lowest interest rate
authorized for such loans under the Code without a requirement that further
interest be imputed.
9. REPRESENTATIONS, WARRANTIES AND OTHER CONDITIONS
In order to induce the Company to enter into this Agreement, the Executive
represents and warrants to the Company as follows:
9.1 Health
The Executive is in good health and knows of no physical or mental disability
which, with any accommodation which may be required by law and which places
no undue burden on the Company, would prevent him from fulfilling his
obligations hereunder. The Executive agrees, if the Company requests, to
submit to reasonable periodic medical examinations by a physician or
physicians designated by, paid for and arranged by the Company. The Executive
agrees that the examination's medical report shall be provided to the Company.
9.2 No Violation of Other Agreements
The Executive represents that neither the execution nor the performance of
this Agreement by the Executive will violate or conflict in any way with any
other agreement by which the Executive may be bound.
-51-
<PAGE>
10. NONDISCLOSURE; RETURN OF MATERIALS
10.1 Nondisclosure
Except as required by his employment with the Company, the Executive will
not, at any time during the term of employment by the Company, or at any time
thereafter, directly, indirectly or otherwise, use, communicate, disclose,
disseminate, lecture upon or publish articles relating to any confidential,
proprietary or trade secret information without the prior written consent of
the Company. The Executive understands that the Company will be relying on
this Agreement in continuing the Executive's employment, paying him
compensation, granting him any promotions or raises, or entrusting him with
any information which helps the Company compete with others.
10.2 Return of Materials
All documents, records, notebooks, notes, memoranda, drawings or other
documents made or compiled by the Executive at any time, or in his
possession, including any and all copies thereof, shall be the property of
the Company and shall be held by the Executive in trust and solely for the
benefit of the Company, and shall be delivered to the Company by the
Executive upon termination of employment or at any other time upon request by
the Company.
11. NOTICE AND CURE OF BREACH
Whenever a breach of this Agreement by either party is relied upon as
justification for any action taken by the other party pursuant to any
provision of this Agreement, other than clause (a), (b), (c) or (d) of
Section 8.6 hereof, before such action is taken, the party asserting the
breach of this Agreement shall give the other party at least ten days' prior
written notice of the existence and the nature of such breach before taking
further action hereunder and shall give the party purportedly in breach of
this Agreement the opportunity to correct such breach during the ten-day
period.
12. FORM OF NOTICE
Every notice required by the terms of this Agreement shall be given in
writing by serving the same upon the party to whom it was addressed
personally or by registered or certified mail, return receipt requested, at
the address set forth below or at such other address as may hereafter be
designated by notice given in compliance with the terms hereof:
If to the Executive: John F. Clifford
If to the Company: ProCyte Corporation
12040 l 15th Avenue N.E., Suite 210
Kirkland, Washington 98034
Attn: Corporate Secretary
With a copy to: Perkins Coie
Attn: James R. Lisbakken
1201 Third Avenue, 40th Floor
Seattle, Washington 98101-3099
Except as set forth in Section 7.4 hereof, if notice is mailed, such notice
shall be effective upon mailing.
-52-
<PAGE>
13. ASSIGNMENT
This Agreement is personal to the Executive and shall not be assignable by
the Executive. The Company shall assign to and require any successor
(whether direct or indirect, by purchase, merger, consolidation or otherwise)
to all or substantially all the business and/or assets of the Company to
assume expressly and agree to perform this Agreement in the same manner and
to the same extent that the Company would be required to perform it if no
such succession had taken place. As used in this Agreement, "Company" shall
mean ProCyte Corporation and any successor to its business and/or assets as
aforesaid which assumes and agrees to perform this Agreement by operation of
law, or otherwise. All the terms and provisions of this Agreement shall be
binding upon and inure to the benefit of and be enforceable by the parties
hereto and their respective successors and permitted assigns.
14. WAIVERS
No delay or failure by any party hereto in exercising, protecting or
enforcing any of its rights, titles, interests or remedies hereunder, and no
course of dealing or performance with respect thereto, shall constitute a
waiver thereof. The express waiver by a party hereto of any right, title,
interest or remedy in a particular instance or circumstance shall not
constitute a waiver thereof in any other instance or circumstance. All rights
and remedies shall be cumulative and not exclusive of any other rights or
remedies.
15. AMENDMENTS IN WRITING
No amendment, modification, waiver, termination or discharge of any provision
of this Agreement, nor consent to any departure therefrom by either party
hereto, shall in any event be effective unless the same shall be in writing,
specifically identifying this Agreement and the provision intended to be
amended, modified, waived, terminated or discharged and signed by the Company
and the Executive, and each such amendment, modification, waiver, termination
or discharge shall be effective only in the specific instance and for the
specific purpose for which given. No provision of this Agreement shall be
varied, contradicted or explained by any oral agreement, course of dealing or
performance or any other matter not set forth in an agreement in writing and
signed by the Company and the Executive.
16. APPLICABLE LAW
This Agreement shall in all respects, including all matters of construction,
validity and performance, be governed by, and construed and enforced in
accordance with, the laws of the State of Washington, without regard to any
rules governing conflicts of laws.
17. ARBITRATION; ATTORNEYS' FEES
Except in connection with enforcing Section 10 of this Agreement, for which
legal and equitable remedies may be sought in a court of law, any dispute
arising under this Agreement shall be subject to arbitration. The arbitration
proceeding shall be conducted in accordance with the Commercial Arbitration
Rules of the American Arbitration Association then in effect, conducted by
one arbitrator either mutually agreed upon or selected in accordance with the
AAA Rules. The arbitration shall be conducted in King County, Washington
under the jurisdiction of the Seattle office of the American Arbitration
Association. The arbitrator shall have authority only to interpret and apply
the provisions of this Agreement, and shall have no authority to add to,
subtract from, or otherwise modify the terms of this Agreement. Any demand
for arbitration must be made within sixty (60) days of the event(s) giving
rise to the claim that this Agreement has been breached. The arbitrator's
decision shall be final and binding, and each party agrees to be bound to by
arbitrator's award subject only to an appeal therefrom in accordance with the
laws of the State of Washington. Either party may obtain judgment upon the
arbitrator's award in the Superior Court of King, County, Washington.
-53-
<PAGE>
If it becomes necessary to pursue or defend any legal proceeding, whether in
arbitration or court, in order to resolve a dispute arising under this
Agreement, the prevailing party in any such proceeding shall be entitled to
recover its reasonable costs and attorneys' fees.
18. SEVERABILITY
If any provision of this Agreement shall be held invalid, illegal or
unenforceable in any jurisdiction, for any reason, including, without
limitation, the duration of such provision, its geographical scope or the
extent of the activities prohibited or required by it, then, to the full
extent permitted by law, (a) all other provisions hereof shall remain in full
force and effect in such jurisdiction and shall be liberally construed in
order to carry out the intent of the parties hereto as nearly as may be
possible, (b) such invalidity, illegality or unenforceability shall not
affect the validity, legality or enforceability of any other provision
hereof, and (c) any court or arbitrator having jurisdiction thereover shall
have the power to reform such provision to the extent necessary for such
provision to be enforceable under applicable law.
19. ENTIRE AGREEMENT
This Agreement on and as of the date hereof constitutes the entire agreement
between the Company and the Executive with respect to the subject matter
hereof and all prior or contemporaneous oral or written communications,
understandings or agreements between the Company and the Executive with
respect to such subject matter are hereby superseded and nullified in their
entireties, except that the Proprietary Information and Invention Agreement
between the Executive and the Company shall continue in full force and effect
to the extent not superseded by Section 10 hereof.
20. WITHHOLDING
The Company may withhold from any amounts payable under this Agreement such
federal, state or local taxes as shall be required to be withheld pursuant to
any applicable law or regulation.
21. COUNTERPARTS
This Agreement may be executed in counterparts, each of which counterpart
shall be deemed an original, but all of which together shall constitute one
and the same instrument.
IN WITNESS WHEREOF, the parties have executed and entered into this Agreement
effective on the date first set forth above.
EXECUIVE
By: /S/ John F. Clifford
---------------------------------
JACK CLIFFORD
PROCYTE CORPORATION
By: /S/ Karen L. Kedine
---------------------------------
KAREN L. HEDINE
Its: Vice President Business Development & Administration
-54-
<PAGE>
Appendix A to
Change of Control Agreement Between
ProCyte Corporation and John F. Clifford
For purposes of this Agreement, a "Change of Control" shall mean:
(a) A "Board Change" which, for purposes of this Agreement, shall have
occurred if a majority (excluding vacant seats) of the seats on the
Company's Board are occupied by individuals who were neither (i)
nominated by a majority of the Incumbent Directors nor (ii) appointed
by directors so nominated. An "Incumbent Director" is a member of the
Board who has been either (i) nominated by a majority of the directors
of the Company then in office or (ii) appointed by directors so
nominated, but excluding, for this purpose, any such individual whose
initial assumption of office occurs as a result of either an actual or
threatened election contest (as such terms are used in Rule 14a-11 of
Regulation 14A promulgated under the Securities Exchange Act of 1934,
as amended (the "Exchange Act")) or other actual or threatened
solicitation of proxies or consents by or on behalf of a Person (as
hereinafter defined) other than the Board; or
(b) The acquisition by any individual, entity or group (within the meaning
of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a "Person") of
beneficial ownership (within the meaning of Rule 13d-3 promulgated
under the Exchange Act) of (i) 20% or more of either (A) the then
outstanding shares of Common Stock of the Company (the "Outstanding
Company Common Stock") or (B) the combined voting power of the then
outstanding voting securities of the Company entitled to vote
generally in the election of directors (the "Outstanding Company
Voting Securities"), in the case of either (A) or (B) of this clause
(i), which acquisition is not approved in advance by a majority of the
Incumbent Directors, or (ii) 33% or more of either (A) the Outstanding
Company Common Stock or (B) the Outstanding Company Voting Securities,
in the case of either (A) or (B) of this clause (ii), which
acquisition is approved in advance by a majority of the Incumbent
Directors; provided, however, that the following acquisitions shall
not constitute a Change of Control: (x) any acquisition by the
Company, (y) any acquisition by any employee benefit plan (or related
trust) sponsored or maintained by the Company or any corporation
controlled by the Company or (z) any acquisition by any corporation
pursuant to a reorganization, merger or consolidation, if, following
such reorganization, merger or consolidation, the conditions described
in clauses (i), (ii) and (iii) of subsection (c) of this Appendix A
are satisfied; or
(c) Approval by the stockholders of the Company of a reorganization,
merger or consolidation, in each case, unless, immediately following
such reorganization, merger or consolidation, (i) more than 60% of,
respectively, the then outstanding shares of common stock of the
corporation resulting from such reorganization, merger or
consolidation and the combined voting power of the then outstanding
voting securities of such corporation entitled to vote generally in
the election of directors is then beneficially owned, directly or
indirectly, by all or substantially all the individuals and entities
who were the beneficial owners, respectively, of the Outstanding
Company Common Stock and the Outstanding Company Voting Securities
immediately prior to such reorganization, merger or consolidation in
substantially the same proportion as their ownership immediately prior
to such reorganization, merger or consolidation of the Outstanding
Company Common Stock and the Outstanding Company Voting Securities, as
the case may be, (ii) no Person (excluding the Company, any employee
benefit plan (or related trust) of the Company or such corporation
resulting from such reorganization, merger or consolidation and any
Person beneficially owning, immediately prior to such reorganization,
merger or consolidation, directly or indirectly, 33% or more of the
Outstanding Company Common Stock or the Outstanding Voting Securities,
as the case may be) beneficially owns, directly or indirectly, 33% or
more of, respectively, the then outstanding shares of common stock of
the corporation resulting from such reorganization, merger or
consolidation or the combined voting power of the then outstanding
voting securities of such corporation entitled to vote generally in
the election of directors, and (iii) at least a majority of the
members of the board of directors of the corporation resulting from
such reorganization, merger or consolidation were the Incumbent
Directors at the time of the execution of the initial agreement
providing for such reorganization, merger or consolidation; or
-55-
<PAGE>
(d) Approval by the stockholders of the Company of (i) a complete
liquidation or dissolution of the Company or (ii) the sale or other
disposition of all or substantially all the assets of the Company,
other than to a corporation with respect to which immediately
following such sale or other disposition, (A) more than 60% of,
respectively, the then outstanding shares of common stock of such
corporation and the combined voting power of the then outstanding
voting securities of such corporation entitled to vote generally in
the election of directors is then beneficially owned, directly or
indirectly, by all or substantially all the individuals and entities
who were the beneficial owners, respectively, of the Outstanding
Company Common Stock and the Outstanding Company Voting Securities
immediately prior to such sale or other disposition in substantially
the same proportion as their ownership, immediately prior to such sale
or other disposition, of the Outstanding Company Common Stock and the
Outstanding Company Voting Securities, as the case may be, (B) no
Person (excluding the Company, any employee benefit plan (or related
trust) of the Company or such corporation and any Person beneficially
owning, immediately prior to such sale or other disposition, directly
or indirectly, 33% or more of the Outstanding Company Common Stock or
the Outstanding Company Voting Securities, as the case may be)
beneficially owns, directly or indirectly, 33% or more of,
respectively, the then outstanding shares of common stock of such
corporation and the combined voting power of the then outstanding
voting securities of such corporation entitled to vote generally in
the election of directors and (C) at least a majority of the members
of the board of directors of such corporation were approved by a
majority of the Incumbent Directors at the time of the execution of
the initial agreement or action of the Board providing for such sale
or other disposition of assets of the Company.
-56-
<PAGE>
EXHIBIT 10.13
KEY EXECUTIVE SEVERANCE AGREEMENT
BETWEEN PROCYTE CORPORATION AND MR. JOHN F. CLIFFORD
This Key Executive Severance Agreement (this "Agreement"), dated and
effective as of February 19, 1997, is between PROCYTE CORPORATION, a
Washington corporation (the "Company"), and JOHN F. CLIFFORD (the
"Executive").
The Board of Directors of the Company (the "Board") has determined that it is
in the best interests of the Company and its stockholders to ensure that the
Company will have the continued dedication of the Executive, notwithstanding
the fact that the Executive does not have any form of traditional employment
contract or other assurance of job security. The Board believes it is
imperative to diminish any distraction of the Executive arising from the
personal uncertainty and insecurity that arises in the absence of any
assurance of job security by providing the Executive with reasonable
compensation and benefit arrangements in the event of termination of
Executive's employment by the Company under certain defined circumstances.
In order to accomplish these objectives, the Board has caused the Company to
enter into this Agreement.
1. TERM
The term of this Agreement ("Term") shall be for a period of two (2) years
from the date of this Agreement as first entered above, at which time this
Agreement shall terminate without further action by either the Company or the
Executive.
2. EMPLOYMENT
The Executive and the Company acknowledge that, except as may otherwise be
provided under any other written agreement between the Executive and the
Company, the employment of the Executive by the Company or by any affiliated
or successor company is "at will" and may be terminated by either the
Executive or the Company or its affiliated companies at any time with or
without cause, subject to the termination payments prescribed herein.
3. ATTENTION AND EFFORT
During any period of time that Executive remains in the employ of the
Company, and excluding any periods of vacation and sick leave to which the
Executive is entitled, the Executive will devote all of his productive time,
ability, attention and effort to the business and affairs of the Company and
the discharge of the responsibilities assigned to him hereunder, and will use
his reasonable best efforts to perform faithfully and efficiently such
responsibilities. It shall not be a violation of this Agreement for the
Executive to (a) serve on corporate, civic or charitable boards or
committees, (b) deliver lectures, fulfill speaking engagements or teach at
educational institutions, and (c) manage personal investments, so long as
such activities do not significantly interfere with the performance of the
Executive's responsibilities in accordance with this Agreement. It is
expressly understood and agreed that to the extent any such activities have
been conducted by the Executive prior to the Term, the continued conduct of
such activities (or the conduct of activities similar in nature and scope
thereto) during the Term shall not thereafter be deemed to interfere with the
performance of the Executive's responsibilities to the Company.
4. TERMINATION
During the Term, employment of the Executive may be terminated as follows
but, in any case, the nondisclosure provisions set forth in Section 7 hereof
shall survive the termination of this Agreement and the termination of the
Executive's employment with the Company:
-57-
<PAGE>
4.1 By the Company or the Executive
At any time during the Term, the Company may terminate the employment of the
Executive with or without Cause (as defined below), and the Executive may
terminate his employment for Good Reason (as defined below) or for any
reason, upon giving Notice of Termination (as defined below).
4.2 Automatic Termination
This Agreement and the Executive's employment shall terminate automatically
upon the death or Total Disability of the Executive. The term "Total
Disability" as used herein shall mean the Executive's inability (with such
accommodation as may be required by law and which places no undue burden on
the Company), as determined by a physician selected by the Company and
acceptable to the Executive, to perform the Executive's essential duties for
a period or periods aggregating 120 calendar days in any 12-month period as a
result of physical or mental illness, loss of legal capacity or any other
cause beyond the Executive's control, unless the Executive is granted a leave
of absence by the Board.
4.3 Notice of Termination
Any termination by the Company or by the Executive during the Term shall be
communicated by Notice of Termination to the other party given in accordance
with Section 9 hereof. The term "Notice of Termination" shall mean a written
notice which (a) indicates the specific termination provision in this
Agreement relied upon and (b) to the extent applicable, sets forth in
reasonable detail the facts and circumstances claimed to provide a basis for
termination of the Executive's employment under the provision so indicated.
The failure by the Executive or the Company to set forth in the Notice of
Termination any fact or circumstance which contributes to a showing of Good
Reason or Cause shall not waive any right of the Executive or the Company
hereunder or preclude the Executive or the Company from asserting such fact
or circumstance in enforcing the Executive's or the Company's rights
hereunder.
4.4 Date of Termination
"Date of Termination" means (a) if the Executive's employment is terminated
by reason of death, the last day of the calendar month in which the
Executive's death occurs, (b) if the Executive's employment is terminated by
reason of Total Disability, immediately upon a determination by the Company
of the Executive's Total Disability, and (c) in all other cases, five days
after the date of personal delivery or mailing of the Notice of Termination.
The Executive's employment and performance of services will continue during
such five-day period; provided, however, that the Company may, upon notice to
the Executive and without reducing the Executive's compensation during such
period, excuse the Executive from any or all of his duties during such period.
5. TERMINATION PAYMENTS
In the event of termination of the Executive's employment during the Term,
all compensation and benefits shall terminate except as specifically provided
in this Section 5.
5.1 Termination by the Company Other Than for Cause or by the Executive for
Good Reason
If during the Term the Company terminates the Executive's employment other
than for Cause or the Executive terminates his employment for Good Reason,
the Executive shall be entitled to:
(a) receive payment of the following accrued obligations (the "Accrued
Obligations"):
(i) the Executive's then current annual base salary through the Date
of Termination to the extent not theretofore paid; and
(ii) any compensation previously deferred by the Executive (together
with accrued interest or earnings thereon, if any) and any
accrued vacation pay which would be payable under the Company's
standard policy, in each case to the extent not theretofore paid;
-58-
<PAGE>
(b) for twelve months after the Date of Termination, the Company shall pay
the Executive's premiums for health insurance benefit continuation for
Executive and his family members, if applicable, which the Company
provides to the Executive under the provisions of the federal
Comprehensive Omnibus Budget Reconciliation Act of 1986, as amended
("COBRA") to the extent that the Company would have paid such premiums
had the Executive remained employed by the Company (such continued
payment is hereinafter referred to as "COBRA Continuation"); and
(c) an amount as severance pay equal to one times the Executive's then
current annual base salary for the fiscal year in which the Date of
Termination occurs, subject to payment and potential reduction as set
forth in Section 5.5 hereof
5.2 Termination for Cause or Other Than for Good Reason
If during the Term the Executive's employment shall be terminated by the
Company for Cause or by the Executive for other than Good Reason, this
Agreement shall terminate without further obligation on the part of the
Company to the Executive, other than the Company's obligation to pay the
Executive the Accrued Obligations to the extent theretofore unpaid.
5.3 Expiration of Term
In the case of a termination of the Executive's employment at the expiration
of the Term, this Agreement shall terminate without further obligation on the
part of the Company to the Executive, other than the Company's obligation to
pay the Executive the Accrued Obligations.
5.4 Termination Because of Death or Total Disability
If the Executive's employment is terminated during the Term by reason of the
Executive's death or Total Disability, this Agreement shall terminate
automatically without further obligation on the part of the Company to the
Executive or his legal representatives under this Agreement, other than the
Company's obligation to pay the Executive the Accrued Obligations (which
shall be paid to the Executive's estate or beneficiary, as applicable in the
case of the Executive's death), and to provide COBRA Continuation.
5.5 Payment Schedule and Offset for Other Earnings
All payments of Accrued Obligations, or any portion thereof payable pursuant
to this Section 5, shall be made to the Executive within ten working days of
the Date of Termination. Any severance payments payable to the Executive
pursuant to Section 5.1(c) shall be made to the Executive in the form of
salary continuation, payable at normal payroll intervals during the six-month
severance period, and subject to offset for other earnings received by the
Executive as follows:
(a) The Executive shall have no affirmative duty to seek other employment
or otherwise mitigate lost earnings during the six-month severance
period;
(b) The Executive shall disclose to the Company any earnings received (or
which the Executive had the right to receive) from employment,
consulting or performance of other personal services during the
six-month severance period, and the source(s) of such earnings; and
(c) The Company, in each payroll period that a severance payment is due,
shall have the right to offset on a dollar-for-dollar basis all such
earnings which the Executive received or had the right to receive
during that payroll period.
5.6 Cause
For purposes of this Agreement, "Cause" means cause given by the Executive to
the Company and shall include, without limitation, the occurrence of one or more
of the following events:
(a) A clear refusal to carry out any material lawful duties of the
Executive or any directions of the Board or senior management of the
Company reasonably consistent with those duties;
(b) Persistent failure to carry out any lawful duties of the Executive or
any directions of the Board or senior management reasonably consistent
with those duties, provided Executive has been given reasonable notice
and opportunity to correct any such failure;
-59-
<PAGE>
(c) Violation by the Executive of a state or federal criminal law
involving the commission of a crime against the Company or any other
criminal act involving moral turpitude;
(d) Current abuse by the Executive of alcohol or controlled substances;
deception, fraud, misrepresentation or dishonesty by the Executive; or
any incident materially compromising the Executive's reputation or
ability to represent the Company with investors, customers or the
public; or
(e) Any other material violation of any provision of this Agreement by the
Executive, subject to the notice and opportunity to cure requirements
of Section 8.
5.7 Good Reason
For purposes of this Agreement, "Good Reason" means
(a) Reduction of the Executive's annual base salary to a level more than
fifteen percent below the level in effect on the date of this
Agreement, regardless of any change in the Executive's duties or
responsibilities;
(b) The Company's requiring the Executive to be based at any office or
location more than thirty (30) miles from the Company's current
location in Kirkland, Washington;
(c) Any failure by the Company to comply with and satisfy Section 10
hereof, provided that the Company's successor has received at least
ten days' prior written notice from the Company or the Executive of
the requirements of Section 10 hereof; or
(d) Any other material violation of any provision of this Agreement by the
Company, subject to the notice and opportunity to cure requirements of
Section 8.
6. REPRESENTATIONS, WARRANTIES AND OTHER CONDITIONS
In order to induce the Company to enter into this Agreement, the Executive
represents and warrants to the Company as follows:
6.1 Health
The Executive is in good health and knows of no physical or mental disability
which, with any accommodation which may be required by law and which places
no undue burden on the Company, would prevent him from fulfilling his
obligations hereunder. The Executive agrees, if the Company requests, to
submit to reasonable periodic medical examinations by a physician or
physicians designated by, paid for and arranged by the Company. The
Executive agrees that the examination's medical report shall be provided to
the Company.
6.2 No Violation of Other Agreements
The Executive represents that neither the execution nor the performance of
this Agreement by the Executive will violate or conflict in any way with any
other agreement by which the Executive may be bound.
7. NONDISCLOSURE; RETURN OF MATERIALS
7.1 Nondisclosure
Except as required by his employment with the Company, the Executive will
not, at any time during the term of employment by the Company, or at any time
thereafter, directly, indirectly or otherwise, use, communicate, disclose,
disseminate, lecture upon or publish articles relating to any confidential,
proprietary or trade secret information without the prior written consent of
the Company. The Executive understands that the Company will be relying on
this covenant in continuing the Executive's employment, paying him
compensation, granting him any promotions or raises, or entrusting him with
any information which helps the Company compete with others.
7.2 Return of Materials
All documents, records, notebooks, notes, memoranda, drawings or other
documents made or compiled by the Executive at any time while employed by the
Company, or in his possession, including any and all copies thereof, shall be
the property of the Company and shall be held by the Executive in trust and
solely for the benefit of the Company, and shall be delivered to the Company
by the Executive upon termination of employment or at any other time upon
request by the Company.
-60-
<PAGE>
8. NOTICE AND CURE OF BREACH
Whenever a breach of this Agreement by either party is relied upon as
justification for any action taken by the other party pursuant to any provision
of this Agreement, other than clause (a), (b), (c) or (d) of Section 5.6 hereof,
before such action is taken, the party asserting the breach of this Agreement
shall give the other party at least ten days' prior written notice of the
existence and the nature of such breach before taking further action hereunder
and shall give the party purportedly in breach of this Agreement the opportunity
to correct such breach during the ten-day period.
9. FORM OF NOTICE
Every notice required by the terms of this Agreement shall be given in writing
by serving the same upon the party to whom it was addressed personally or by
registered or certified mail, return receipt requested, at the address set forth
below or at such other address as may hereafter be designated by notice given in
compliance with the terms hereof:
If to the Executive: John F. Clifford
If to the Company: ProCyte Corporation
12040 115th Avenue N.E., Suite 210
Kirkland, Washington 98034
Attn: Corporate Secretary
With a copy to: Perkins Coie
Attn: James R. Lisbakken
1201 Third Avenue, 40th Floor
Seattle, WA 98101-3099
or such other address as shall be provided in accordance with the terms hereof.
Except as set forth in Section 4.4 hereof, if notice is mailed, such notice
shall be effective upon mailing.
10. ASSIGNMENT
This Agreement is personal to the Executive and shall not be assignable by the
Executive.
The Company shall assign to and require any successor (whether direct or
indirect, by purchase, merger, consolidation or otherwise) to all or
substantially all the business and/or assets of the Company to assume expressly
and agree to perform this Agreement in the same manner and to the same extent
that the Company would be required to perform it if no such succession had taken
place. As used in this Agreement, "Company" shall mean ProCyte Corporation and
any affiliated company or successor to its business and/or assets as aforesaid
which assumes and agrees to perform this Agreement by contract, operation of
law, or otherwise; and as long as such successor assumes and agrees to perform
this Agreement, the termination of Executive's employment by one such entity and
the immediate hiring and continuation of the Executive's employment by the
succeeding entity shall not be deemed to constitute a termination or trigger any
severance obligation under this Agreement. All the terms and provisions of this
Agreement shall be binding upon and inure to the benefit of and be enforceable
by the parties hereto and their respective successors and permitted assigns.
11. WAIVERS
No delay or failure by any party hereto in exercising, protecting or enforcing
any of its rights, titles, interests or remedies hereunder, and no course of
dealing or performance with respect thereto, shall constitute a waiver thereof.
The express waiver by a party hereto of any right, title, interest or remedy in
a particular instance or circumstance shall not constitute a waiver thereof in
any other instance or circumstance. All rights and remedies shall be cumulative
and not exclusive of any other rights or remedies.
-61-
<PAGE>
12. AMENDMENTS IN WRITING
No amendment, modification, waiver, termination or discharge of any provision of
this Agreement, nor consent to any departure therefrom by either party hereto,
shall in any event be effective unless the same shall be in writing,
specifically identifying this Agreement and the provision intended to be
amended, modified, waived, terminated or discharged and signed by the Company
and the Executive, and each such amendment, modification, waiver, termination or
discharge shall be effective only in the specific instance and for the specific
purpose for which given. No provision of this Agreement shall be varied,
contradicted or explained by any oral agreement, course of dealing or
performance or any other matter not set forth in an agreement in writing and
signed by the Company and the Executive.
13. APPLICABLE LAW
This Agreement shall in all respects, including all matters of construction,
validity and performance, be governed by, and construed and enforced in
accordance with, the laws of the State of Washington, without regard to any
rules governing conflicts of laws.
14. ARBITRATION; ATTORNEYS' FEES
Except in connection with enforcing Section 7 of this Agreement, for which legal
and equitable remedies may be sought in a court of law, any dispute arising
under this Agreement shall be subject to arbitration. The arbitration
proceeding shall be conducted in accordance with the Commercial Arbitration
Rules of the American Arbitration Association then in effect, conducted by one
arbitrator either mutually agreed upon or selected in accordance with the AAA
Rules. The arbitration shall be conducted in King County, Washington under the
jurisdiction of the Seattle office of the American Arbitration Association. The
arbitrator shall have authority only to interpret and apply the provisions of
this Agreement, and shall have no authority to add to, subtract from, or
otherwise modify the terms of this Agreement. Any demand for arbitration must
be made within sixty (60) days of the event(s) giving rise to the claim that
this Agreement has been breached. The arbitrator's decision shall be final and
binding, and each party agrees to be bound to by arbitrator's award subject only
to an appeal therefrom in accordance with the laws of the State of Washington.
Either party may obtain judgment upon the arbitrator's award in the Superior
Court of King, County, Washington.
If it becomes necessary to pursue or defend any legal proceeding, whether in
arbitration or court, in order to resolve a dispute arising under this
Agreement, the prevailing party in any such proceeding shall be entitled to
recover its reasonable costs and attorneys' fees.
15. SEVERABILITY
If any provision of this Agreement shall be held invalid, illegal or
unenforceable in any jurisdiction, for any reason, including, without
limitation, the duration of such provision, its geographical scope or the extent
of the activities prohibited or required by it, then, to the full extent
permitted by law, (a) all other provisions hereof shall remain in full force and
effect in such jurisdiction and shall be liberally construed in order to carry
out the intent of the parties hereto as nearly as may be possible, (b) such
invalidity, illegality or unenforceability shall not affect the validity,
legality or enforceability of any other provision hereof, and (c) any court or
arbitrator having jurisdiction thereover shall have the power to reform such
provision to the extent necessary for such provision to be enforceable under
applicable law.
-62-
<PAGE>
16. COORDINATION WITH CHANGE OF CONTROL AGREEMENT
The Company and the Executive are contemporaneously entering into a Change of
Control Agreement dated as of the date hereof, which agreement provides for
certain forms of severance and benefit payments in the event of termination of
Executive's employment under certain defined circumstances. This Agreement is
in addition to the Change of Control Agreement, providing certain assurances to
the Executive in circumstances that the Change of Control Agreement does not
cover, and in no way supersedes or nullifies the Change of Control Agreement.
Nevertheless, it is possible that a termination of employment by the Company or
by the Executive may fall within the scope of both agreements. In such event,
payments made to Executive under Section 5.1 hereof shall be coordinated with
payments made to Executive under Section 8.1 of the Change of Control Agreement
as follows:
(a) Accrued Obligations under this Agreement need not be paid if already
paid as Accrued Obligations under the Change of Control Agreement;
(b) COBRA Continuation under this Agreement need not be provided if COBRA
Continuation is provided for at least as long a period of time under
the Change of Control Agreement; and
(c) The severance payment required under Section 5.1(c) of this Agreement
shall be paid in addition to any severance payment required under
Section 8.1(c) of the Change of Control Agreement.
17. ENTIRE AGREEMENT
Except as described in Section 16 hereof, this Agreement constitutes the entire
agreement between the Company and the Executive with respect to the subject
matter hereof, and all prior or contemporaneous oral or written communications,
understandings or agreements between the Company and the Executive with respect
to such subject matter are hereby superseded and nullified in their entireties;
provided, however, that the Proprietary Information and Invention Agreement
between the Executive and the Company shall continue in full force and effect to
the extent not superseded by Section 10 hereof.
18. WITHHOLDING
The Company may withhold from any amounts payable under this Agreement such
federal, state or local taxes as shall be required to be withheld pursuant to
any applicable law or regulation.
19. COUNTERPARTS
This Agreement may be executed in counterparts, each of which counterpart shall
be deemed an original, but all of which together shall constitute one and the
same instrument.
IN WITNESS WHEREOF, the parties have executed and entered into this Agreement
effective on the date first set forth above.
PROCYTE CORPORATION EXECUTIVE
By:_______________________ By:______________________
Title: Title
-63-
<PAGE>
EXHIBIT 10.13 (Cont.)
KEY EXECUTIVE SEVERANCE AGREEMENT
BETWEEN PROCYTE CORPORATION AND MS. KAREN HEDINE
This Key Executive Severance Agreement (this "Agreement"), dated and effective
as of February 19, 1997, is between PROCYTE CORPORATION, a Washington
corporation (the "Company"), and KAREN HEDINE (the "Executive").
The Board of Directors of the Company (the "Board") has determined that it is in
the best interests of the Company and its stockholders to ensure that the
Company will have the continued dedication of the Executive, notwithstanding the
fact that the Executive does not have any form of traditional employment
contract or other assurance of job security. The Board believes it is
imperative to diminish any distraction of the Executive arising from the
personal uncertainty and insecurity that arises in the absence of any assurance
of job security by providing the Executive with reasonable compensation and
benefit arrangements in the event of termination of Executive's employment by
the Company under certain defined circumstances.
In order to accomplish these objectives, the Board has caused the Company to
enter into this Agreement.
1. TERM
The term of this Agreement ("Term") shall be for a period of two (2) years from
the date of this Agreement as first entered above, at which time this Agreement
shall terminate without further action by either the Company or the Executive.
2. EMPLOYMENT
The Executive and the Company acknowledge that, except as may otherwise be
provided under any other written agreement between the Executive and the
Company, the employment of the Executive by the Company or by any affiliated or
successor company is "at will" and may be terminated by either the Executive or
the Company or its affiliated companies at any time with or without cause,
subject to the termination payments prescribed herein.
3. ATTENTION AND EFFORT
During any period of time that Executive remains in the employ of the Company,
and excluding any periods of vacation and sick leave to which the Executive is
entitled, the Executive will devote all of his productive time, ability,
attention and effort to the business and affairs of the Company and the
discharge of the responsibilities assigned to him hereunder, and will use his
reasonable best efforts to perform faithfully and efficiently such
responsibilities. It shall not be a violation of this Agreement for the
Executive to (a) serve on corporate, civic or charitable boards or committees,
(b) deliver lectures, fulfill speaking engagements or teach at educational
institutions, and (c) manage personal investments, so long as such activities do
not significantly interfere with the performance of the Executive's
responsibilities in accordance with this Agreement. It is expressly understood
and agreed that to the extent any such activities have been conducted by the
Executive prior to the Term, the continued conduct of such activities (or the
conduct of activities similar in nature and scope thereto) during the Term shall
not thereafter be deemed to interfere with the performance of the Executive's
responsibilities to the Company.
4. TERMINATION
During the Term, employment of the Executive may be terminated as follows but,
in any case, the nondisclosure provisions set forth in Section 7 hereof shall
survive the termination of this Agreement and the termination of the Executive's
employment with the Company:
-64-
<PAGE>
4.1 By the Company or the Executive
At any time during the Term, the Company may terminate the employment of the
Executive with or without Cause (as defined below), and the Executive may
terminate his employment for Good Reason (as defined below) or for any reason,
upon giving Notice of Termination (as defined below).
4.2 Automatic Termination
This Agreement and the Executive's employment shall terminate automatically upon
the death or Total Disability of the Executive. The term "Total Disability" as
used herein shall mean the Executive's inability (with such accommodation as may
be required by law and which places no undue burden on the Company), as
determined by a physician selected by the Company and acceptable to the
Executive, to perform the Executive's essential duties for a period or periods
aggregating 120 calendar days in any 12-month period as a result of physical or
mental illness, loss of legal capacity or any other cause beyond the Executive's
control, unless the Executive is granted a leave of absence by the Board.
4.3 Notice of Termination
Any termination by the Company or by the Executive during the Term shall be
communicated by Notice of Termination to the other party given in accordance
with Section 9 hereof. The term "Notice of Termination" shall mean a written
notice which (a) indicates the specific termination provision in this Agreement
relied upon and (b) to the extent applicable, sets forth in reasonable detail
the facts and circumstances claimed to provide a basis for termination of the
Executive's employment under the provision so indicated. The failure by the
Executive or the Company to set forth in the Notice of Termination any fact or
circumstance which contributes to a showing of Good Reason or Cause shall not
waive any right of the Executive or the Company hereunder or preclude the
Executive or the Company from asserting such fact or circumstance in enforcing
the Executive's or the Company's rights hereunder.
4.4 Date of Termination
"Date of Termination" means (a) if the Executive's employment is terminated by
reason of death, the last day of the calendar month in which the Executive's
death occurs, (b) if the Executive's employment is terminated by reason of Total
Disability, immediately upon a determination by the Company of the Executive's
Total Disability, and (c) in all other cases, five days after the date of
personal delivery or mailing of the Notice of Termination. The Executive's
employment and performance of services will continue during such five-day
period; provided, however, that the Company may, upon notice to the Executive
and without reducing the Executive's compensation during such period, excuse the
Executive from any or all of his duties during such period.
5. TERMINATION PAYMENTS
In the event of termination of the Executive's employment during the Term, all
compensation and benefits shall terminate except as specifically provided in
this Section 5.
5.1 Termination by the Company Other Than for Cause or by the Executive
for Good Reason
If during the Term the Company terminates the Executive's employment other than
for Cause or the Executive terminates his employment for Good Reason, the
Executive shall be entitled to:
(a) receive payment of the following accrued obligations (the "Accrued
Obligations"):
(i) the Executive's then current annual base salary through the Date
of Termination to the extent not theretofore paid; and
(ii) any compensation previously deferred by the Executive (together
with accrued interest or earnings thereon, if any) and any
accrued vacation pay which would be payable under the Company's
standard policy, in each case to the extent not theretofore paid;
-65-
<PAGE>
(b) for twelve months after the Date of Termination, the Company shall pay
the Executive's premiums for health insurance benefit continuation for
Executive and his family members, if applicable, which the Company
provides to the Executive under the provisions of the federal
Comprehensive Omnibus Budget Reconciliation Act of 1986, as amended
("COBRA") to the extent that the Company would have paid such premiums
had the Executive remained employed by the Company (such continued
payment is hereinafter referred to as "COBRA Continuation"); and
(c) an amount as severance pay equal to one-half the Executive's then
current annual base salary for the fiscal year in which the Date of
Termination occurs, subject to payment and potential reduction as set
forth in Section 5.5 hereof.
5.2 Termination for Cause or Other Than for Good Reason
If during the Term the Executive's employment shall be terminated by the Company
for Cause or by the Executive for other than Good Reason, this Agreement shall
terminate without further obligation on the part of the Company to the
Executive, other than the Company's obligation to pay the Executive the Accrued
Obligations to the extent theretofore unpaid.
an amount as severance pay equal to one-half the Executive's then current annual
base salary for the fiscal year in which the Date of Termination occurs, subject
to payment and potential reduction as set forth in Section 5.5 hereof. In the
case of a termination of the Executive's employment at the expiration of the
Term, this Agreement shall terminate without further obligation on the part of
the Company to the Executive, other than the Company's obligation to pay the
Executive the Accrued Obligations.
5.4 Termination Because of Death or Total Disability
If the Executive's employment is terminated during the Term by reason of the
Executive's death or Total Disability, this Agreement shall terminate
automatically without further obligation on the part of the Company to the
Executive or his legal representatives under this Agreement, other than the
Company's obligation to pay the Executive the Accrued Obligations (which shall
be paid to the Executive's estate or beneficiary, as applicable in the case of
the Executive's death), and to provide COBRA Continuation.
5.5 Payment Schedule and Offset for Other Earnings
All payments of Accrued Obligations, or any portion thereof payable pursuant to
this Section 5, shall be made to the Executive within ten working days of the
Date of Termination. Any severance payments payable to the Executive pursuant
to Section 5.1(c) shall be made to the Executive in the form of salary
continuation, payable at normal payroll intervals during the six-month severance
period, and subject to offset for other earnings received by the Executive as
follows:
(a) The Executive shall have no affirmative duty to seek other employment
or otherwise mitigate lost earnings during the six-month severance
period;
(b) The Executive shall disclose to the Company any earnings received (or
which the Executive had the right to receive) from employment,
consulting or performance of other personal services during the
six-month severance period, and the source(s) of such earnings; and
(c) The Company, in each payroll period that a severance payment is due,
shall have the right to offset on a dollar-for-dollar basis all such
earnings which the Executive received or had the right to receive
during that payroll period.
5.6 Cause
For purposes of this Agreement, "Cause" means cause given by the Executive to
the Company and shall include, without limitation, the occurrence of one or more
of the following events:
(a) A clear refusal to carry out any material lawful duties of the
Executive or any directions of the Board or senior management of the
Company reasonably consistent with those duties;
(b) Persistent failure to carry out any lawful duties of the Executive or
any directions of the Board or senior management reasonably consistent
with those duties, provided Executive has been given reasonable notice
and opportunity to correct any such failure;
-66-
<PAGE>
(c) Violation by the Executive of a state or federal criminal law
involving the commission of a crime against the Company or any other
criminal act involving moral turpitude;
(d) Current abuse by the Executive of alcohol or controlled substances;
deception, fraud, misrepresentation or dishonesty by the Executive; or
any incident materially compromising the Executive's reputation or
ability to represent the Company with investors, customers or the
public; or
(e) Any other material violation of any provision of this Agreement by the
Executive, subject to the notice and opportunity to cure requirements
of Section 8.
5.7 Good Reason
For purposes of this Agreement, "Good Reason" means
(a) Reduction of the Executive's annual base salary to a level more than
fifteen percent below the level in effect on the date of this
Agreement, regardless of any change in the Executive's duties or
responsibilities;
(b) The Company's requiring the Executive to be based at any office or
location more than thirty (30) miles from the Company's current
location in Kirkland, Washington;
(c) Any failure by the Company to comply with and satisfy Section 10
hereof, provided that the Company's successor has received at least
ten days' prior written notice from the Company or the Executive of
the requirements of Section 10 hereof; or
(d) Any other material violation of any provision of this Agreement by the
Company, subject to the notice and opportunity to cure requirements of
Section 8.
6. REPRESENTATIONS, WARRANTIES AND OTHER CONDITIONS
In order to induce the Company to enter into this Agreement, the Executive
represents and warrants to the Company as follows:
6.1 Health
The Executive is in good health and knows of no physical or mental disability
which, with any accommodation which may be required by law and which places no
undue burden on the Company, would prevent him from fulfilling his obligations
hereunder. The Executive agrees, if the Company requests, to submit to
reasonable periodic medical examinations by a physician or physicians designated
by, paid for and arranged by the Company. The Executive agrees that the
examination's medical report shall be provided to the Company.
6.2 No Violation of Other Agreements
The Executive represents that neither the execution nor the performance of this
Agreement by the Executive will violate or conflict in any way with any other
agreement by which the Executive may be bound.
7. NONDISCLOSURE; RETURN OF MATERIALS
7.1 Nondisclosure
Except as required by his employment with the Company, the Executive will not,
at any time during the term of employment by the Company, or at any time
thereafter, directly, indirectly or otherwise, use, communicate, disclose,
disseminate, lecture upon or publish articles relating to any confidential,
proprietary or trade secret information without the prior written consent of the
Company. The Executive understands that the Company will be relying on this
covenant in continuing the Executive's employment, paying him compensation,
granting him any promotions or raises, or entrusting him with any information
which helps the Company compete with others.
7.2 Return of Materials
All documents, records, notebooks, notes, memoranda, drawings or other documents
made or compiled by the Executive at any time while employed by the Company, or
in his possession, including any and all copies thereof, shall be the property
of the Company and shall be held by the Executive in trust and solely for the
benefit of the Company, and shall be delivered to the Company by the Executive
upon termination of employment or at any other time upon request by the Company.
-67-
<PAGE>
8. NOTICE AND CURE OF BREACH
Whenever a breach of this Agreement by either party is relied upon as
justification for any action taken by the other party pursuant to any provision
of this Agreement, other than clause (a), (b), (c) or (d) of Section 5.6 hereof,
before such action is taken, the party asserting the breach of this Agreement
shall give the other party at least ten days' prior written notice of the
existence and the nature of such breach before taking further action hereunder
and shall give the party purportedly in breach of this Agreement the opportunity
to correct such breach during the ten-day period.
9. FORM OF NOTICE
Every notice required by the terms of this Agreement shall be given in writing
by serving the same upon the party to whom it was addressed personally or by
registered or certified mail, return receipt requested, at the address set forth
below or at such other address as may hereafter be designated by notice given in
compliance with the terms hereof:
If to the Executive: Karen Hedine
If to the Company: ProCyte Corporation
12040 115th Avenue N.E., Suite 210
Kirkland, Washington 98034
Attn: President
With a copy to: Perkins Coie
Attn: James R. Lisbakken
1201 Third Avenue, 40th Floor
Seattle, WA 98101-3099
or such other address as shall be provided in accordance with the terms hereof.
Except as set forth in Section 4.4 hereof, if notice is mailed, such notice
shall be effective upon mailing.
10. ASSIGNMENT
This Agreement is personal to the Executive and shall not be assignable by the
Executive.
The Company shall assign to and require any successor (whether direct or
indirect, by purchase, merger, consolidation or otherwise) to all or
substantially all the business and/or assets of the Company to assume expressly
and agree to perform this Agreement in the same manner and to the same extent
that the Company would be required to perform it if no such succession had taken
place. As used in this Agreement, "Company" shall mean ProCyte Corporation and
any affiliated company or successor to its business and/or assets as aforesaid
which assumes and agrees to perform this Agreement by contract, operation of
law, or otherwise; and as long as such successor assumes and agrees to perform
this Agreement, the termination of Executive's employment by one such entity and
the immediate hiring and continuation of the Executive's employment by the
succeeding entity shall not be deemed to constitute a termination or trigger any
severance obligation under this Agreement. All the terms and provisions of this
Agreement shall be binding upon and inure to the benefit of and be enforceable
by the parties hereto and their respective successors and permitted assigns.
11. WAIVERS
No delay or failure by any party hereto in exercising, protecting or enforcing
any of its rights, titles, interests or remedies hereunder, and no course of
dealing or performance with respect thereto, shall constitute a waiver thereof.
The express waiver by a party hereto of any right, title, interest or remedy in
a particular instance or circumstance shall not constitute a waiver thereof in
any other instance or circumstance. All rights and remedies shall be cumulative
and not exclusive of any other rights or remedies.
-68-
<PAGE>
12. AMENDMENTS IN WRITING
No amendment, modification, waiver, termination or discharge of any provision of
this Agreement, nor consent to any departure therefrom by either party hereto,
shall in any event be effective unless the same shall be in writing,
specifically identifying this Agreement and the provision intended to be
amended, modified, waived, terminated or discharged and signed by the Company
and the Executive, and each such amendment, modification, waiver, termination or
discharge shall be effective only in the specific instance and for the specific
purpose for which given. No provision of this Agreement shall be varied,
contradicted or explained by any oral agreement, course of dealing or
performance or any other matter not set forth in an agreement in writing and
signed by the Company and the Executive.
13. APPLICABLE LAW
This Agreement shall in all respects, including all matters of construction,
validity and performance, be governed by, and construed and enforced in
accordance with, the laws of the State of Washington, without regard to any
rules governing conflicts of laws.
14. ARBITRATION; ATTORNEYS' FEES
Except in connection with enforcing Section 7 of this Agreement, for which legal
and equitable remedies may be sought in a court of law, any dispute arising
under this Agreement shall be subject to arbitration. The arbitration
proceeding shall be conducted in accordance with the Commercial Arbitration
Rules of the American Arbitration Association then in effect, conducted by one
arbitrator either mutually agreed upon or selected in accordance with the AAA
Rules. The arbitration shall be conducted in King County, Washington under the
jurisdiction of the Seattle office of the American Arbitration Association. The
arbitrator shall have authority only to interpret and apply the provisions of
this Agreement, and shall have no authority to add to, subtract from, or
otherwise modify the terms of this Agreement. Any demand for arbitration must
be made within sixty (60) days of the event(s) giving rise to the claim that
this Agreement has been breached. The arbitrator's decision shall be final and
binding, and each party agrees to be bound to by arbitrator's award subject only
to an appeal therefrom in accordance with the laws of the State of Washington.
Either party may obtain judgment upon the arbitrator's award in the Superior
Court of King, County, Washington.
If it becomes necessary to pursue or defend any legal proceeding, whether in
arbitration or court, in order to resolve a dispute arising under this
Agreement, the prevailing party in any such proceeding shall be entitled to
recover its reasonable costs and attorneys' fees.
15. SEVERABILITY
If any provision of this Agreement shall be held invalid, illegal or
unenforceable in any jurisdiction, for any reason, including, without
limitation, the duration of such provision, its geographical scope or the extent
of the activities prohibited or required by it, then, to the full extent
permitted by law, (a) all other provisions hereof shall remain in full force and
effect in such jurisdiction and shall be liberally construed in order to carry
out the intent of the parties hereto as nearly as may be possible, (b) such
invalidity, illegality or unenforceability shall not affect the validity,
legality or enforceability of any other provision hereof, and (c) any court or
arbitrator having jurisdiction thereover shall have the power to reform such
provision to the extent necessary for such provision to be enforceable under
applicable law.
-69-
<PAGE>
16. ENTIRE AGREEMENT
This Agreement constitutes the entire agreement between the Company and the
Executive with respect to the subject matter hereof, and all prior or
contemporaneous oral or written communications, understandings or agreements
between the Company and the Executive with respect to such subject matter are
hereby superseded and nullified in their entireties; provided, however, that the
Proprietary Information and Invention Agreement between the Executive and the
Company shall continue in full force and effect to the extent not superseded by
Section 10 hereof.
17. WITHHOLDING
The Company may withhold from any amounts payable under this Agreement such
federal, state or local taxes as shall be required to be withheld pursuant to
any applicable law or regulation.
18. COUNTERPARTS
This Agreement may be executed in counterparts, each of which counterpart shall
be deemed an original, but all of which together shall constitute one and the
same instrument.
IN WITNESS WHEREOF, the parties have executed and entered into this Agreement
effective on the date first set forth above.
PROCYTE CORPORATION EXECUTIVE
By:________________________________________ By:____________________________
Title: Title
-70-
<PAGE>
EXHIBIT 10.13 (Cont.)
KEY EXECUTIVE SEVERANCE AGREEMENT
BETWEEN PROCYTE CORPORATION AND MR. KENNETH GREEN
This Key Executive Severance Agreement (this "Agreement"), dated and effective
as of February 19, 1997, is between PROCYTE CORPORATION, a Washington
corporation (the "Company"), and KENNETH GREEN (the "Executive").
The Board of Directors of the Company (the "Board") has determined that it is in
the best interests of the Company and its stockholders to ensure that the
Company will have the continued dedication of the Executive, notwithstanding the
fact that the Executive does not have any form of traditional employment
contract or other assurance of job security. The Board believes it is
imperative to diminish any distraction of the Executive arising from the
personal uncertainty and insecurity that arises in the absence of any assurance
of job security by providing the Executive with reasonable compensation and
benefit arrangements in the event of termination of Executive's employment by
the Company under certain defined circumstances.
In order to accomplish these objectives, the Board has caused the Company to
enter into this Agreement.
1. TERM
The term of this Agreement ("Term") shall be for a period of two (2) years from
the date of this Agreement as first entered above, at which time this Agreement
shall terminate without further action by either the Company or the Executive.
2. EMPLOYMENT
The Executive and the Company acknowledge that, except as may otherwise be
provided under any other written agreement between the Executive and the
Company, the employment of the Executive by the Company or by any affiliated or
successor company is "at will" and may be terminated by either the Executive or
the Company or its affiliated companies at any time with or without cause,
subject to the termination payments prescribed herein.
3. ATTENTION AND EFFORT
During any period of time that Executive remains in the employ of the Company,
and excluding any periods of vacation and sick leave to which the Executive is
entitled, the Executive will devote all of his productive time, ability,
attention and effort to the business and affairs of the Company and the
discharge of the responsibilities assigned to him hereunder, and will use his
reasonable best efforts to perform faithfully and efficiently such
responsibilities. It shall not be a violation of this Agreement for the
Executive to (a) serve on corporate, civic or charitable boards or committees,
(b) deliver lectures, fulfill speaking engagements or teach at educational
institutions, and (c) manage personal investments, so long as such activities do
not significantly interfere with the performance of the Executive's
responsibilities in accordance with this Agreement. It is expressly understood
and agreed that to the extent any such activities have been conducted by the
Executive prior to the Term, the continued conduct of such activities (or the
conduct of activities similar in nature and scope thereto) during the Term shall
not thereafter be deemed to interfere with the performance of the Executive's
responsibilities to the Company.
4. TERMINATION
During the Term, employment of the Executive may be terminated as follows but,
in any case, the nondisclosure provisions set forth in Section 7 hereof shall
survive the termination of this Agreement and the termination of the Executive's
employment with the Company:
-71-
<PAGE>
4.1 By the Company or the Executive
At any time during the Term, the Company may terminate the employment of the
Executive with or without Cause (as defined below), and the Executive may
terminate his employment for Good Reason (as defined below) or for any reason,
upon giving Notice of Termination (as defined below).
4.2 Automatic Termination
This Agreement and the Executive's employment shall terminate automatically upon
the death or Total Disability of the Executive. The term "Total Disability" as
used herein shall mean the Executive's inability (with such accommodation as may
be required by law and which places no undue burden on the Company), as
determined by a physician selected by the Company and acceptable to the
Executive, to perform the Executive's essential duties for a period or periods
aggregating 120 calendar days in any 12-month period as a result of physical or
mental illness, loss of legal capacity or any other cause beyond the Executive's
control, unless the Executive is granted a leave of absence by the Board.
4.3 Notice of Termination
Any termination by the Company or by the Executive during the Term shall be
communicated by Notice of Termination to the other party given in accordance
with Section 9 hereof. The term "Notice of Termination" shall mean a written
notice which (a) indicates the specific termination provision in this Agreement
relied upon and (b) to the extent applicable, sets forth in reasonable detail
the facts and circumstances claimed to provide a basis for termination of the
Executive's employment under the provision so indicated. The failure by the
Executive or the Company to set forth in the Notice of Termination any fact or
circumstance which contributes to a showing of Good Reason or Cause shall not
waive any right of the Executive or the Company hereunder or preclude the
Executive or the Company from asserting such fact or circumstance in enforcing
the Executive's or the Company's rights hereunder.
4.4 Date of Termination
"Date of Termination" means (a) if the Executive's employment is terminated by
reason of death, the last day of the calendar month in which the Executive's
death occurs, (b) if the Executive's employment is terminated by reason of Total
Disability, immediately upon a determination by the Company of the Executive's
Total Disability, and (c) in all other cases, five days after the date of
personal delivery or mailing of the Notice of Termination. The Executive's
employment and performance of services will continue during such five-day
period; provided, however, that the Company may, upon notice to the Executive
and without reducing the Executive's compensation during such period, excuse the
Executive from any or all of his duties during such period.
5. TERMINATION PAYMENTS
In the event of termination of the Executive's employment during the Term, all
compensation and benefits shall terminate except as specifically provided in
this Section 5.
5.1 Termination by the Company Other Than for Cause or by the Executive
for Good Reason
If during the Term the Company terminates the Executive's employment other than
for Cause or the Executive terminates his employment for Good Reason, the
Executive shall be entitled to:
(a) receive payment of the following accrued obligations (the "Accrued
Obligations"):
(i) the Executive's then current annual base salary through the Date
of Termination to the extent not theretofore paid; and
(ii) any compensation previously deferred by the Executive (together
with accrued interest or earnings thereon, if any) and any
accrued vacation pay which would be payable under the Company's
standard policy, in each case to the extent not theretofore paid;
-72-
<PAGE>
(b) for twelve months after the Date of Termination, the Company shall pay
the Executive's premiums for health insurance benefit continuation for
Executive and his family members, if applicable, which the Company
provides to the Executive under the provisions of the federal
Comprehensive Omnibus Budget Reconciliation Act of 1986, as amended
("COBRA") to the extent that the Company would have paid such premiums
had the Executive remained employed by the Company (such continued
payment is hereinafter referred to as "COBRA Continuation"); and
(c) an amount as severance pay equal to one-half the Executive's then
current annual base salary for the fiscal year in which the Date of
Termination occurs, subject to payment and potential reduction as set
forth in Section 5.5 hereof.
5.2 Termination for Cause or Other Than for Good Reason
If during the Term the Executive's employment shall be terminated by the Company
for Cause or by the Executive for other than Good Reason, this Agreement shall
terminate without further obligation on the part of the Company to the
Executive, other than the Company's obligation to pay the Executive the Accrued
Obligations to the extent theretofore unpaid.
5.3 Expiration of Term
In the case of a termination of the Executive's employment at the expiration of
the Term, this Agreement shall terminate without further obligation on the part
of the Company to the Executive, other than the Company's obligation to pay the
Executive the Accrued Obligations.
5.4 Termination Because of Death or Total Disability
If the Executive's employment is terminated during the Term by reason of the
Executive's death or Total Disability, this Agreement shall terminate
automatically without further obligation on the part of the Company to the
Executive or his legal representatives under this Agreement, other than the
Company's obligation to pay the Executive the Accrued Obligations (which shall
be paid to the Executive's estate or beneficiary, as applicable in the case of
the Executive's death), and to provide COBRA Continuation.
5.5 Payment Schedule and Offset for Other Earnings
All payments of Accrued Obligations, or any portion thereof payable pursuant to
this Section 5, shall be made to the Executive within ten working days of the
Date of Termination. Any severance payments payable to the Executive pursuant
to Section 5.1(c) shall be made to the Executive in the form of salary
continuation, payable at normal payroll intervals during the six-month severance
period, and subject to offset for other earnings received by the Executive as
follows:
(a) The Executive shall have no affirmative duty to seek other employment
or otherwise mitigate lost earnings during the six-month severance
period;
(b) The Executive shall disclose to the Company any earnings received (or
which the Executive had the right to receive) from employment,
consulting or performance of other personal services during the
six-month severance period, and the source(s) of such earnings; and
(c) The Company, in each payroll period that a severance payment is due,
shall have the right to offset on a dollar-for-dollar basis all such
earnings which the Executive received or had the right to receive
during that payroll period.
5.6 Cause
For purposes of this Agreement, "Cause" means cause given by the Executive to
the Company and shall include, without limitation, the occurrence of one or more
of the following events:
(a) A clear refusal to carry out any material lawful duties of the
Executive or any directions of the Board or senior management of the
Company reasonably consistent with those duties;
(b) Persistent failure to carry out any lawful duties of the Executive or
any directions of the Board or senior management reasonably consistent
with those duties, provided Executive has been given reasonable notice
and opportunity to correct any such failure;
-73-
<PAGE>
(c) Violation by the Executive of a state or federal criminal law
involving the commission of a crime against the Company or any other
criminal act involving moral turpitude;
(d) Current abuse by the Executive of alcohol or controlled substances;
deception, fraud, misrepresentation or dishonesty by the Executive; or
any incident materially compromising the Executive's reputation or
ability to represent the Company with investors, customers or the
public; or
(e) Any other material violation of any provision of this Agreement by the
Executive, subject to the notice and opportunity to cure requirements
of Section 8.
5.7 Good Reason
For purposes of this Agreement, "Good Reason" means
(a) Reduction of the Executive's annual base salary to a level more than
fifteen percent below the level in effect on the date of this
Agreement, regardless of any change in the Executive's duties or
responsibilities;
(b) The Company's requiring the Executive to be based at any office or
location more than thirty (30) miles from the Company's current
location in Kirkland, Washington;
(c) Any failure by the Company to comply with and satisfy Section 10
hereof, provided that the Company's successor has received at least
ten days' prior written notice from the Company or the Executive of
the requirements of Section 10 hereof; or
(d) Any other material violation of any provision of this Agreement by the
Company, subject to the notice and opportunity to cure requirements of
Section 8.
6. REPRESENTATIONS, WARRANTIES AND OTHER CONDITIONS
In order to induce the Company to enter into this Agreement, the Executive
represents and warrants to the Company as follows:
6.1 Health
The Executive is in good health and knows of no physical or mental disability
which, with any accommodation which may be required by law and which places no
undue burden on the Company, would prevent him from fulfilling his obligations
hereunder. The Executive agrees, if the Company requests, to submit to
reasonable periodic medical examinations by a physician or physicians designated
by, paid for and arranged by the Company. The Executive agrees that the
examination's medical report shall be provided to the Company.
6.2 No Violation of Other Agreements
The Executive represents that neither the execution nor the performance of this
Agreement by the Executive will violate or conflict in any way with any other
agreement by which the Executive may be bound.
7. NONDISCLOSURE; RETURN OF MATERIALS
7.1 Nondisclosure
Except as required by his employment with the Company, the Executive will not,
at any time during the term of employment by the Company, or at any time
thereafter, directly, indirectly or otherwise, use, communicate, disclose,
disseminate, lecture upon or publish articles relating to any confidential,
proprietary or trade secret information without the prior written consent of the
Company. The Executive understands that the Company will be relying on this
covenant in continuing the Executive's employment, paying him compensation,
granting him any promotions or raises, or entrusting him with any information
which helps the Company compete with others.
7.2 Return of Materials
All documents, records, notebooks, notes, memoranda, drawings or other documents
made or compiled by the Executive at any time while employed by the Company, or
in his possession, including any and all copies thereof, shall be the property
of the Company and shall be held by the Executive in trust and solely for the
benefit of the Company, and shall be delivered to the Company by the Executive
upon termination of employment or at any other time upon request by the Company.
-74-
<PAGE>
8. NOTICE AND CURE OF BREACH
Whenever a breach of this Agreement by either party is relied upon as
justification for any action taken by the other party pursuant to any provision
of this Agreement, other than clause (a), (b), (c) or (d) of Section 5.6 hereof,
before such action is taken, the party asserting the breach of this Agreement
shall give the other party at least ten days' prior written notice of the
existence and the nature of such breach before taking further action hereunder
and shall give the party purportedly in breach of this Agreement the opportunity
to correct such breach during the ten-day period.
9. FORM OF NOTICE
Every notice required by the terms of this Agreement shall be given in writing
by serving the same upon the party to whom it was addressed personally or by
registered or certified mail, return receipt requested, at the address set forth
below or at such other address as may hereafter be designated by notice given in
compliance with the terms hereof:
If to the Executive: Kenneth Green
If to the Company: ProCyte Corporation
12040 115th Avenue N.E., Suite 210
Kirkland, Washington 98034
Attn: President
With a copy to: Perkins Coie
Attn: James R. Lisbakken
1201 Third Avenue, 40th Floor
Seattle, WA 98101-3099
or such other address as shall be provided in accordance with the terms hereof.
Except as set forth in Section 4.4 hereof, if notice is mailed, such notice
shall be effective upon mailing.
10. ASSIGNMENT
This Agreement is personal to the Executive and shall not be assignable by the
Executive.
The Company shall assign to and require any successor (whether direct or
indirect, by purchase, merger, consolidation or otherwise) to all or
substantially all the business and/or assets of the Company to assume expressly
and agree to perform this Agreement in the same manner and to the same extent
that the Company would be required to perform it if no such succession had taken
place. As used in this Agreement, "Company" shall mean ProCyte Corporation and
any affiliated company or successor to its business and/or assets as aforesaid
which assumes and agrees to perform this Agreement by contract, operation of
law, or otherwise; and as long as such successor assumes and agrees to perform
this Agreement, the termination of Executive's employment by one such entity and
the immediate hiring and continuation of the Executive's employment by the
succeeding entity shall not be deemed to constitute a termination or trigger any
severance obligation under this Agreement. All the terms and provisions of this
Agreement shall be binding upon and inure to the benefit of and be enforceable
by the parties hereto and their respective successors and permitted assigns.
11. WAIVERS
No delay or failure by any party hereto in exercising, protecting or enforcing
any of its rights, titles, interests or remedies hereunder, and no course of
dealing or performance with respect thereto, shall constitute a waiver thereof.
The express waiver by a party hereto of any right, title, interest or remedy in
a particular instance or circumstance shall not constitute a waiver thereof in
any other instance or circumstance. All rights and remedies shall be cumulative
and not exclusive of any other rights or remedies.
-75-
<PAGE>
12. AMENDMENTS IN WRITING
No amendment, modification, waiver, termination or discharge of any provision of
this Agreement, nor consent to any departure therefrom by either party hereto,
shall in any event be effective unless the same shall be in writing,
specifically identifying this Agreement and the provision intended to be
amended, modified, waived, terminated or discharged and signed by the Company
and the Executive, and each such amendment, modification, waiver, termination or
discharge shall be effective only in the specific instance and for the specific
purpose for which given. No provision of this Agreement shall be varied,
contradicted or explained by any oral agreement, course of dealing or
performance or any other matter not set forth in an agreement in writing and
signed by the Company and the Executive.
13. APPLICABLE LAW
This Agreement shall in all respects, including all matters of construction,
validity and performance, be governed by, and construed and enforced in
accordance with, the laws of the State of Washington, without regard to any
rules governing conflicts of laws.
14. ARBITRATION; ATTORNEYS' FEES
Except in connection with enforcing Section 7 of this Agreement, for which legal
and equitable remedies may be sought in a court of law, any dispute arising
under this Agreement shall be subject to arbitration. The arbitration
proceeding shall be conducted in accordance with the Commercial Arbitration
Rules of the American Arbitration Association then in effect, conducted by one
arbitrator either mutually agreed upon or selected in accordance with the AAA
Rules. The arbitration shall be conducted in King County, Washington under the
jurisdiction of the Seattle office of the American Arbitration Association. The
arbitrator shall have authority only to interpret and apply the provisions of
this Agreement, and shall have no authority to add to, subtract from, or
otherwise modify the terms of this Agreement. Any demand for arbitration must
be made within sixty (60) days of the event(s) giving rise to the claim that
this Agreement has been breached. The arbitrator's decision shall be final and
binding, and each party agrees to be bound to by arbitrator's award subject only
to an appeal therefrom in accordance with the laws of the State of Washington.
Either party may obtain judgment upon the arbitrator's award in the Superior
Court of King, County, Washington.
If it becomes necessary to pursue or defend any legal proceeding, whether in
arbitration or court, in order to resolve a dispute arising under this
Agreement, the prevailing party in any such proceeding shall be entitled to
recover its reasonable costs and attorneys' fees.
15. SEVERABILITY
If any provision of this Agreement shall be held invalid, illegal or
unenforceable in any jurisdiction, for any reason, including, without
limitation, the duration of such provision, its geographical scope or the extent
of the activities prohibited or required by it, then, to the full extent
permitted by law, (a) all other provisions hereof shall remain in full force and
effect in such jurisdiction and shall be liberally construed in order to carry
out the intent of the parties hereto as nearly as may be possible, (b) such
invalidity, illegality or unenforceability shall not affect the validity,
legality or enforceability of any other provision hereof, and (c) any court or
arbitrator having jurisdiction thereover shall have the power to reform such
provision to the extent necessary for such provision to be enforceable under
applicable law.
-76-
<PAGE>
16. ENTIRE AGREEMENT
This Agreement constitutes the entire agreement between the Company and the
Executive with respect to the subject matter hereof, and all prior or
contemporaneous oral or written communications, understandings or agreements
between the Company and the Executive with respect to such subject matter are
hereby superseded and nullified in their entireties; provided, however, that the
Proprietary Information and Invention Agreement between the Executive and the
Company shall continue in full force and effect to the extent not superseded by
Section 10 hereof.
17. WITHHOLDING
The Company may withhold from any amounts payable under this Agreement such
federal, state or local taxes as shall be required to be withheld pursuant to
any applicable law or regulation.
18. COUNTERPARTS
This Agreement may be executed in counterparts, each of which counterpart shall
be deemed an original, but all of which together shall constitute one and the
same instrument.
IN WITNESS WHEREOF, the parties have executed and entered into this Agreement
effective on the date first set forth above.
PROCYTE CORPORATION EXECUTIVE
By__________________________________: By:___________________________________
Title: Title:
-77-
<PAGE>
EXHIBIT 13.1
FINANCIAL DATA SCHEDULE
Item 6 Selected Financial Data
<TABLE>
<CAPTION>
Years ended December 31,
Statements of Operations Data: 1996 1995 1994 1993 1992
- -------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Revenues $3,275,957 $4,320,056 $4,472,983 $1,939,517 $240,769
Costs and expenses 12,633,076 16,714,991 16,626,701 9,612,531 5,671,142
----------- ----------- ------------ ---------- -----------
Net loss $(9,357,119) $(12,394,935) $(12,153,718) $(7,673,014) $(5,430,373)
----------- ----------- ------------ ---------- -----------
----------- ----------- ------------ ---------- -----------
Net Loss per common share $(0.71) $(0.95) $(0.97) $(0.80) $(0.79)
----------- ----------- ------------ ---------- -----------
----------- ----------- ------------ ---------- -----------
Weighted average
number of common
shares used in computing
net loss per
common share 13,210,036 13,100,818 12,593,131 9,575,218 6,871,263
----------- ----------- ------------ ---------- -----------
----------- ----------- ------------ ---------- -----------
<CAPTION>
December 31,
Balance Sheet Data: 1996 1995 1994 1993 1992
- -------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
Cash, cash equivalents and
short-term investments $20,846,836 $36,077,520 $43,014,137 $22,653,578 $8,038,789
Working capital 20,647,423 30,438,486 41,746,596 21,170,301 7,383,177
Totals assets 27,963,658 45,093,558 50,013,086 26,265,524 10,076,855
Total liabilities 1,124,881 9,209,004 1,863,311 1,797,292 935,430
Accumulated deficit (55,870,339) (46,513,220) (34,118,285) (21,964,567) (14,291,553)
Stockholders equity 26,838,777 35,884,554 48,149,775 24,468,232 9,141,425
</TABLE>
-78-
<PAGE>
Management's Discussion and Analysis of Financial Conditions
and Results of Operations
Overview
This discussion contains forward-looking statements and such statements are
subject to certain risks and uncertainties which could cause actual results to
differ materially from those projected. See "Important Factors Regarding
Forward-Looking Statements" included in the Company's annual report to the
Securities Exchange Commission ("SEC") on Form 10-K for the period ended
December 31, 1996 and incorporated herein by reference. Readers are cautioned
not to place undue reliance on these forward-looking statements which reflect
the Company's position only as of the date hereof. The Company undertakes no
obligation to publicly release the result of any revisions to these
forward-looking statements which may be made to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.
Results of Operations
ProCyte Corporation (the "Company") continued its important restructuring in
1996 - building upon the Company's technology strengths and seeking to build
near-term revenue opportunities. The Company's primary objectives that were set
into motion in 1995 continued to serve as fundamental elements in the Company's
positioning for future growth.
ProCyte's mission is to provide innovative, user-responsive and cost effective
wound care products - a growing segment of disease management that has long been
underserved. To accomplish this objective, the Company continued to build on
its technical foundation that features two unique technologies - copper peptide
compounds and polymers.
In 1996, ProCyte received clearance under the United States Food and Drug
Administration's ("FDA") 510(k) medical device regulations to market
Iamin-Registered Trademark- Hydrating Gel for the care and management of human
acute and chronic wounds. U.S. product launch occurred in late July 1996.
A related product, Iamin-Registered Trademark--Vet skin care Gel, was introduced
to the veterinary wound care market during the year, and is used to treat
dermatological disorders and acute and chronic wounds in large and small
animals.
Kissei Pharmaceutical Co., Ltd., ProCyte's partner in Japan, China, Taiwan and
Korea for the development of the Iamin-Registered Trademark- compound, completed
its Phase I study in Japan during the year. In the second half of 1996, ProCyte
commenced a Phase II study of the Iamin-Registered Trademark- copper peptide
compound in the United Kingdom for the treatment of venous leg ulcers.
At year end, ProCyte received its second 510(k) product clearance - for the
OsmoCyte-TM- Pillow Wound Dressings. U.S. product launch occurred in late
December 1996. These highly absorptive wound care products incorporate the
unique polymer technology to which ProCyte licensed the worldwide rights,
outside of Asia, for wound care applications, and the worldwide rights for wound
care drug delivery.
ProCyte presently markets its human wound care products through its own sales
and marketing personnel and distribution networks. The Company's initial
products are sold to the veterinary wound care market by specialty distributors.
The Company plans to continue to build upon its wound care commitment and
related market applications for its technologies, and expects to introduce
additional products in 1997. At year end, the Company had five new 510(k)
submissions pending with the FDA. The Company is seeking registration and
distribution for its wound care products in Europe and elsewhere and plans to
continue to evaluate complementary products and technologies for North American
acquisition or distribution by the Company.
-79-
<PAGE>
In November 1996, ProCyte completed an early-stage, placebo-controlled,
multi-center clinical trial of investigational Iamin-IB-Registered Trademark-
solution (GHK:Cu 2:1 administered via retention enema) for the treatment of
mild to moderate ulcerative colitis, a form of inflammatory bowel disease.
Results of the study, based on the prospectively designed clinical endpoints,
showed that the high dose investigational compound induced slight improvement
in disease remission and statistically significant difference in the number
of patients with improved disease symptoms.
The patient enrollment and treatment phases of the Company's initial Phase II
effectiveness evaluation study of another proprietary peptide-copper compound,
PC1358, tradenamed Tricomin-Registered Trademark- solution, was completed in
late 1996. The study was designed to evaluate effectiveness of different doses
of the compound versus placebo in the treatment of androgenetic alopecia - or
male pattern baldness. Data analysis from the completed study is underway.
The Company intends to seek suitable corporate partners or licensees for
continued development and commercialization of the hair growth and inflammatory
bowel disease applications of its technology and is also evaluating alternative
registrations of the technologies worldwide.
The Company continued to provide contract manufacturing services to select
clients in the biotechnology and pharmaceutical industries in 1996. ProCyte
also expanded its wound care production facility during the year, while entering
working relationships with specialty manufacturers for components of certain of
the Company's wound care products.
By year end 1996, ProCyte had provided or was still performing contract
manufacturing services on behalf of its clients, including a multinational
pharmaceutical company, and several biotechnology companies. Given the risks
and uncertain timelines associated with device, pharmaceutical and biotechnology
products being developed, tested, reviewed or sold by clients of the
manufacturing facility, and the Company itself, the Company will be required to
strive to maintain sufficient clientele to counter the effect that regulatory
delays, product failures, product recalls, and other such circumstances may have
on its contract manufacturing capabilities and revenue expectations.
ProCyte expects to continue to provide contract manufacturing services in 1997
and future years, and to produce clinical and commercial quantities of certain
of its copper-peptide compounds for its use and those of partners or licensees.
The Company expects to utilize at least 75% of the plant's current capacity for
these endeavors in 1997, though, for the reasons outlined above, and including
such things as unexpected or unsuccessful plant audits or regulatory
inspections, the impact of adverse weather conditions on plant operations, and
other such reasons all of which are not enumerated here, there can be no
assurance that it will be successful.
In 1997, the Company plans to consolidate its operations by relocating its
Kirkland-based corporate offices and labs to the facility housing the Company's
manufacturing facility in Redmond, Washington.
Year Ended December 31, 1996 Compared with the Year Ended December 31, 1995
Total revenue from collaborative research agreements, license fees, initial
product sales and contract manufacturing totaled $1,638,667 in 1996 compared to
$1,688,152 in 1995. The Company's license fees and collaborative research and
development agreement with Kissei Pharmaceutical Co. Ltd. ("Kissei"), and past
partnership with Kaken Pharmaceutical Co., Ltd. ("Kaken"), accounted for 56% and
91% of the Company's revenue from collaborative research agreements, license
fees and contract manufacturing in 1996 and 1995, respectively. Revenue from
collaborative research agreements and license fees decreased approximately 41%
over 1995 due mainly to Kissei's satisfaction of research funding commitments
and termination of the Kaken partnership. Revenue from contract manufacturing
services totaled $708,104, a 366% increase from $151,836 in 1995.
-80-
<PAGE>
Total operating expenses, excluding the Company's settlement of the shareholder
suit filed against the Company and certain of its officers and directors in
October 1994, decreased 3% to $11,619,166 in 1996 from $11,964,991 in 1995.
Research and development expenses, and expenses related to earlier-stage,
smaller clinical trials underway in 1996 decreased by 7% to $6,738,911 from
7,235,298 in 1995. General and administrative expenses increased 3% to
$4,880,255 in 1996 compared to 4,729,693 in 1995, primarily as a result of the
Company's defense and settlement of the October 1994 shareholder suit and
related insurance arbitrations continuing in 1997.
Investment income in 1996 decreased to $1,622,944 from 2,6341,904 in 1995. The
decrease was primarily attributable to reduced cash available for investment.
The Company's net loss decreased to $9,357,119 for 1996 as compared to
$12,394,935 for 1995.
Year Ended December 31, 1995 Compared with the Year Ended December 31, 1994
In 1995, ProCyte earned $1,536,316 in research and development funding from
Kissei and Kaken, compared to $2,773,154 in 1994.
Total operating expenses, excluding amounts accrued by the Company in the then
tentative settlement of the shareholder suit filed against the Company and
certain of its officers and directors in October 1994, decreased approximately
28% to $11,964,991 in 1995 from $16,626,701 in 1994. Research and development
expenses related primarily to clinical development of copper peptide compounds
in Company-sponsored inflammatory bowel disease and hair growth studies,
decreased by approximately 46% to $7,235,298 in 1995 from $13,298,942 in 1994.
General and administrative expenses increased approximately 42% to $4,729,693 in
1995 compared to $3,327,759 in 1994, primarily as a result of staff additions,
business development license fees and shareholder litigation expenses.
Investment income increased to $2,631,904 in 1995 from $1,699,829 in 1994. The
increase was primarily attributable to higher interest rates.
The Company's net loss increased to $12,394,935 in 1995, compared to a net loss
of $12,153,718 for 1994.
Financial Condition
Liquidity and Capital Resources
The Company has financed its operations since inception through public and
private sales of common stock, investment income, contract manufacturing,
initial product sales and revenue from strategic partners. Through December 31,
1996, the Company had raised approximately $81.4 million in net proceeds from
sales of common stock. It has earned approximately $8.7 million in investment
income and $10.8 million in research and development-related revenues and other
fees.
At December 31, 1996, the Company had approximately $20.8 million in cash, cash
equivalents and securities available for sale. Through December 31, 1996, the
Company has invested a total of approximately $4.0 million in laboratory and
computer equipment, furniture and leasehold improvements. In addition, the
Company has invested approximately $6.1 million in leasehold improvements and
equipment for its manufacturing plant. The Company anticipates that its
operating expenses will increase in 1997 and subsequent years as the Company
expands its manufacturing plant and purchases equipment to process its planned
wound care products, hires additional personnel, particularly in the fields of
sales and marketing and manufacturing, and advances potential product candidates
in development.
-81-
<PAGE>
The Company expects to continue to try to negotiate strategic collaborations or
other suitable partnerships for certain applications of its technology, and to
seek product acquisition and/or distribution agreements with other parties whose
products, capabilities or interests complement the Company's goals and abilities
internationally. Certain of these relationships may involve commitments from
ProCyte to fund some or all of certain research and development projects or to
make royalty payments based on products sold during a defined period.
Although strategic partnerships have provided revenue to the Company in the
past, there can be no assurance that similar sources of funds will be available
to the Company in the future. Additionally, though the Company makes every
effort to extensively review products it may seek to acquire, distribute or
in-license, there can be no assurance that products so obtained will be
commercialized successfully, if at all.
Further expenditures will be required for manufacturing, including but not
limited to, adding equipment for the manufacture of the polymer-based wound care
products; building a sales organization and marketing program for the Company's
products in North America and elsewhere; patent and other legal fees; and for
office and related space and equipment to accommodate the activities and
personnel associated with bringing potential products into development or the
marketplace. All these activities, and others that may not have been
anticipated at this time, will require substantial financial resources. There
can be no assurance that the Company will have sufficient resources to fund the
cost of such activities, or that it will be able to obtain any additional
financial resources on acceptable terms or in time to fund any necessary or
desirable expenditures.
The Company anticipates that its existing capital resources should be sufficient
to fund its cash requirements for approximately two years. However, the amounts
and timing of expenditures will depend on such things as the progress and
results of ongoing clinical development programs, the rate at which operating
losses are incurred, the execution of in-licensing or product distribution
agreements with others, the establishment of out-licensing agreements or
strategic alliances for certain of the Company's products or technology, the FDA
regulatory process and similar processes among similar agencies in other
countries, and other factors, many of which are beyond the Company's control,
such as changes in healthcare product reimbursement schedules.
Capital Expenditures
During 1996, capital expenditures totaled $1,739,875 compared with $0 and
$3,849,667 in 1995 and 1994, respectively. Of the total capital expenditures
during 1996, 1995 and 1994, respectively, approximately $1,246,807, $0, and
$3,811,096 represented leasehold improvement costs associated with certain of
the Company's facilities. With the exception of leasehold improvement costs,
virtually all of the capital expenditures during 1996, 1995 and 1994 represented
laboratory and office equipment and scientific instrumentation necessary to
support the research, development and manufacturing infrastructure.
Capital expenditures during 1997 are expected to be approximately $500,000 to
support the corporate office and laboratory consolidation and relocation to the
Redmond, Washington facility which houses the manufacturing plant, and
expenditures required to support product commercialization and research and
development activities.
Price Range of Common Stock
ProCyte Corporation's common stock is quoted on the Nasdaq National Market
System under the symbol PRCY. As of March 7, 1997, there were 485 holders of
record of common stock. The Company has never paid any cash dividends and does
not anticipate paying any cash dividends in the foreseeable future. The Company
intends to retain future earnings and capital for use in its business. The high
and low sale prices for the common stock as reported by the Nasdaq National
Market System for each quarter during 1995, 1996, and 1997 to date are as
follows:
-82-
<PAGE>
High Low
1995 First Quarter 3 9/32 2
Second Quarter 2 13/16 2 1/8
Third Quarter 3 3/8 2
Fourth Quarter 3 1/16 2 1/8
1996 First Quarter 5 1/4 2 9/16
Second Quarter 5 1/8 3 5/16
Third Quarter 3 7/8 2 7/16
Fourth Quarter 3 2
1997 First Quarter (through 3/7/97) 2 7/16 1 13/16
-83-
<PAGE>
EXHIBIT 27.1
FINANCIAL DATA SCHEDULE
EBS.XLS
Part I - FINANCIAL INFORMATION
Item 1. Financial Statements
ProCyte Corporation
(a development stage company)
Balance Sheets
<TABLE>
<CAPTION>
December 31,
---------------------------
1996 1995
------------ ------------
<S> <C> <C>
ASSETS
CURRENT ASSETS
Cash and cash equivalents.................................................. $ 1,804,875 $ 6,019,740
Securities available for sale ............................................. 19,041,961 30,057,780
Insurance claim receivable, net of $1 million allowance - 1996............. 0 3,000,000
Inventories................................................................ 596,740 0
Other...................................................................... 318,580 477,116
------------ ------------
Total current assets..................................................... 21,762,156 39,554,636
PROPERTY AND EQUIPMENT, at cost
Equipment.................................................................. 3,604,764 3,328,829
Leasehold improvements..................................................... 5,097,833 5,097,833
Improvements in progress................................................... 1,463,940 0
Less accumulated depreciation and amortization............................. (4,306,094) (3,244,799)
------------ ------------
Property and equipment, net.............................................. 5,860,443 5,181,863
PATENTS, at cost........................................................... 290,930 290,930
Less accumulated amortization.............................................. (109,270) (93,270)
------------ ------------
Patents, net............................................................. 181,660 197,660
OTHER...................................................................... 159,399 159,399
------------ ------------
TOTAL ASSETS............................................................... $ 27,963,658 $ 45,093,558
------------ ------------
------------ ------------
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable........................................................... $ 334,843 $ 678,698
Accrued liabilities........................................................ 779,890 687,452
Payable to stockholders for settlement of litigation....................... 0 7,750,000
------------ ------------
Total current liabilities................................................ 1,114,733 9,116,150
DEFERRED LEASE PAYMENTS.................................................... 10,148 69,172
DEFERRED STATE SALES TAXES................................................. 0 23,682
COMMITMENTS
STOCKHOLDERS' EQUITY
Preferred stock $.01 par value: 2,000,000 shares
authorized; no shares issued or outstanding.............................
Common stock $.01 par value: 30,000,000 shares
authorized; shares issued and outstanding 13,364,958
- December 31, 1996 and 13,318,495 - December 31, 1995.................. 132,776 131,311
Additional paid-in capital.................................................. 82,576,340 82,350,862
Deficit accumulated during the development stage............................ (55,870,339) (46,513,220)
Unearned compensation....................................................... 0 (84,399)
------------ ------------
Total stockholders' equity............................................... 26,838,777 35,884,554
------------ ------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY.................................. $ 27,963,658 $ 45,093,558
------------ ------------
------------ ------------
</TABLE>
See notes to financial statements
-84-
<PAGE>
EPL.XLS
ProCyte Corporation
(a development stage company)
Statements of Operations
<TABLE>
<CAPTION>
January 1,
1985
(predecessor
Year ended December 31, inception) to
---------------------------------------- December 31,
1996 1995 1994 1996
---------- ----------- ------------ --------------
<S> <C> <C> <C> <C>
REVENUES
Product revenues..................................................... $ 30,563 $ 0 $ 0 $ 30,563
Research and development
revenues under collaborative
agreements......................................................... 0 1,536,316 2,773,154 7,754,711
Contract manufacturing............................................... 708,104 151,836 0 859,940
License fees......................................................... 900,000 0 0 1,500,000
Interest income...................................................... 1,622,944 2,631,904 1,699,829 8,658,745
Other ............................................................... 14,346 712,110
----------- ------------ ------------ -----------
Total revenues....................................................... 3,275,957 4,320,056 4,472,983 19,516,069
----------- ------------ ------------ -----------
COSTS AND EXPENSES
Cost of product sales................................................ 13,910 0 0 13,910
Research and
development........................................................ 6,738,911 7,235,298 13,298,942 49,879,269
Litigation settlement............................................... 1,000,000 4,750,000 0 5,750,000
General and administrative.......................................... 4,880,255 4,729,693 3,327,759 19,746,017
----------- ------------ ------------ -----------
Total costs and expenses............................................ 12,633,076 16,714,991 16,626,701 75,389,196
----------- ------------ ------------ -----------
NET LOSS............................................................. $(9,357,119) $(12,394,935) $(12,153,718) $(55,873,127)
----------- ------------ ------------ -----------
----------- ------------ ------------ -----------
NET LOSS PER
COMMON SHARE....................................................... $ (0.71) $ (0.95) $ (0.97) $ (7.18)
----------- ------------ ------------ -----------
----------- ------------ ------------ -----------
Weighted average number of
common shares used in computing
net loss per common share.......................................... 13,210,036 13,100,818 12,593,131 7,786,448
----------- ------------ ------------ -----------
----------- ------------ ------------ -----------
</TABLE>
See notes to financial statements
-85-
<PAGE>
ECSH.XLS
ProCyte Corporation
(a development stage company)
Statements of Cash Flows
<TABLE>
<CAPTION>
January 1,
1985
(predecessor
Years ended December 31 inception) to
--------------------------------------- December 31,
OPERATING ACTIVITIES 1996 1995 1994 1996
----------- ------------ ------------ -------------
<S> <C> <C> <C> <C>
Net Loss ($9,357,119) ($12,394,935) ($12,153,718) $(55,873,127)
Adjustments to reconcile net loss
to net cash used in operating activities:
Depreciation...................................................... 1,061,294 781,445 745,984 4,556,763
Patent expense.................................................... 16,000 213,358 44,258 786,929
Amortization of discount on marketable securities................. (15,625)
(Gain) loss on sale of securities available for sale.............. 50,036 (324,534) 136,910 (137,588)
Restricted and other stock grants................................. 259,000 32,634 332,721
Compensation expense on stock options............................. (58,101) 69,657 174,375 597,638
Changes in assets and liabilities:
Increase in inventories......................................... (596,740) 0 0 (596,740)
(Increase) decrease in other current assets...................... 158,536 (16,892) (298,270) (318,583)
(Increase) decrease in insurance claim receivable................ 3,000,000 (3,000,000) 0 0
Decrease in deferred offering expenses.......................... 0 0 99,112 0
Increase in other assets........................................ 0 0 (2,341) (9,399)
Increase (decrease) in accounts payable......................... (343,855) 385,232 101,395 249,724
Increase (decrease) in accrued liabilities...................... 92,438 (406,502) 428,320 724,982
Increase (decrease) in litigation settlement payable............ (7,750,000) 7,750,000 0
Decrease in deferred income..................................... 0 (340,344) (447,181) 0
Increase (decrease) in deferred lease payments.................. (59,024) (13,831) 1,977 10,148
Decrease in deferred use tax.................................... (23,682) (28,862) (18,492) (94,713)
----------- ------------ ----------- -----------
Net cash used in operating activities................................ (13,551,217) (7,293,574) (11,187,671) (49,786,870)
----------- ------------ ----------- -----------
----------- ------------ ----------- -----------
FINANCING ACTIVITIES
Proceeds from issuance of stock - net.............................. 110,444 27,423 35,660,886 81,405,340
Proceeds from borrowings........................................... 500,000
----------- ------------ ----------- -----------
Net cash provided by financing activities............................ 110,444 27,423 35,660,886 81,905,340
----------- ------------ ----------- -----------
INVESTING ACTIVITIES
Purchase of property and equipment.................................. (1,739,875) 0 (3,849,667) (10,321,276)
Purchase of securities available-for-sale........................... (171,186,634) (142,491,420) (27,865,785) (379,680,429)
Proceeds from sale or maturity of securities available for sale..... 182,152,417 129,528,389 10,958,660 360,791,681
Patents:
Expenditures........................................................ 0 0 (136,011) (1,018,117)
Reimbursements...................................................... 0 5,000 9,932 64,546
Other............................................................... (150,000)
----------- ------------ ----------- -----------
Net cash used in investing activities................................. 9,225,908 (12,958,031) 20,882,871 (30,313,595)
----------- ------------ ----------- -----------
NET INCREASE IN CASH AND CASH EQUIVALENTS............................ (4,214,865) (20,224,182) 3,590,344 1,804,875
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD...................... 6,019,740 26,243,922 22,653,578
----------- ------------ ----------- -----------
CASH AND CASH EQUIVALENTS AT END OF PERIOD............................ $1,804,875 $6,019,740 $26,243,922 $1,804,875
----------- ------------ ----------- -----------
----------- ------------ ----------- -----------
SUPPLEMENTAL SCHEDULE OF NON-CASH
FINANCING AND INVESTING ACTIVITIES
Conversion of debt to common stock................................ $ 500,000
----------
----------
Issuance of stock for patents..................................... $ 27,790
----------
----------
</TABLE>
See notes to financial statements
-86-
<PAGE>
<TABLE>
<CAPTION>
EEQUITY.XLS
ProCyte Corporation
(a development stage company)
Statements of Stockholders' Equity
Deficit
Accumulated
Common Stock Additional During the
------------------- Paid-in Development Unearned
Shares ParValue Capital Stage Compensation Total
------ -------- --------- ----------- ------------ ----------
<S> <C> <C> <C> <C> <C> <C>
Balance, September 22, 1986
(Company inception)......................
Issuance to Iama, Inc. for certain assets
($.03 per share) - September 22.......... 835,200 $ 8,352 $ 20,505 $ 28,857
Issuance for cash ($.09 per share)
September 22............................. 290,000 2,900 21,800 24,700
Issuance for services ($.09 per share)
December 31.............................. 17,400 174 1,326 1,500
Net loss................................... $ (22,476) (22,476)
--------- -------- --------- ----------- ------------- ---------
Balance, December 31, 1986................. 1,142,600 11,426 43,631 (22,476) 32,581
Other issuance to officer for cash
($.09 per share) January 29.............. 92,800 928 7,072 8,000
Issuance for services ($.09 per share)
February 19.............................. 17,400 174 1,326 1,500
Issuance for cash ($.86 per share)
March 19 to May 27....................... 1,403,600 14,036 1,191,925 1,205,961
Net loss................................... (649,333) (649,333)
--------- -------- --------- ----------- ------------- ---------
Balance, December 31, 1987................. 2,656,400 26,564 1,243,954 (671,809) 598,709
Issuance for cash ($1.51 per share)
April 29 to June 22...................... 297,373 2,974 441,791 444,765
Issuance for cash ($1.51 per share)
July 25.................................. 251,140 2,511 373,103 375,614
Issuance for cash ($2.16 per share)
August 2................................. 742,400 7,424 1,480,734 1,488,158
Exercise of stock options
($.86 per share) October 31.............. 1,160 12 988 1,000
Net loss................................... (1,451,540) (1,451,540)
--------- -------- --------- ----------- ------------- ---------
Balance, December 31, 1988................. 3,948,473 39,485 3,540,570 (2,123,349) 1,456,706
Issuance to Schering Corporation for
cash ($5.76 per share) May 18............ 433,724 4,337 2,493,314 2,497,651
Conversion of debt to common stock
($2.16 per share) May 26................. 232,000 2,320 497,680 500,000
Grants to officers for services
($5.76 per share) July 27................ 3,472 35 19,965 20,000
Issuance for cash - Initial public offering
($8.00 per share) November 16............ 1,300,000 13,000 9,284,318 9,297,318
Compensatory stock option grants Oct. 2.... 183,270 $(183,270)
Amortization of unearned compensation...... 6,490 6,490
Net loss................................... (617,714) (617,714)
--------- -------- --------- ----------- ------------- ---------
Balance, December 31, 1989 (Forward)....... 5,917,669 $ 59,177 $16,019,117 $ (2,741,063) $ (176,780) $ 13,160,451
</TABLE>
See notes to financial statements
-87-
<PAGE>
<TABLE>
<CAPTION>
ProCyte Corporation
(a development stage company)
Statements of Stockholders' Equity - Continued
Deficit
Accumulated
Common Stock Additional During the
------------------- Paid-in Development Unearned
Shares ParValue Capital Stage Compensation Total
------ -------- --------- ----------- ------------ ----------
<S> <C> <C> <C> <C> <C> <C>
Balance, December 31, 1989 (Forward)...... 5,917,669 $ 59,177 $16,019,117 $ (2,741,063) $ (176,780) $ 13,160,451
Compensatory stock option grants Jan. 9... 6,500 (6,500)
Grant to officer for services
($5.63 per share) May 1................. 3,000 30 16,845 16,875
Exercise of stock options
($2.16 per share) May 15 to July 9...... 3,132 31 6,733 6,764
($.86 per share) June 22 to July 24..... 27,276 273 23,185 23,458
Amortization of unearned compensation..... 35,148 35,148
Net loss.................................. (2,189,019) (2,189,019)
--------- -------- ------------ ------------- ------------ -----------
Balance, December 31, 1990 ............... 5,951,077 59,511 16,072,380 (4,930,082) (148,132) 11,053,677
Grant to officer for services
($5.50 per share) February 4............ 766 7 4,205 4,212
Exercise of stock options
($5.76 per share) Jan. 17 to May 28..... 116 1 667 668
($.86 per share) Feb. 28 to Dec. 12..... 26,444 264 22,477 22,741
($2.16 per share) May 7 to Dec 30....... 16,688 168 35,878 36,046
($7.00 per share) November 5............ 200 2 1,398 1,400
($5.63 per share) December 12........... 600 6 3,369 3,375
($6.59 per share) December 12........... 2,000 20 13,160 13,180
Compensatory stock option
grants April 1.......................... 131,948 (131,948)
Amortization of unearned compensation..... 57,090 57,090
Net loss.................................. (3,931,098) (3,931,098)
--------- -------- ------------ ------------- ------------ -----------
Balance, December 31, 1991................ 5,997,891 59,979 16,285,482 (8,861,180) (222,990) 7,261,291
Exercise of stock options
($2.16 per share) Jan. 1 to Nov. 19..... 6,576 66 14,136 14,202
($.86 per share) Jan. 13 to Aug 12..... 15,360 153 13,056 13,209
($5.63 per share) January 20............ 200 2 1,123 1,125
($4.62 per share) Jan. 20 to Nov. 9..... 600 6 2,766 2,772
($6.59 per share) January 26............ 2,000 20 13,160 13,180
($5.76 per share) March 11.............. 464 5 2,669 2,674
($2.50 per share) December 9............ 3,000 30 7,470 7,500
($5.00 per share) December 10 to 17..... 700 7 3,493 3,500
($1.51 per share) in exchange for
2292 issued shares December 28....... 12,708 127 (122) 5
Issuance for cash - Public offering
($5.50 per share) May 19................ 1,437,500 14,375 7,080,565 7,094,940
Cancel compensatory stock option
grants March 13......................... (6,960) 6,960
Compensatory stock option
grants February 12...................... 322,000 (322,000)
Amortization of unearned compensation..... 157,400 157,400
Net loss.................................. (5,430,373) (5,430,373)
--------- -------- ------------ ------------- ------------ -----------
Balance, December 31, 1992 (Forward)...... 7,476,999 $ 74,770 $23,738,838 $ (14,291,553) $ (380,630) $ 9,141,425
See notes to financial statements
-88-
</TABLE>
<PAGE>
<TABLE>
<CAPTION>
ProCyte Corporation
(a development stage company)
Statements of Stockholders' Equity - Continued
Deficit
Accumulated
Common Stock Additional During the
------------------- Paid-in Development Unearned
Shares ParValue Capital Stage Compensation Total
------ -------- --------- ----------- ------------ ----------
<S> <C> <C> <C> <C> <C> <C>
Balance, December 31, 1992 (Forward)...... 7,476,999 $ 74,770 $23,738,838 $ (14,291,553) $ (380,630) $ 9,141,425
Exercise of stock options
($2.16 per share) January 15 to Dec. 20 13,584 136 29,205 29,341
($5.00 per share) February 9 to June 24 750 7 3,743 3,750
($1.51 per share) in exchange for
12,966 issued shares March 4.......... 64,834 648 (642) 6
($7.00 per share) May 3 to July 30...... 200 2 1,398 1,400
($5.625 per share) June 2 .............. 600 6 3,369 3,375
($5.125 per share) June 9 to Oct. 17.... 10,200 102 52,173 52,275
($5.76 per share) June 24............... 100 1 575 576
($0.86 per share) Oct. 1................ 6,320 63 5,372 5,435
($2.50 per share) Oct. 1................ 15,000 150 37,350 37,500
($7.25 per share) Oct. 1 to Nov. 2...... 600 6 4,344 4,350
($11.25 per share) Oct. 1 to Dec. 15.... 500 5 5,620 5,625
($5.53 per share) Nov. 5................ 10,000 100 55,200 55,300
Issuance for cash - Public offering
($9.00 per share) February 9........... 2,275,000 22,750 18,895,668 18,918,418
Issuance to Kissei Pharmaceutical
for cash ($25.73 per share) Dec. 1..... 155,461 1,555 3,725,336 3,726,891
Cancel compensatory stock option
grants September 10.................... (39,120) 39,120
Compensatory stock option
grants September 15.................... 142,500 (142,500)
Amortization of unearned compensation.... 155,579 155,579
Net loss................................. (7,673,014) (7,673,014)
------ -------- --------- ----------- ------------ ----------
Balance, December 31, 1993............... 10,030,148 100,301 46,660,929 (21,964,567) (328,431) 24,468,232
Exercise of stock options
($0.86 per share) Oct 10............... 1,392 14 1,183 1,197
($5.00 per share) January 18 to June 14 800 8 3,992 4,000
($2.16 per share) January 24........... 1,856 19 3,990 4,009
($7.75 per share) May 10............... 10,000 100 77,400 77,500
($7.00 per share) July 13.............. 100 1 699 700
($9.44 per share) August 23............ 1,000 10 9,430 9,440
Issuance for cash - Public offering
($13.25 per share) February 8.......... 2,500,000 25,000 30,900,000 30,925,000
Issuance for cash - Public offering overal-
lotment ($13.25 per share) February 22. 375,000 3,750 4,635,290 4,639,040
Amortization of unearned compensation.... 174,375 174,375
Net loss................................. (12,153,718) (12,153,718)
------ -------- --------- ----------- ------------ ----------
Balance, December 31, 1994............... 12,920,296 129,203 82,292,913 (34,118,285) (154,056) 48,149,775
Exercise of stock options:
($2.16 per share) January 23........... 9,000 90 19,350 19,440
($.09 per share) in exchange for
5,681 issued shares February 3....... 179,919 1,799 (1,797) 2
($0.86 per share) February 14.......... 9,280 93 7,888 7,981
Hymedix Restricted Stock
($2.59 per share) December 31........... 12,600 126 32,508 32,634
Amortization of unearned compensation.... 69,657 69,657
Net loss................................. (12,394,935) (12,394,935)
------ -------- --------- ----------- ------------ ----------
Balance, December 31, 1995............... 13,131,095 131,311 82,350,862 (46,513,220) (84,399) 35,884,554
------ -------- --------- ----------- ------------ ----------
Exercise of stock options:
($2.64 per share) January 5 to October 31. 11,368 114 29,898 30,012
($2.53 per share) January 5 to October 11. 12,503 125 31,508 31,633
($2.16 per share) April 1 to September 13. 22,592 227 48,572 48,799
Hymedix Restricted Stock:
($2.59 per share) March 31.............. 25,000 250 64,500 64,750
($2.59 per share) June 30............... 25,000 250 64,500 64,750
($2.59 per share) September 30.......... 25,000 250 64,500 64,750
($2.59 per share) December 31........... 25,000 250 64,500 64,750
Cancel compensatory stock option grants.. (142,500) (142,500)
Amortization of unearned compensation.... 84,399 84,399
Net loss................................. (9,357,119) (9,357,119)
------ -------- --------- ----------- ------------ ----------
Balance, December 31, 1996............... 13,277,558 $132,776 $82,576,340 ($55,870,339) $0 $26,838,777
------ -------- --------- ----------- ------------ ----------
------ -------- --------- ----------- ------------ ----------
</TABLE>
See notes to financial statements
89
<PAGE>
Notes to financial statements
1. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
DESCRIPTION OF BUSINESS
Nature of Operations
ProCyte Corporation is a development stage healthcare products company engaged
in the discovery, development and commercialization of a new class of
proprietary copper-containing compounds and other wound care technologies.
ProCyte Corporation (the "Company") commenced operations on September 22, 1986
(inception). To date, the Company's research and development programs have
focused principally on wound healing, tissue repair and hair growth applications
with its topically administered peptide-copper compounds. In November 1995, the
Company acquired certain rights to a polymer technology for use in wound care.
Presently, the Company is working to commercialize its wound care technologies
and also is seeking to partner or out-license it's technology applications for
potential treatment of inflammatory bowel disease, and hair loss conditions.
On September 22, 1986, the Company issued 835,200 shares of common stock in
exchange for substantially all of the assets of Iama, Inc., a predecessor
company (the "Predecessor"), some of whose stockholders were founders of the
Company. These assets consisted principally of patents and intellectual property
rights related to the use of peptide-copper compounds. The patents were stated
at $26,570, the Predecessor's historical cost. The Predecessor's operating
results from January 1, 1985 ("Predecessor inception") to September 21, 1986,
are included in net losses since inception in the accompanying financial
statements.
To date, the Company's revenues have been principally from research, license
fees, contract manufacturing and interest income. At year end 1996, revenues
generated from product sales total $30,563. From inception through December 31,
1996, the Company incurred expenses for research, development, administration,
and settlement of litigation, resulting in an accumulated deficit of
approximately $55,870,000. Further expenditures will be required for
development, clinical testing, regulatory submissions, marketing and
manufacturing for ProCyte's product candidates. There can be no assurance that
the Company will be able to successfully commercialize its products or achieve a
profitable level of operation.
The Company announced a corporate restructuring on October 21, 1994, in which it
reduced staff by thirty-five percent in order to devote a greater percentage of
the Company's capital resources in support of its corporate strategy to (1)
continue to develop its proprietary copper-based compounds; and polymer-based
products and (2) seek a other suitable technology-rich acquisition or merger
candidates to enhance the Company's ability to provide nearer-term product
introductions; and (3) provide contract manufacturing services to
pharmaceutical, biotechnology, and other industries in order to fully utilize
its existing facilities. The Company has invested a total of approximately $6.1
million for the construction of its bulk substance and wound care manufacturing
facility, the latter of which was constructed in 1997. The Company currently
uses the manufacturing facility to provide services for industry clients and to
manufacture and improve the processes for its own product candidates. At this
time, management believes that the cost of the facility will be recovered
through processing current and expected bulk substance requirements for the
Company, and/or its collaborative partners and/or from contract manufacturing
services.
A substantial amount of additional funds will be required for the Company to
complete commercialization of certain of its product candidates, to build
manufacturing, sales, and marketing capabilities, and to fund additional
operating losses expected to be incurred in the next few years. Management's
plans for obtaining additional funding may include equity offerings and
strategic alliances or product out-licensing for certain of the Company's
technology applications. If such funding is not obtained, the Company's ability
to continue its development and production efforts at the current level will be
limited, which would require that the Company reduce its development, sales and
marketing, and commercialization expenditures.
91
<PAGE>
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Revenue recognition
Product revenues are recognized when related products are shipped.
Development revenues, consisting of cost reimbursements, are recognized when the
related costs have been incurred.
Development revenues under collaborative agreements and nonrefundable license
fees are recognized when earned for the performance of research activities
under contract terms. Contract manufacturing revenues are recognized when
services are performed.
Research and development
Research and development costs are expensed as incurred. The Company enters into
contracts with outside laboratories for certain clinical, biocompatibility and
toxicology studies. Payments for such contracts are typically made in
installments at the initiation, completion, and other specified stages of the
studies. The Company recognizes the expenses associated with these contracts
when the related services are performed.
Inventories
Inventories are stated at the lower of cost, determined using the first-in,
first-out method, or market, and consists of materials, work in process, and
finished goods, totaling $100,000, $317,000 and $180,000, respectively, as of
December 31, 1996.
Depreciation and amortization
Equipment is depreciated using accelerated methods over the estimated useful
lives of the related assets, ranging from 5 to 20 years. Leasehold improvements
are amortized over the term of the lease or the asset's useful life, whichever
is shorter.
Long-lived assets
In accordance with SFAS 121, the Company periodically reviews long-lived assets,
including intangible assets, for impairment to determine whether events or
changes in circumstances indicate that the carrying amount of the assets may not
be recoverable and makes adjustments accordingly. No loss provisions have been
required.
Patents and amortization
Patent application costs are amortized on a straight line basis over 17 years
from the date the related patents are issued. Application costs for abandoned
patents are expensed in the period abandoned.
Beginning in fourth quarter 1992, the Company changed its accounting policy to
capitalize only those recoverable patent costs which relate to indications for
which licensing agreements have been in place. As a result, in fourth quarters
1992 and 1995, the Company recorded a non-cash writedown of $378,615 and
$200,760, respectively, for previously capitalized patent costs which do not
meet the above criteria. No additional patents were capitalized in 1996.
92
<PAGE>
Net loss per common share
Net loss per common share is based upon the weighted average number of common
shares outstanding. Common stock equivalents include shares issuable upon the
exercise of stock options and assignment of shares granted (see note 3).
However, only the vested portion of the shares granted is considered in the
computation of the net loss per common share as the remaining shares would have
an anti-dilutive effect.
Federal income taxes
The Company accounts for income taxes in accordance with Statement of Financial
Accounting Standards No. 109, Accounting for Income Taxes (SFAS 109).
The Company has provided a full valuation allowance for tax benefits of net
operating losses and research and development tax credit carryforwards.
Cash equivalents
The Company considers all highly liquid investments purchased with a maturity
of three months or less to be cash equivalents. Such investments are
primarily in a United States Treasury money market fund.
Securities available for sale
In 1994, the Company implemented Statement of Financial Accounting Standards No.
115, Accounting for Certain Investments in Debt and Equity Securities (SFAS
115), which requires classification of debt and equity securities as either
"trading," "available for sale," or "held to maturity."
The Company's investments, consisting of U.S. Treasury notes and bills, are
all classified as "available for sale" and are stated at fair value, with
valuation adjustments recorded directly to equity. Fair value is based upon
quoted market prices. For purposes of computing realized gains and losses,
the specific identification method is used to determine the cost of
investments sold.
Stock options
In 1996, the Company adopted Statement of Financial Accounting Standards No.
123 "Accounting for Stock-Based Compensation" (SFAS123). The statement
defines a fair value method of accounting for an employee stock option or
similar equity instrument and encourages, but does not require, adoption of
that method. Under SFAS 123 an employer's financial statements should
include certain disclosures about stock-based compensation arrangements
regardless of the method used to account for them. As permitted by SFAS 123,
the Company continues to follow the existing accounting requirements for
stock options and stock-based awards contained in APB opinion No. 25
"Accounting for Stock issued to Employees". See note 7 for disclosures
required be SFAS 123 for entities electing not to adopt the fair value method
specified in SFAS 123.
Use of estimates in financial statements
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ form those estimates. The most significant such
estimates relate to impairment and the allowance for the insurance claim
receivable, as discussed in note 6. It is reasonably possible that actual
losses on that receivable may be less than the amounts accrued.
93
<PAGE>
2. INVESTMENTS
At December 31, 1996 and 1995, the Company's investments consist primarily of
U.S. Treasury notes and bills and are classified as "available for sale." The
amortized cost and estimated market value for the investments maturing in one
year or less is $14,271,630 and those maturing in one through five years is
$4,770,330. Unrealized gains or losses at December 31, 1996 and 1995, were
insignificant, and realized gains and (losses) from sales of investments during
1996 and 1995 were ($50,036) and $324,534 respectively.
3. COLLABORATIVE AGREEMENTS
The Company earned revenue under collaborative agreements as follows:
<TABLE>
<CAPTION>
Years ended December 31,
1996 1995 1994
<S> <C> <C> <C>
R&D Funding:
Kaken Pharmaceutical $0 $690,345 $1,497,180
Kissei Pharmaceutical 0 750,000 1,000,000
Cost Reimbursements:
Kaken Pharmaceutical 0 3,027 2,663
Kissei Pharmaceutical 0 92,944 273,311
License Fees 900,000
----------------------------------------------------------------
Totals $900,000 $1,536,316 $2,773,154
----------------------------------------------------------------
</TABLE>
HYMEDIX INTERNATIONAL, INC.
In November 1995, the Company entered into a license agreement with Hymedix
International, Inc. ("Hymedix"). Under the agreement, the Company acquired from
Hymedix an exclusive license to make, have made, use and sell products for the
wound care field using Hymedix's HYPAN-Registered Trademark- polymer technology.
The Company has acquired exclusive worldwide rights, outside of Asia, to five
wound care products that have received market clearance from the United States
Food and Drug Administration. The Company also acquired non-exclusive rights in
the same territory to a sixth wound care product, and acquired exclusive
worldwide rights to the drug delivery applications of the technology for wound
healing.
Under the terms of the agreement, the Company is to make certain research and
development, milestone and royalty payments to Hymedix. Further, under the
terms of a stock acquisition agreement between the parties, the Company
issued to Hymedix 200,000 shares of the Company's common stock releasable in
four equal assignments of 50,000 shares each over a two year period, unless
Hymedix has materially breached the license agreement or the Company has
terminated the license agreement. The stock is subject to SEC Rule 144
restrictions and has piggyback registration rights for a limited period of
time. The Company may terminate the agreement at any time upon sixty days'
written notice.
KISSEI PHARMACEUTICAL CO., LTD.
In November 1993, the Company entered into a strategic alliance with Kissei
Pharmaceutical Co., Ltd. ("Kissei"). Under the terms of the agreement, the
Company granted Kissei an exclusive license to make, have made, use and sell the
Iamin-Registered Trademark- compound in Japan, China, Korea and Taiwan for
topical wound healing applications, including chronic human dermal wounds such
as diabetic, venous stasis or pressure ulcers, surgical wounds and burns.
On March 7, 1997, the Company agreed to terminate its license agreement with
Kissei. The Company will regain the exclusive license rights for its
peptide-copper products in Japan, China, Korea and Taiwan for topical would
healing applications.
94
<PAGE>
KAKEN PHARMACEUTICAL CO., LTD.
In December 1992, the Company entered into an agreement with Kaken
Pharmaceutical Co., Ltd. ("Kaken") for developing and marketing hair growth
products in Asia based on the Company's technology. The agreement gave Kaken
exclusive license rights for peptide-copper hair growth and hair loss prevention
products in Asian countries. In 1995 Kaken satisfied all of its R&D funding
obligations under the agreement.
On January 31, 1996, the Company's license agreement with Kaken was terminated.
The Company has regained the exclusive license rights for its peptide-copper
hair growth and hair loss prevention products in Asian countries.
4. FEDERAL INCOME TAXES
The following is a summary of the components of deferred taxes (in millions) at
December 31, 1996 and December 31, 1995:
<TABLE>
<CAPTION>
December 31, December 31,
1996 1995
<S> <C> <C>
Deferred tax asset $18.4 $15.5
Valuation allowance (18.4) (15.5)
----------------------------------------
$0.0 $0.0
----------------------------------------
</TABLE>
At December 31, 1996, the Company had net operating loss and research and
development tax credit carryforwards of approximately $48.5 million and $1.4
million, respectively, scheduled to expire from 2000 to 2010. As a result of
issuing common stock subsequent to inception, the Company's ability to use
these net operating losses and tax credit carryforwards in the future will be
subject to limitations under Internal Revenue Code Section 382. No tax
benefits have been recorded for net operating losses incurred and tax credits
generated since inception.
5. LEASE COMMITMENTS
The Company leases approximately 28,000 square feet of laboratory and
administrative facilities in Kirkland, Washington under a ten year operating
lease which commenced July 1, 1990. Subject to certain payments, the lease is
cancelable by the Company at the end of seven years, and contains a renewal
option for the Company to extend the original term by an additional five years.
The Company has given notice of intent to terminate the Kirkland lease
effective July 1, 1997, and to move all laboratory and administrative
functions to its Redmond, Washington site at that time. No early termination
fee will be incurred by the Company as a result of the Kirkland lease
termination. However, a provision of $464,000 was made in 1996 related to
fixed assets to be disposed.
The Company also currently leases approximately 16,000 square feet of
manufacturing and expansion space in Redmond, Washington under a seventy-nine
month operating lease. Beginning on July 1, 1997, the Company plans to lease
an additional 16,000 square feet at the Redmond, Washington site, to house
the laboratory and administrative facilities, and has incorporated this space
with the plant in a ten year lease commencing April 1, 1997.
Future minimum lease payments on the total leased space of approximately 32,000
square feet are as follows:
<TABLE>
<CAPTION>
<S> <C>
1997.......................... $ 311,513
1998.......................... 288,486
1999.......................... 379,944
2000.......................... 388,068
2001.......................... 408,844
Thereafter.................... 2,564,616
---------
Total......................... $4,341,471
</TABLE>
96
<PAGE>
Rent expense in 1996, 1995 and 1994 was $519,629, $536,212, and $504,017,
respectively.
97
<PAGE>
6. LEGAL PROCEEDINGS
On March 5, 1996, the Company announced that it had elected to settle the
shareholder lawsuit filed in October 1994 against the Company and certain of
its officers and directors rather than continue to pursue costly litigation
expenses. The Company continues to believe that there was no wrongdoing on
the part of the Company and/or any of its officers and directors, but reached
the settlement agreement in an effort to focus management's attention and
corporate financial resources on the important business of building long-term
shareholder value in the Company. As of December 31, 1995, the Company
accrued the tentative settlement liability to stockholders of $7,750,000 and
related insurance claims receivable totaling $3,000,000.
The settlement, which was for $7.75 million, received court approval on
September 12, 1996. The court directed that approximately $2.7 million of
the settlement fund be paid to the plaintiffs' counsel for their fees and to
reimburse their expenses. On October 22, 1996, the Company paid the $5.25
million balance owing the settlement fund with cash, rather than shares of
the Company's common stock. ProCyte and one of its insurance carriers had
previously paid $2.5 million of the settlement in June 1996. At December 31,
1996, the Company had a remaining $1 million insurance claim receivable from
a carrier that had denied coverage. In late 1996, the matter was submitted
to binding arbitration as the parties were unable to reach agreement.
Although management believes its position is strong, it provided a full
allowance for the remaining $1,000,000 insurance claim receivable, because of
the uncertainties and risks of arbitration. In March 1997, the Company began
discussions with the carrier regarding potential settlement. Settlement
payments, if any, will be recognized if and when the matter is finalized.
Another carrier has denied coverage for a claim of $2 million, and the matter
has also been submitted to arbitration. However, no amounts have been accrued
for such claims.
7. STOCKHOLDERS' EQUITY
Common stock
On October 2, 1989, the Board of Directors declared a 1.16 for 1 common stock
split to be effected in the form of a dividend to holders of record on that
date. Since this occurred before the Company's stock was publicly traded and the
Company had no retained earnings, this transaction has been accounted for
retroactively as a stock split.
Accordingly, all outstanding common shares and per common share amounts, except
par value, have been restated in these financial statements to give effect to
the split.
On November 16, 1989, the Company sold 1,300,000 shares of common stock in its
initial public offering at $8.00 per share. Prior to the public offering, the
Company had issued shares of its common stock in several private placements.
In 1989 and 1990, the Board of Directors granted common stock bonuses to
officers. Compensation expense was recognized based on estimated fair market
value of the stock on the date of grant.
During 1989, the Company borrowed $500,000 under a note convertible to common
stock of the Company at $2.16 per share, which was the estimated fair market
value at the date of the note as determined by the Board of Directors. This
note was converted and the stock was issued shortly after the borrowing.
In May 1989, the Company issued 433,724 shares of common stock to Schering
Corporation for cash of approximately $2.5 million under a share purchase
agreement.
On May 19, 1992, the Company sold 1,437,500 shares of common stock in a public
offering at $5.50 per share.
98
<PAGE>
On February 9, 1993, the Company sold 2,275,000 shares of common stock in a
public offering at $9.00 per share.
On December 1, 1993, the Company sold 155,461 shares of common stock to Kissei
Pharmaceutical Co., Ltd. at $25.73 per share under a stock purchase agreement.
On February 8 and 22, 1994, the Company sold 2,500,000 and 375,000 shares,
respectively, of common stock in a public offering at $13.25 per share.
In December 1994, the Board of Directors adopted a shareholder rights plan
(the "Rights Plan"), declaring a dividend of one preferred share purchase
right (the "Rights") for each outstanding share of common stock of the
Company. Upon the earlier of the close of business on the tenth business day
after the date the Company learns that a person or group (an "Acquiring
Person") has acquired or obtained the right to acquire beneficial ownership
of 15% or more of the outstanding common stock of the Company, or the date
designated by the board following commencement of, or first public disclosure
of an intent to commence, a tender or exchange offer for outstanding shares
of common stock of the Company, that could result in the offeror becoming
beneficial owner of 15% or more of the outstanding shares of common stock of
the Company, each Right will become exercisable (other than by an Acquiring
Person) for shares, or fractions of shares, of preferred stock of the
Company, or may, at the election of the board, be exchanged for shares of
preferred stock. In the event the Company is acquired, each Right will
represent the right to acquire shares of the acquiring or surviving
corporation or other entity. The Rights will expire on December 7, 2004.
On November 15, 1995, the Company issued 200,000 shares of its common stock
to Hymedix International, Inc. pursuant to a stock purchase agreement. These
shares are releasable to Hymedix over a two-year period in four equal
assignments of 50,000 shares each, unless Hymedix has materially breached the
license agreement or the Company has terminated the license agreement. The
stock is subject to SEC Rule 144 restrictions and has piggyback registration
rights for a limited period of time. The Company may terminate the agreement
at any time upon sixty days' written notice.
Stock options
The Company has stock option plans for officers, employees and consultants,
which provide for granting of nonqualified and incentive stock options and
grants. Options generally are granted at fair market value, expire between
five and ten years from grant date and vest ratably over three to five years.
During 1991, the Company adopted a stock option plan for nonemployee
directors, that was ratified by the shareholders in 1992. Such plan provides
for the grant of 200,000 nonqualified common stock options, which generally
vest over three years, with other terms substantially equivalent to the
Company's other plans.
During 1991, grants for 75,000 shares at fair market value were made from
this plan. During 1994, grants for 79,000 shares at fair market value were
made from this plan.
During 1992, the shareholders ratified an amendment to increase the shares of
common stock available under the 1989 Restated Stock Option Plan for option
grants to officers and employees by 500,000 shares, of which 200,000 shares
were granted by the Board of Directors to an officer.
During 1994, the shareholders ratified amendments to increase the shares of
common stock available under the 1989 Restated Stock Option Plan for option
grants to officers and employees by 652,000 shares, and to increase the
number of shares which could be granted to nonemployee directors under the
1991 Restated Stock Option Plan for Nonemployee Directors.
99
<PAGE>
The Company has granted stock options to key employees with option prices
below fair market value at the date of grant. Unearned compensation has been
recorded for the difference and is charged to operations ratably over the
period that services are to be performed. Unamortized unearned compensation
is shown as a reduction of stockholders' equity. In 1993, the Board of
Directors granted nonqualified stock options to purchase 75,000 shares of
common stock to an officer of the Company at 85% of the fair market value on
the date of the grant. All options are subject to vesting schedules.
In July 1996, the Board of Directors approved, subject to shareholder approval
at the May 1997 Annual Shareholders' Meeting, adoption of the 1996 Stock Option
Plan. The plan authorizes 550,000 stock options to be set aside for the use in
granting stock options to employees and consultants of the Company.
The Board of Directors also approved, subject to shareholder approval at the
1997 Annual Meeting of the Shareholders and amendment to the 1991 Restated
Stock Option Plan for Non-Employee Directors. If approved by the
shareholders, two directors are eligible to each receive grants of 6,000
shares of the Company's common stock.
During 1996, the Company adopted the provisions of SFAS 123. The Company
applies APB No. 25 and related interpretations in accounting for its plans.
Accordingly, no compensation expense has been recognized for stock option
grants, other than those granted at exercise prices below fair value of the
stock at the grant date as discussed above.
At December 31, 1996, options to purchase 742,383 shares were exercisable and
there were 775,598 shares available for future grant, including 52,000 shares
related to the 1991 plan for nonemployee directors, and 450,000 shares from
the proposed 1996 Stock Option Plan, subject to shareholder approval in May
1997.
The following summarizes information about stock options outstanding at
December 31, 1996 and activity in 1994, 1995, and 1996.
<TABLE>
<CAPTION>
Weighted
Average Weighted No. of Weighted
No. of Options Remaining Average Options Average
Outstanding at Contractual Exercise Exercisable at Exercise
Range of Exercise Prices 12/31/96 Life Price 12/31/96 Price
- ------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C>
$2.16 - 2.53 154,272 6.6 $2.45 113,763 $2.42
2.59 - 2.64 230,420 8.1 2.63 136,617 2.63
2.78 - 2.84 302,000 9.5 2.84 27,000 2.84
2.94 - 4.20 457,834 8.3 2.99 167,336 2.95
5.13 - 5.53 260,000 2.9 5.35 260,000 5.35
7.25 - 11.88 37,667 7.2 11.68 37,667 11.68
- ------------------------------------------------------------------------------------------------------------------------
Total 1,442,193 7.3 $3.50 742,383 $4.09
- ------------------------------------------------------------------------------------------------------------------------
</TABLE>
100
<PAGE>
<TABLE>
<CAPTION>
1996 1995 1994
Wtd. Avg. Wtd. Avg. Wtd. Avg.
Exercise Exercise Exercise
Shares Price Shares Price Shares Price
- -----------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
Outstanding beg. of yr. 1,536,957 $4.44 1,412,710 $4.63 1,019,808 $6.16
Granted 402,000 2.94 479,500 2.90 637,130 4.64
Exercised (46,463) 2.38 (203,880) .22 (15,148) 6.39
Canceled or expired (450,301) 6.34 (151,373) 7.20 (229,080) 11.11
- -----------------------------------------------------------------------------------------------------------------------
Outstanding, end of yr. 1,422,193 $3.50 1,536,957 $4.44 1,412,710 $4.63
- -----------------------------------------------------------------------------------------------------------------------
Exercisable, end of yr. 742,383 705,788 665,278
- -----------------------------------------------------------------------------------------------------------------------
</TABLE>
As required by SFAS 123, the Company has determined the fair value of stock
options granted during 1996 and 1995 using the Black-Scholes option pricing
model and the following assumptions:
<TABLE>
<CAPTION>
Weighted Average 1996 1995
<S> <C> <C>
Risk-free interest rate 5.88% 5.75%
Expected option life (years) 5.81 5.81
Dividend yield 0 0
Expected volatility 79% 47%
</TABLE>
The weighted average fair value of options granted during 1996 was
approximately $2.04. The effect on net loss had the Company elected to adopt
SFAS 123 would have been an increase in the net loss for the periods ending
December 31, 1996 and December 31, 1995 by $552,913, to $9,910,032 and by
$318,632 to $12,713,567, respectively. On a proforma basis, net loss per
share would have increased by $.04 to $.75 and by $.02 to $.97, respectively.
8. BENEFIT PLANS
On April 1, 1991, the Company adopted the 1991 ProCyte Corporation Profit
Sharing and Salary Deferral 401(k) Plan. The plan is funded by voluntary
employee pretax salary deferrals, to the extent permitted under law, and
provides for employer matching contributions, at the discretion of the Board of
Directors. No employer contribution has been made since adoption of the 401(k)
plan.
Independent Auditors' Report
Board of Directors
ProCyte Corporation
Kirkland, Washington
We have audited the accompanying balance sheets of ProCyte Corporation (a
development stage company) as of December 31, 1996 and 1995, and the related
statements of operations, cash flows and stockholders' equity for each of the
three years in the period ended December 31, 1996, and the period from
inception to December 31, 1996. These financial statements are the
responsibility of the Company's management. Our responsibility is to express
an opinion on these financial statements based on our audits.
101
<PAGE>
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free
of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements.
An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, such financial statements present fairly, in all material
respects, the financial position of the Company as of December 31, 1996 and
1995, and the results of its operations and its cash flows for each of the
three years in the period ended December 31, 1996 and for the period from
inception to December 31, 1996 in conformity with generally accepted
accounting principles.
As discussed in Note 1 to the financial statements, the Company changed its
method of accounting for investments in 1994.
DELOITTE & TOUCHE LLP
Seattle, Washington
March 13, 1997
102
<PAGE>
EXHIBIT 23.1
CONSENT OF DELOITTE & TOUCHE
INDEPENDENT AUDITORS' CONSENT
Board of Directors
ProCyte Corporation
Kirkland, Washington
We consent to the incorporation by reference in Registration Statement No.
33-48809 of ProCyte Corporation on Form S-8 of our report dated March 13, 1997,
incorporated by reference in this Annual Report on Form 10-K of ProCyte
Corporation for the year ended December 31, 1996.
DELOITTE & TOUCHE LLP
Seattle, Washington
March 25, 1997
-103-
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-01-1996
<PERIOD-END> DEC-31-1996
<CASH> 1,804,875
<SECURITIES> 19,041,961
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 596,740
<CURRENT-ASSETS> 21,762,156
<PP&E> 10,166,537
<DEPRECIATION> 4,306,094
<TOTAL-ASSETS> 27,963,658
<CURRENT-LIABILITIES> 1,114,733
<BONDS> 0
0
0
<COMMON> 132,776
<OTHER-SE> 26,706,001
<TOTAL-LIABILITY-AND-EQUITY> 27,963,658
<SALES> 30,563
<TOTAL-REVENUES> 3,275,957
<CGS> 13,910
<TOTAL-COSTS> 0
<OTHER-EXPENSES> 12,633,076
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (9,357,119)
<INCOME-TAX> 0
<INCOME-CONTINUING> (9,357,119)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (9,357,119)
<EPS-PRIMARY> (.71)
<EPS-DILUTED> (.71)
</TABLE>
